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Afferent chemoreceptor activity was recorded from the peripheral
cut end of the sinus nerve in anaesthetized cats and rabbits. It was
found that intracarotid injection of dopamine inhibited spontaneous
chemoreceptor activity in both species. 5~Hydroxytryptamine evoked
a brief excitation followed by inhibition of discharge in both species.
In cats, apomorphine caused a prolonged inhibition of chemoreceptor
activity. Following administration of a~flupenthixol or haloperidol
in cats and a-f1upenthixol in rabbits, dopamine no longer evoked an
inhibitory response but instead tended to cause an increase in chemo¬
receptor discharge. Responses to the chemoreceptor stimulants sodium
cyanide and hypoxia were potentiated following administration of
dopamine-blocking agents. These results suggest the possibility
that endogenous dopamine acts to depress afferent carotid chemoreceptor
activity.
Subsequent experiments in cats showed that the dopamine-uptake
blockers benztropine and nomifensine, but not the monoamineoxidase
inhibitor pargyline, potentiate the inhibitory action of injected
dopamine and also potentiate chemoreceptor responses to sodium
cyanide and hypoxia. These results imply that, in addition to its
inhibitory action, endogenous dopamine has an excitatory action on
chemoreceptor activity. It is suggested that the most likely
physiological role for dopamine in the carotid body is as a chemical
mediator in an 'amplification' system, modulating activity in sensory
nerve endings which are themselves the chemoreceptors.
Injection of acetylcholine in rabbits caused inhibition of
afferent chemoreceptor activity, in contrast to the stimulation
evoked in cats and dogs. In some experiments high doses of
acetylcholine evoked a slight excitation which preceded the inhibition.
This effect was probably brought about by an action on nicotinic
receptors since it was blocked by mecamylamine but is unlikely to be
of physiological significance. The muscarinic agonists methacholine
and bethanechol, but not the nicotinic agonist subery1dicholine,
also inhibited spontaneous chemoreceptor discharge indicating that
the inhibition was brought about by an action on muscarinic receptors.
The inhibition was blocked by atropine, although high doses were
required to produce this effect. The inhibition is unlikely to be
a consequence of a vascular action of acetylcholine since the vaso¬
dilator drugs sodium nitrite and sodium nitroprusside had little
effect on chemoreceptor activity. The inhibition evoked by acetyl¬
choline was not reduced by a-f1upenthixol and is, therefore, unlikely
to be secondary to dopamine release. It is proposed that acetylcholine
may act as a transmitter in an inhibitory efferent pathway to the
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B.P. - arterial blood pressure
cAMP - cyclic adenosine monophosphate
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The mammalian carotid body is an organ composed of groups of
specialised cells in a complex vascular network. It is a small
structure, usually located bilaterally in the vicinity of the
carotid bifurcation and attached either to the internal or the
external carotid arteries or to the bifurcation itself. A major
function of this organ is the generation of afferent sensory
discharge at a frequency dependent on the pC>2, pC02 and the pH of
the blood perfusing it. Important cardiovascular and respiratory
reflexes rely on the integrity of this 1chemoreceptor1 faculty, the
mechanism of which is unknown.
EARLY HISTORY
The history of the discovery of the carotid body and the
development of early ideas concerning its function have been reviewed
in great detail (Funke, 190A; Adams, 1958; Pick, 1959) and only a
general treatment of the subject will be given here.
Early anatomists generally considered the carotid body to be
a sympathetic ganglion. The macroscopic appearance of the organ and
its proximity to the superior cervical ganglion no doubt made this
seem a reasonable assumption. Studies of the microscopic structure
of the carotid body led to two new interpretations of the nature
of the organ. Lushka (1862) considered the carotid body to be a
glandular structure while Arnold (1865) believed it to be a simple
vascular glomerulus. A controversy developed which lasted for
several years until Stilling (1892) combined the two ideas by
suggesting that the carotid body was a highly vascular gland. Stilling
emphasised the similarities between this structure and the adrenals -
in particular the fact that some cells in the carotid body stained
brown with potassium dichromate as did cells in the adrenals. This
idea was taken up and developed by Kohn (1900) who suggested that
the chromaffine cells in the carotid body, i .e. those stained brown
with potassium dichromate, were derived embryologically from nervous
tissue. As a result of its supposed intimacy with the sympathetic
nervous system and the ability of some of its cells to exhibit the
chromaffine reaction, Kohn included the carotid body in his group of
so-called paraganglia and named it the 1paraganglion intercaroticum1.
Attempts to demonstrate functional similarities between the carotid
body and the adrenals were generally unsuccessful, however, and
several workers questioned the chromaffinity of carotid body cells
(see Adams, 1958).
The work of De Castro (1926) clearly showed that the predominant
innervation of the organ comes from the glossopharyngeal nerve and
not the sympathetic system, which was a serious blow to the notion
of the carotid body as a paragang1 ion. The concept was correspondingly
modified to allow for paragang1ionic cells derived from the para¬
sympathetic system which were non-chromaffine thus allowing for the
predominance of non-chromaffine cells in the carotid body and its
innervation by the glossopharyngeal nerve (for references see Adams,
1958) . By this time however, De Castro had convincingly shown that
the innervation of the carotid body was sensory and not motor as
had previously been supposed (De Castro, 1928). De Castro correctly
surmised that the carotid body is "un organe sensorial special dedie
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a percevoir quelques modifications qualitatives du sang, plutot qu'un
appareil destinee a recevoir les variations de la pression sanguine",
and so not only ascribed the carotid body a chemoreceptor function
but denied it the baroreceptor function which had been supposed by
others (Druner, 1925; Jacobvici, Nitzescu and Pop, 1928). This
contribution by De Castro marks a turning point in research in this
field.
Around the same time as De Castro published his classical
papers on the morphology and innervation of the carotid body, J.F.
and C. Heymans demonstrated chemoreceptor reflexes arising from the
cardio-aortic zone (Heymans, J.F. and C., 1927). Apparently unaware
of De Castro's work, C. Heymans and his co-workers investigated the
possibility that the carotid bifurcation region might also be a
reflexogenic zone. In a long series of papers starting in 1928
(for references, see Heymans and Neil, 1958), C. Heymans and his
associates characterized the reflexes arising from the carotid
bifurcation region and identified the chemoreceptor reflex with the
carotid body. This work provided substantial experimental evidence
for De Castro's postulate and provided a basis for modern research.
6
NEUROTRANSMITTERS IN THE CAROTID BODY
The carotid chemoreceptors respond to hypoxic, histoxic and
stagnant hypoxia but not to anaemic hypoxia (Comroe and Schmidt,
1938). The insensitivity of the chemoreceptors to anaemic hypoxia
suggests that their discharge frequency is dependent on carotid
body blood flow but not only because of the amount of O2 the blood
carries to them (see Torrance, 1968). This has led to the view
(Neil, 1951) that the blood supplies the chemoreceptors with something,
other than O2, a lack of which will cause them to discharge, e.g.
HCO3. Alternatively, the blood carries away some substance which
is produced in the carotid body and is concerned in the excitation
of sensory nerve endings. The latter possibility is of particular
importance to the present discussion since this suggests that chemical
transmission of sensory impulses might occur in the carotid body.
A number of putative neurotransmitters are present in the carotid
body. Two such substances - acetylcholine (ACh) and dopamine (DA) -
have been considered in this thesis, the purpose of which was to
investigate, us ing quantitative techniques where possible, the
contribution, if any, of these substances to the mechanism whereby
chemoreceptor activity is initiated in the carotid body.
Several reports have appeared in the literature which either
support or reject the idea that one or other of these substances
P.T.O.
acts as a chemical transmitter in the carotid body. As a background
to the experimental work performed in the present study, the relevant
literature for ACh and for DA and related catecholamines will be
reviewed in turn. Some experiments were performed with 5-hydroxy-
tryptamine (5_HT) and for completeness the relevant literature for
5~HT will also be reviewed.
ACETYLCHOLINE
Schweitzer and Wright (1938) first suggested the possibility
that ACh might act as a sensory transmitter in arterial chemoreceptors.
They showed that neostigmine (prostigmine), an anticholinesterase
drug, caused reflex stimulation of respiration in anaesthetized cats
by an action on peripheral chemoreceptors and found that the chemo-
receptor stimulant effects of ACh were intensified following
administration of either neostigmine or physostigmine (eserine).
They suggested that drugs or changes in the chemical composition of
the blood which stimulate the chemoreceptors might "produce their
effects by liberating ACh as a chemical intermediary". A similar
suggestion was made by Winder in 1938 (see Schmidt and Comroe, 19^0).
Results from several studies indicated that ACh caused a
reflex stimulation of respiration by an action on peripheral chemo¬
receptors (Heymans, Bouckaert and Handovsky, 1935; Heymans, Bouckaert,
Farber and Hsu, 1936; De Wispelaere, 1937; Philipot, 1937)- Prior
to this, however, a variety of nicotinic drugs other than ACh had
been shown to cause reflex stimulation of respiration by an action
on structures in the region of the carotid bifurcation (Heymans,
Bouckaert and Dautrebande, 1931a, 1931b; Owen and Gessel, 1931;
Zunz and Tremonti, 1931; Dautrebande, 1932; Mercier and Rizzo, 1932;
Dautrebande and Marechal, 1933; Mercier, 1933). Several different
authors noticed the close correlation between the nicotinic cholino¬
mimetic properties of drugs and their ability to stimulate carotid
chemoreceptors (Mercier, Rizzo and Delphaut, 193**; Anichkov, 1937;
Phillipot, 1937; Comroe and Schmidt, 1938). Derivatives of g-methyl
choline which exhibit muscarinic rather than nicotinic cholinomimetic
properties were found to be weak or inactive (Comroe and Starr,
1933; Phillipot, 1937; Comroe and Schmidt, 1938). De Wispelaere
(1937), however, reported that the acetyl ester (methacholine) and
ethyl ether of g-methyl choline were effective chemoreceptor stimulants.
Liljestrand and Zotterman (195*0 also found that methacholine was a
chemoreceptor stimulant. It has since been shown, however, that the
stimulant effects of methacholine are due to a weak nicotinic
cholinomimetic action of the drug (McQueen, 1978).
All the experiments described above were performed on
anaesthetized cats or dogs or on decerebrate cats. It is interesting
to note that Verzar, Szecsenyi-Nagy, Haffter and Wirz (1937) found
that intravenous (l.V.) injection of ACh, physostigmine, or
neostigmine caused inhibition of respiratory movement and diaphragmatic
tone in anaesthetized rabbits. This result, however, is generally
overlooked in later literature.
The development of a technique for recording afferent activity
in single or few fibre preparations of the carotid sinus nerve
(Bronk and Stella, 1932) provided a more direct method of monitoring
sensory activity arising from the carotid sinus region. Using this
technique Euler, Liljestrand and Zotterman (1939) showed that l.V.
injections of small doses of ammonia in anaesthetized cats caused a
temporary abolition of chemoreceptor discharge without affecting
baroreceptor discharge. In these experiments, chemoreceptor
stimulation produced by hypoxia, hypercapnia or I.V. injection of
potassium cyanide (KCN) was reduced by ammonia while the stimulant
effects of nicotine and lobeline were unaffected. Since ammonia
reduced the response to 'natural' stimulation but not that to
nicotine or lobeline, the authors reasoned that the latter substances
must act at a site central to the chemoreceptors proper. Pointing
out that chemoreceptor stimulation was brought about by "very much
the same agents as cause a discharge of post-gang1 ionic impulses
from a sympathetic ganglion", they suggested that such agents may
increase afferent chemoreceptor di scharge by an action on ganglion
cells intercalated in the afferent pathway whereas natural stimulants
such as hypoxia, hypercapnia and acid act by increasing the pH at the
chemoreceptors. The authors, however, offered no suggestion as to
the nature of the chemoreceptors and were unclear about the anatomical
relationship between ganglion cells and chemoreceptors. This
concept was later modified to allow for the possibility that ACh was
released from structures located in specific chemoreceptor cells and
acted directly on sensory nerve endings (Zotterman, 19^; Landgren,
Liljestrand and Zotterman, 1952).
The formulation of an hypothesis implicating ACh as a sensory
transmitter in the carotid body prompted several workers to investigate
whether or not this might be the case. The techniques employed in
such studies have been varied, however, and the results obtained
often equivocal. A number of criteria must be satisfied before a
substance proposed as a neurotransmitter can be accepted as such
(McLennan, 1963), i.e. the substance should mimic the effects of
physiological stimuli, the substance must be stored in the tissue
and released by physiological stimuli, there must be a mechanism
present for the synthesis of the proposed transmitter and for its
inactivation and drugs which block or enhance the effect of the
proposed transmitter should similarly modify the effects of
physiological stimuli. To what extent these criteria apply to
sensory mechanisms is uncertain. Nevertheless, it will be convenient
to discuss the literature in terms of these criteria.
Storage and release of acetylcholine
If chemical transmission of sensory impulses occurs in the
carotid body it would be desirable to measure tissue levels of
transmitter substances and to demonstrate their release during chemo-
receptor stimulation. The small size and awkward location of the
carotid body make this difficult, if not impossible, to do. This
problem was partly overcome by the development of a technique for
superfusing the carotid body with oxygenated Locke solution in
vitro (Eyzaguirre and Lewin, 1961). Using this technique, Eyzaguirre
and Koyano (1965c) studied the effects of electrical stimulation
of the cat carotid body on the frequency of chemoreceptor discharge
recorded from the sinus nerve. They found that stimulation of the
carotid body with repeated electrical impulses of short duration
On withdrawal of the stimulus there was an increase in discharge
above control levels which they termed post-stimulation activation
(PSA). The phenomenon of PSA was dependent on the flow rate of the
superfusate, being more marked at slower rates. They concluded that
PSA was due to accumulation of a chemical transmitter, released
during stimulation of the carotid body, which activated sensory
(0.1 msec) caused a depression of afferent chemoreceptor discharge.
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nerve ends on withdrawal of the electrical stimulus. They also
showed that the magnitude of the PSA was reduced after prolonged
exposure to gallamine or d-tubocurarine (D-TC) and, in some experi¬
ments, the duration of the PSA was increased by physostigmine. This
suggested to the authors that the transmitter was an ACh-like
substance. These authors obtained similar results using direct
current as the stimulus but in this case the response was dependent
on the polarity of the current. These latter experiments have been
criticized by Biscoe (1971) since, given a random geometry of cells
in the carotid body, the direct current should be equally effective
whatever the direction of current flow.
Eyzaguirre, Koyano and Taylor (1965) produced convincing
evidence for release of a chemical transmitter during chemoreceptor
stimulation using a modification of the above technique. Two
carotid bodies were superfused in series in a stream of oxygenated
Locke solution. Stimulation of the upstream preparation resulted
in increased chemoreceptor activity in the downstream preparation,
presumably as the result of overflow of a chemical transmitter.
These 'Loewi-type' experiments were repeated by Eyzaguirre and
Zapata (1968b) who further showed that the 1 Loewi-effect1 (i.e. the
increase in discharge in the downstream preparation following
stimulation of the upstream preparation) was depressed by hexamethoniurn,
blocked by either mecamylamine or acetylcholinesterase and enhanced
by physostigmine. The authors suggested that ACh was released during
stimulation of the upstream carotid body and caused excitation of
the downstream carotid body. Paintal (1969) has criticized these
results on the basis that there would be insufficient ACh available
in the carotid body to explain results in preparations which had not
been treated with anticholinesterases. Estimation of the ACh
content of the cat carotid body by bioassay yields a value of about
20 pg/g tissue (Eyzaguirre et al, 1965; Jones, 1975) which is
comparable to the ACh content of the superior cervical ganglion.
Nevertheless, since a cat carotid body weighs approximately 2 mg
(Jones, 1975), the ACh content of the whole organ, based on these
figures, is only of the order of bO ng. The threshold concentration
of ACh required to stimulate the cat carotid body in vitro is about
10 ng/ml (Eyzaguirre and Zapata, 1968b). Since the flow rates used
in the 'Loewi-type' experiments were 0.6-0.1 ml/min and the period
of stimulation was one minute, the upstream carotid body would have
to release a minimum of 15-25 per cent of its entire store of ACh
in order to achieve the threshold dose of ACh required to stimulate
the downstream preparation. This proportion would in fact be much
higher since some of the released ACh would be destroyed by
cholinesterase enzymes. Such a situation seems unlikely. Recently
Fidone, Weintraub and Stavinoha (1976) measured the ACh content of
the cat carotid body by pyrolysis gas chromatography/mass fragment-
ography and reported values only a tenth of those found by bioassay.
The authors suggested that this discrepancy may be due to the
presence in the organ of another substance with ACh-like biological
activity, e.g. carotidin (Christie, 1933). In any case it appears
unlikely that the Loewi effect is due solely to ACh release from
the upstream carotid body, although this may be a contributing
factor. It is possible that stimulation of the upstream preparation
increases its oxygen consumption thereby decreasing the oxygen
tension of the superfusate and consequently reducing the oxygen
supply to the downstream preparation. Such an idea has been
discussed by Eyzaguirre and Zapata (1968b) who considered it unlikely,
and in any case this explanation does not allow for the effects of
cholinergic blocking agents or of physostigmine. An alternative
explanation may be that ACh modulates the release of a second substance,
the identity of which is unknown, and it is this substance which is
responsible for the Loewi-effect. If this were the case, one might
expect drugs which affect the cholinergic system to modify responses
in Loewi-type experiments and also only small amounts of ACh may be
required to subserve such a role.
Metz (1969) measured the ACh content of the venous effluent
from the dog carotid body and found that the concentration of ACh
increased during hypoxia. In these experiments however, the venous
blood was allowed to accumulate on a layer of muscle and consequently
the source of the ACh in the samples could have been the muscle
rather than the carotid body. Jones (1975) repeated Metz's experi¬
ments using cats instead of dogs but could not confirm his results.
Enzyme distribution and activity
Several workers have studied the distribution and activity of
cho1inesterase enzymes in the carotid body. Hollinshead and Sawyer
(19^5) found that the cat carotid body contained high levels of non¬
specific cholinesterase but only low levels of acetylcholinesterase.
Since high levels of acetylcholinesterase normally occur in structures
where ACh acts as a chemical transmitter, these authors considered
it unlikely that ACh was a sensory transmitter in the carotid body.
Koelle (1950, 1951) and Ross (1957) also found a predominance of non¬
specific cholinesterase in the cat carotid body, thus confirming
the results of Hollinshead and Sawyer, and added that the cholinesterase
enzymes appeared to be localised in the type I (chief, glomus,
parenchymal, epithelioid) cells and surrounding nerve fibres.
Similar results have been reported for dog (Serafini-Fracassini and
Frasson, 1966) and human (Pryse-Davies, Dawson and Westbury, 196A)
carotid bodies. Fillenz and Woods (1966) found that in the rabbit
carotid body, acetylcholinesterase was localised in type I cells
while non-specific cholinesterase was located in nerve fibres and
bundles around the cells. Korkala and Waris (1977) found acetyl¬
cholinesterase in type I cells in the rat carotid body.
Biscoe and Silver (1966) studied the effect of selective
sectioning of the sinus nerve and the pre- and post-ganglionic
sympathetic nerve supply on the distribution of cholinesterases in
the cat carotid body. Their results suggested that both types of
cholinesterase enzyme were associated with postganglionic
sympathetic nerve fibres running from the superior cervical ganglion
to the carotid body.
Although the level of acetylcholinesterase and its distribution
is a useful indicator as to whether or not ACh is involved in
transmission at efferent synapses, this may not be the case for
afferent mechanisms. Lee (1968) suggested that a study of the choline
acetylase activity would give a better indication as to whether or
not cells are cholinergic. The level of choline acetylase in the
carotid body appears to be very low however. Hebb (1968) found that
choline acetylase activity in the cat carotid body was only 5 per
cent of the activity found in the superior cervical ganglion and
Jones (1975) h as reported similarly low levels. Jones, however,
pointed out that since there appears to be a predominance of non¬
specific cholinesterase in the carotid body and since this enzyme
hydrolyses ACh at a slower rate than does acetylcholinesterase, then
relatively low levels of choline acetylase may be adequate to maintain
stores of ACh in the carotid body.
Pharmacological studies
1. Anticho1inesterases
Following the example of Schweitzer and Wright (1938) several
groups of workers studied the effects of anticholinesterase drugs
on the chemoreceptors. Heymans, Bouckaert and Pannier (19*+^) found
that, in dogs, local application of physostigmine to the carotid
body enhanced the chemoreceptor response to ACh but not to lobeline.
This result was confirmed by Landgren, Liljestrand and Zotterman
(1952) who used cats. Kaindl and Werner (19^8) found that I.V.
injection of lew doses of physostigmine increased carotid chemo¬
receptor activity in the cat while higher doses abolished discharge.
These results were confirmed by Landgren et al (1952) who further
showed that injections of small doses of physostigmine, di-
isopropylf1uorophosphate (DFP) or tetraethy1pyrophosphate (TEPP) given
close-artertelly to the carotid body enhanced chemoreceptor discharge
during normoxia, hypoxia or hyperoxia. This latter result was
considered by the authors as evidence in favour of the idea that
ACh acts as a sensory transmitter in the carotid body.
Landgren et al also confirmed the observation of Schweitzer
and Wright (1938) that neostigmine has a stimulant effect on the
chemoreceptors although they point out that neostigmine may have a
direct cholinomimetic action as well as its better known anti¬
cholinesterase effects. This is an interesting point since
Schweitzer and Wright did not observe chemoreceptor stimulation
following administration of physostigmine and their suggestion that
ACh may act as a sensory transmitter was, as they themselves pointed
out, based on the assumption that the stimulant effects of neostigmine
were due to the anticholinesterase properties of the drug.
Liljestrand (1951, 1952) obtained further evidence in favour
of the 'ACh hypothesis', i.e. the idea that ACh acts as a sensory
transmitter in the carotid body. He found that local application
of physostigmine to the carotid body of the cat leads to an increased
respiratory response to hypoxia and also to hypercapnia.
Verbecke (I9^9a, 19^9b), however, showed that in the dog both
DFP and TEPP potentiate the response of the carotid chemoreceptors
to ACh but not to KCN. Atanackovic (1950, 1951) found that, in the
dog, tetramethoquinemethiodide, another anticholinesterase drug,
potentiated the chemoreceptor response to ACh but not to nicotine,
lobeline, sodium sulphide or KCN. A number of authors, also using
dogs, found that the dimethylcarbamate derivative of hydroxypheny1 -
trimethy1ammonium, a potent anticholinesterase drug, potentiated
the chemoreceptor response to ACh (Mazzella and Migliaro, 19^9;
Atanackovic and Da 1gaard-Mikkelson, 1950) but not to sodium sulphide
(Fernandez, 19^9)•
Douglas (195^) found, in contrast to Landgren et al (1952),
that injection or infusion of TEPP into the carotid sinus region
(species not specified) failed to produce any definite effect on the
normal physiological response to hypoxia, although the response to
injected ACh was greatly intensified. Heymans et al (1953) could
find no increase of respiration in dogs following local application
of physostigmine to the carotid body, unlike Liljestrand (1950, 1952)
and Landgren et al (1952). Heymans et al did, however, observe a
slight potentiation of responses to lobeline and KCN after
administration of physostigmine.
Daly (195^0 has suggested that anticholinesterase drugs may
increase chemoreceptor activity in the carotid body by an action on
the superior cervical ganglion rather than directly on the carotid
body itself. Anticholinesterase drugs might be expected to
facilitate ganglionic neurotransmission and consequently increase
sympathetic discharge to the carotid body. It is known that
stimulation of the sympathetic supply to the carotid body leads to
increased chemoreceptor activity in cats (Floyd and Neil, 1952).
From the above results it may be seen that those workers who found
that anticholinesterases enhance chemoreceptor activity and
potentiate responses to chemoreceptor stimuli used cats as their
experimental animal while those workers who found that this is not
the case worked mainly with dogs. The discrepancy between these
results might be explained in terms of a species difference if the
sympathetic supply to the carotid body in dogs has less influence
on chemoreceptor activity than the corresponding innervation in
cats. Unfortunately, the influence of the sympathetic nerves on
chemoreceptor activity in the dog does not seem to have been
inves tigated.
Eyzaguirre and Koyano (1965b) studied the effects of
physostigmine on chemoreceptor activity in the cat carotid body
in vitro - a preparation which is free of the influence of the
sympathetic nerves. They found that physostigmine caused an
increase in chemoreceptor activity only if the superfusate contained
CO2. Eyzaguirre and Zapata (1968a) obtained the same result using
a similar preparation, but in addition they found that the chemo-
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receptor response to acid was unaltered by physostigmine although
the response to ACh was potentiated. It may be that the stimulant
effects of physostigmine observed in these experiments were due to
an action of this substance on the sensory nerve endings themselves
rather than a consequence of blockade of cholinesterase enzymes.
The C02 dependence of the response is difficult to explain in either
case.
v
More recently, McQueen (1977) studied the effect of physo-
stigmine on chemoreceptor activity in the cat carotid body in situ.
He found that the chemoreceptor response to ACh was intensified
following I.V. or close-arterial injection of physostigmine while
responses to sodium cyanide (NaCN) or hypoxia were little affected.
In these experiments the influence of sympathetic activity from
the superior cervical ganglion on chemoreceptor discharge was
removed by section of the gang 1io-glomeru1ar sympathetic nerves.
2. Nicotinic blocking agents
If ACh acted as a sensory transmitter in the carotid body in
a manner analagous to cholinergic transmission in sympathetic
ganglia then nicotinic blocking drugs would be expected to block
the stimulation of afferent chemoreceptor activity produced by
hypoxia or cyanide, as well as that produced by ACh or nicotinic
stimulants.
Several reports have appeared concerning the effects of
nicotinic blocking drugs on the response of the carotid chemo-
receptors to various stimuli. Moe, Capo and Peralta (19^8) found
that in dogs continuous I.V. infusion of tetraethy1ammoniurn (TEA)
blocked the chemoreceptor response to ACh, nicotine and lobeline
but not that to hypoxia or cyanide. Other workers obtained similar
results to Moe et al using hexamethonium in anaesthetized cats
(Douglas, 1952) and TEA, hexamethonium and pendiomide in anaesthetized
cats and dogs (Dontas and Nickerson, 1956). Byck (1961) found that
in dogs hexamethonium blocked the chemoreceptor response to nicotine
but not to cyanide. Boelaert (19^8) reported that TEA had no effect
on the sensitivity of the carotid chemoreceptors in dogs but does not
mention the stimulus used in his experiments. Heymans, Delaunois,
Martini and Janssen (1953) found that in dogs, local application or
I.V. injection of TEA, hexamethonium, methanthe1ine or pendiomide
did not block the chemoreceptor stimulation produced by ACh, lobeline
or cyanide although, as Byck (1961) points out, the results presented
in their paper show a clear reduction in the response to lobeline
after administration of hexamethonium.
These observations presented a serious objection to the ACh
hypothesis. In contrast to the above results, however, Landgren et
al (1952) found that in cats, local injections of TEA or
decamethonium abolished the response of the carotid chemoreceptors
to ACh or lobeline and greatly reduced responses to hypoxia.
GolIwitzer-Meier and Witzleb (1953) found that local injections of
decamethonium, at a dose less than that required to produce respiratory
paralysis, had no effect on afferent chemoreceptor discharge but
pentamethonium inhibited the chemoreceptor response to ACh, lobeline
and hypoxia. More recently, Joels and Neil (1963) studied the
effects of hexamethonium on chemoreceptor activity in the vascularly
isolated carotid body in cats and found, in contrast to Douglas
(1952) , that this ganglion blocking drug not only reduced the chemo¬
receptor response to ACh but also that to hypoxia, 2,A-dinitrophenol
or cyanide. Joels and Neil, however, were not of the opinion that
ACh acts as a sensory transmitter in the carotid body.
It is worth noting that although Landgren et al (1952) observed
a reduction in the chemoreceptor response to hypoxia following
administration of TEA or decamethoniurn, the dose of blocking drug
required to produce this effect was much greater than the dose
required to block responses to ACh or lobeline. GolIwitzer-Meier and
Witzleb (1953) also gave high doses of blocking drug close-arterially.
Joels and Neil (1963) do not mention the dose of hexamethoniurn used
in their experiments. In order to explain this difference in
sensitivity, Landgren et al (1952) suggested, on the basis of the
morphological studies of De Castro (1951) that the functional
chemoreceptor synapses are i n trace 1 lul ar, i.e. the sensory nerve endings
form end plates within the cytoplasm of the glomus cells, and that
these sites are inaccessible to nicotinic blocking drugs. Moe et al
(19^8) made a similar suggestion. This implies, however, that both
nicotinic blocking drugs and cholinergic stimulants act at an
extrasynaptic site. In any case, it is now known that nerve endings
in the carotid body do not invade the cytoplasm of glomus cells
but terminate extrace11ularly (Biscoe, 1971).
ACh can stimulate a variety of sensory receptors and this
effect may be blocked by cholinergic blocking agents without
affecting the response of these receptors to normal physiological
stimulation (for references see Diamond, 1955). Douglas (195*0
drew attention to the similarities between stimulation of the carotid
chemoreceptors by ACh and the action of this substance on other
sensory receptors and suggested that this may be a non-specific
effect of ACh which is "altogether independent of normal transmission
mechanisms" in these structures.
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Eyzaguirre and Koyano (1965b) reinvestigated the effects of
nicotinic blocking agents on chemoreceptor activity in the cat
carotid body in vitro. They found that hexamethonium, D-TC and
gallamine stimulated chemoreceptor activity in small concentrations
and induced depression of sensory discharge in higher concentrations.
Responses to NaCN and anoxia were either unaffected or slightly
reduced by these drugs. The authors did not consider their results
inconsistent with the ACh hypothesis but suggested that ACh may
mediate chemoreceptor impulses during mild chemoreceptor stimulation
while more intense stimulation, such as that produced by NaCN or
anoxia, may involve a separate mechanism.
Eyzaguirre and Zapata (1968a) found that the response of the
cat carotid chemoreceptors in vitro to acid or to ACh was reduced by
hexamethonium, mecamylamine, or dihydro-0-erythroidine (DHE). The
response to anoxia (stoppage of flow) was depressed only by
mecamylamine and DHE. In a second paper (Eyzaguirre and Zapata,
1968b) it was reported that although the chemoreceptor response to
ACh was blocked by mecamylamine, hexamethonium and D-TC this blockade
could be overcome, at least partially, by higher doses of ACh.
Since the concentration of ACh in the synapse during strong chemo¬
receptor stimulation is likely to be high, they argued that this
might overcome the effect of the blocking agents. They further
argued that chemoreceptor synapses, which they considered as a
sensory nerve end apposed to a type I cell, might be fairly
inaccessible to quaternary cholinergic blocking agents such as
hexamethonium due to the presence of sustentacular (type II)
cells enveloping the type I cells. Mecamylamine being a simple
tertiary amine, more readily penetrates membranes and is therefore
more effective.
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Sampson (1971) found that I.V. injection of mecamylamine in
the anaesthetized cat blocked the carotid chemoreceptor response to
ACh but had no effect on responses to NaCN, 0.1 N HC1, or hypoxia.
Similar results were obtained by Nishi and Eyzaguirre (1971) who
given
found that injections of small doses of mecamy 1 amine^close-arterially
to the cat carotid body in situ blocked the chemoreceptor response
to ACh but not that to NaCN. The latter authors, however, also found
that larger doses of mecamylamine blocked the response to both ACh
and NaCN. They showed that the effects of large doses of mecamylamine
were not due to a local anaesthetic action and argued that the lack
of effectiveness of small doses of the drug in blocking the response
to NaCN was due to the high concentration of ACh released into the
synaptic cleft overcoming the blocking effects. These authors also
studied the effects of hexamethoniurn on the response of the carotid
chemoreceptors to NaCN and ACh but could find no consistent effect
on responses to either substance.
Eyzaguirre and Nishi (197*0 studied the effects of mecamylamine
on the 'mass receptor potential1 of the cat carotid chemoreceptors
in vivo. The mass receptor potential is taken as a cumulative
measure of the depolarization of sensory nerve endings in the carotid
body. They found that close-arterial administration of high doses
of mecamylamine blocked the 'receptor depolarization' produced by
either ACh or NaCN.
Thus a conflict of evidence has emerged which may be interpreted
in favour of the ACh hypothesis or against it. In the opinion of
McQueen (1977) this conflict has arisen as a result of subjective
interpretation, by various authors, of qualitative pharmacological
data, in terms of whether the authors did or did not support the ACh
hypothesis. McQueen (1977) quantified the effects of various blocking
agents by calculating the ratio of the dose of a stimulant required
to produce a given response before administration of a blocking
agent to the dose required to produce the same response after. When
sufficient data were available from the present experiments, this
method was used to quantify results presented in this thesis (see
Section II). Using this quantitative method, McQueen showed that
the chemoreceptor response to ACh was completely blocked by
mecamylamine while responses to hypoxia or NaCN were unaffected
even after high doses of mecamylamine given close-arterially. He
also found that a-bungarotoxin, a neuromuscular blocking agent,
caused a slight reduction in responses to both ACh and NaCN.
Data from experiments with nicotinic blocking agents do not
support the acetylcholine hypothesis. While it may be argued that
high synaptic concentrations of ACh can overcome the effects of
blocking agents, this does not occur at other cholinergic synapses
such as are found in sympathetic ganglia or at the neuromuscular
junction. The argument that the sensory synapse in the carotid
body is inaccessible to cholinergic blockers does not apply to
mecamylamine since this substance passes easily through membranes.
In those experiments where mecamylamine was found to be an effective
blocker of chemosensory activity, very high doses of the drug were
required and under these conditions, non-specific actions may have
been responsible for the observed effects.
3. Atropine
Stimulation of carotid chemoreceptors in cats and dogs by ACh
has been shown to be mediated by nicotinic receptors (see above).
Atropine is a drug which is useful mainly for its ability to block
muscarinic cholinergic effects although it also has nicotinic
blocking properties at high doses (Ambache, 1955). Nevertheless,
atropine has been used by several groups of workers to investigate
whether or not ACh acts as a sensory transmitter in the carotid body.
The earliest reports available in the literature showed that
large I.V. doses of atropine had no significant effect on the
respiratory response to ACh (Schweitzer and Wright, 1938; Euler,
Liljestrand and Zotterman, 1939; Schmidt and Comroe, 19^0).
Liljestrand (1952), however, found that local application of a one
per cent solution of atropine sulphate (approximately 1.A x 10"3
mol./l) to the carotid body of the cat decreased the response of the
carotid chemoreceptors to ACh, lobeline, hypoxia or hypercapnia.
Anichkov (1953) similarly found that atropine reduced the chemo-
receptor response to ACh. Heymans et al (1953), however, showed that
these results could be adequately explained by the local anaesthetic
action of atropine.
Eyzaguirre and Koyano (1965b) found that atropine reduced
spontaneous chemoreceptor activity in the cat carotid body in vitro
but had little effect on the response to anoxia or NaCN. Eyzaguirre
and Zapata (1968a) showed that atropine reduced the chemoreceptor
response to acid in vitro. The dose of atropine used was of the
order of 10~5 - 10 ^ mol./l. In a second paper in the same series
(Eyzaguirre and Zapata, 1968b), they showed that doses of atropine
of the order of 10~6 - 10~5 mol./l reduced the response of the carotid
chemoreceptors to ACh. At these doses, however, it is quite possible
that the observed effects were due to the nicotinic blocking action
of atropine or to local anaesthetic effects. Nishi and Eyzaguirre
(1970, 1971), however, showed that atropine blocked the response of
cat carotid chemoreceptors in vivo to NaCN and ACh and that this
was not due to a local anaesthetic action of the drug. Eyzaguirre
and Nishi (197*0 showed that atropine blocked 'receptor depolarization1
induced by ACh or NaCN. In a quantitative study of the effects of
blocking drugs on chemoreceptor responses, McQueen (1977) found that
atropine caused a slight reduction in responses to both NaCN and
ACh.
Since stimulation of the chemoreceptors by ACh appears to be
mediated solely by nicotinic receptors (McQueen, 197*0 , presumably
blockade of the stimulant effects of ACh by atropine is due to a
nicotinic blocking action. In any case, it is not clear from the
above studies whether or not atropine, in doses below those expected
to produce local anaesthetic effects, has any effect on normal
chemoreceptor transmission mechanisms.
*K Drugs acting presynaptica11y
Another pharmacological approach to the study of possible
cholinergic mechanisms in the carotid body has involved the use of
drugs which affect the synthesis or release of ACh. Hemicho1inium-3
(HC-3) is a drug which is thought to act by preventing the uptake
of choline into cholinergic neurons and thereby limiting the
synthesis of ACh. Eyzaguirre and Zapata (1968a) found that the
response of the cat carotid chemoreceptors in vitro to NaCN was
reduced after prolonged exposure to HC-3 while the response to ACh
was unaffected. They also showed that the NaCN response could be
partially restored by washing the preparation with Locke solution
containing choline. Similar results were obtained using HC-3
in vivo (Nishi and Eyzaguirre, 1971; Eyzaguirre and Nishi, 197^0-
McQueen (1977) also studied the effects of HC-3 in vivo. He found
that although responses to NaCN were less intense following
administration of HC-3, the duration of the response was increased,
the net effect being a potentiation. Responsesto ACh were little
affected.
g-Bungarotoxin is a substance reputed to act by preventing
the release of ACh at the neuromuscular junction (Chang, Chen and
Lee, 1973). McQueen (1977) found that this drug had very little
effect on the response of cat carotid chemoreceptors to NaCN but
slightly depressed responses to ACh. This result does not support
the cholinergic hypothesis although it is possible, if ACh is a
sensory transmitter in the carotid body, that the mechanism for
ACh release in the carotid body differs from that at the neuro¬
muscular junction.
The results discussed above from experiments with HC-3 might
be interpreted in favour of the ACh hypothesis although, as was the
case for experiments with postsynaptic blockers and anticholinesterases,
they are equivocal and far from conclusive.
The ACh hypothesis is clearly a controversial issue. Although
several studies, employing various techniques, have been made in an
attempt to reconcile the controversy it is still uncertain whether
or not ACh is a sensory transmitter in the carotid body. The
weight of evidence, however, seems to be against the supposition.
In addition to its proposed role as a sensory transmitter, ACh has
also been suggested as a possible transmitter in an inhibitory
efferent pathway which runs in the sinus nerve (Neil and O'Regan,
1971). Th i s proposal, however, also requires ratification.
26
CATECHOLAMINES
Electron-microscopic studies of the fine structure of the
carotid body have shown that the type I cells contain numerous dense-
cored vesicles (DCVs) throughout their cytoplasm (Lever and Boyd,
1957; Garner and Duncan, 1958; Hoffman and Birrel, 1958). It has
been suggested that these DCVs represent a store of phenolic amines
which might be involved in the initiation of chemoreceptor impulses
(Lever, Lewis and Boyd, 1959).
Evidence from fluorescence microscopic and autoradiographic
studies of catecholamines in the carotid body strongly supports the
idea that these substances are stored in DCVs in type I cells (see
Biscoe, 1971). Results from quantitative studies of the catecholamine
content of the carotid body have been equivocal (see Table 1.1).
Most authors agree that DA is the most abundant catecholamine in
the carotid body with about 25 - 75 per cent as much noradrenaline
(NA) and smaller amounts of adrenaline (ADR) also present. Recently,
however, Mills, Smith, Slotkin and Breese (1978) found four to five
times as much NA as DA in the cat carotid body and have contested
the idea that DA is the most abundant of these two catecholamines
in the carotid body of this species.
It is possible that the NA content of the carotid body is
stored in sympathetic nerve endings rather than in type I cells.
Chronic sympathectomy (3 - 7 days), however, has little effect on the
amine content (Zapata, Hess, Bliss and Eyzaguirre, 1969) or on
dopamine-g-hydroxy1ase activity (Morgado, Llados and Zapata, 1976)
of the cat carotid body, although in this species the carotid body
receives a post-gang 1 ionic sympathetic innervation which is thought
to be noradrenergic (O'Regan, 1977). Presumably, in the cat, the
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contribution of dopamine-g-hydroxy 1 ase activity and NA content of
sympathetic nerve fibres to that of the whole organ is small. In the
rat, chronic sympathectomy (5-7 days) reduces the NA content of the
carotid body by about 50 per cent (Hanbauer and Hellstrom, 1978).
It seems that the NA content of the sympathetic nerve endings does not
account for all the NA stored in the carotid body. It is therefore
possible that both NA and DA are stored in type I cells although
there may be species differences in the ratio of NA to DA stored in
these structures.
It is not clear whether NA and DA are stored in the same DCV,
in separate DCVs in the same cell, or in separate DCVs in separate
cells. Some authors have been able to recognise at least two
varieties of type I cell on the basis of the electron density of their
cytoplasm (Lever, Lewis and Boyd, 1959; Hoglund, 1967; Grimley and
Glenner, 1968; Chen, Yates and Duncan, 1969; Morita, Chiocchio and
Tramezzani, 1969; Abbot, Daly and Howe, 1972) while others have
made a similar distinction based on the size and electron density of
DCVs in different cells (Kobayashi, 1968, 1975; Morita et al, 1969;
McDonald and Mitchell, 1975; Hellstrom, 1975). It may be that
different amines are stored in separate DCVs, and possibly separate
cells, but while the above results are suggestive, there is no
conclusive evidence to support such a notion.
The finding that catecholamines are stored in the carotid body
raises three important questions:
a) Are these substances involved in the mechanism of generation
of afferent chemoreceptor activity?
b) Are these substances released from the carotid body and if
so, under what conditions?
c) Does the carotid body have a second function which is either
related to or independent of its role in arterial chemo-
reception, e.g. as an organ of internal secretion?
The notion that the carotid body acts as an organ of internal
secretion has received limited support (see Karnauchow, 1965; Chen
et al, 1969; Pearse, 1969; Kobayashi, 1971 , 1975) but is not yet
generally accepted. The conditions under which catecholamines are
released in the carotid body and the possible significance of these
substances in the chemoreceptive mechanism are, however, subjects
which have received a great deal of attention, especially in recent
years, and are of particular relevance to the present discussion.
Pharmacological effects
Several studies have been made of the effects of catecholamines
on chemoreceptor activity in the carotid body. Witzleb (1953) found
that local application of either ADR or NA to the carotid body in
cats caused no detectable change in chemoreceptor activity.
Kuznetsov and Belen'kii (see Anichkov and Belen'kii, 1963), however,
showed that ADR, perfused into the isolated carotid artery, induced
mild respiratory excitation in decerebrate cats. Similar results
were obtained by Lee (see Torrance, 1968) who attributed this effect
to a reduction in carotid body blood flow secondary to vasoconstriction.
Joels and Neil (1968) found that ADR and NA, but not DA, caused an
increase in chemoreceptor activity in the perfused cat carotid body
which they also attributed to vascular effects. Studies of the
effects of NA and ADR on chemoreceptor activity in the superfused
cat carotid body in vitro, a preparation in which vascular effects
are precluded, showed that these substances do not stimulate chemo-
receptor activity but, if anything, cause a depression of activity
(Eyzaguirre and Koyano, 1965b).
Experiments in dogs yielded quite different results. Byck
(1957) found that in this species a variety of sympathomimetic amines
including NA and DA, caused reflex hyperpnoea by an action on
carotid chemoreceptors. Jacobs and Comroe (1968) confirmed Byck's
findings and showed that on a molar basis, DA was three times more
potent than NA as a chemoreceptor stimulant. The short latency of
the response suggested to the authors that this was likely to be
due to a direct action of catecholamines on chemoreceptor elements
in the carotid body rather than a response to reduced blood flow
brought about by vascular changes. They also found that chemorecepto
stimulation produced by NaCN or by catecholamines was reduced by
phentolamine, an a-adrenergic antagonist, although this effect was
not consistent. Propranolol, a 3-adrenergic antagonist, had no
apparent effect on the response. Heymans, De Schaepdryver and De
VIeeschhouwer (1968) found that neither a-blockade with phenoxy-
benzamine (PBA) nor B-blockade with propranolol had any effect on
chemoreceptor responses to NaCN or hypoxia in dogs. The latter
authors, however, did not study the effect of these blocking drugs
on the chemoreceptor response to catecholamines.
As well as their work on dogs, Jacobs and Comroe (1968)
reported preliminary results from experiments on cats which suggested
that DA did not stimulate carotid chemoreceptor activity in this
species. This observation was confirmed in a subsequent study
(Black, Comroe and Jacobs, 1972) in which it was shown that DA
depressed chemoreceptor activity in cats. NA was found to cause a
slight depression of chemoreceptor activity in some experiments but
had no consistent effect in this species. Similar results were
reported by Sampson (1972) using anaesthetized cats, although this
author obtained more consistent inhibitory responses to NA than did
Black et al (1972), and in addition found that ADR inhibited chemo-
receptor activity. It was also found that inhibitory responses to
NA and ADR were followed by a period of increased activity, an
effect which the author attributed to vasoconstriction.
The above evidence indicates that the effects of catecholamines
on carotid chemoreceptor activity are species dependent. DA is
found to depress chemoreceptor activity in the cat in vivo while NA
and ADR cause a stimulation of activity which is probably due to
vasoconstriction and may be preceded by a brief inhibitory effect.
Both DA and NA stimulate chemoreceptor activity in the dog by a
mechanism as yet unknown.
Results from studies of the effects of catecholamines on
carotid chemoreceptor activity in vitro have been equivocal. In
contrast to the results of Eyzaguirre and Koyano (1965b) discussed
above, Biscoe (1965) found that NA, ADR and the B-adrenergic
agonist isoprenaline all stimulated chemoreceptor activity in the
superfused cat carotid body in vitro and that the chemoreceptor
response to these substances as well as that to ACh or hypoxia was
blocked by the B-adrenergic antagonists nethalide and dichloro-
isoprenaline (DC I). Zapata, Hess, Bliss and Eyzaguirre (1969),
however, using a similar preparation to Biscoe, found that catecholamines
neither excited nor depressed chemoreceptor activity and that the
inhibitory effects of DC I were due to the local anaesthetic
properties of this drug rather than its B-receptor blocking action.
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Zapata (1975) reinvestigated the effects of DA and NA on
chemoreceptor activity in vitro. In agreement with his earlier
study (Zapata, Hess, Bliss and Eyzaguirre, 1969), the author
reported that NA did not affect chemoreceptor activity. In contrast
to previous results, DA was found to cause a transient depression of
chemoreceptor activity. Following repeated injections of DA
administered at short intervals, the inhibitory response was changed
to a biphasic response, i.e. an initial inhibitory effect followed by
stimulation of activity. Successive injections of DA ultimately
resulted in a pure excitatory response. DL-Dopa, a precursor to
DA in the synthetic pathway, was also found to produce excitatory
effects. The inhibitory effects of DA but not its excitatory
effects were blocked by spiroperidol, a DA receptor antagonist, or
by dibenamine, an a-adrenergic antagonist.
It has also been found that DA-induced inhibition of chemoreceptor
activity in the cat carotid body in situ is blocked by a-adrenergic
blocking agents (Sampson, 1972, 1975; Sampson, Aminoff, Jaffe and
Vidruk, 1976b; Mitchell and McDonald, 1975) although some workers
have found that this is not the case (Nishi, 1977; Zapata, 1977;
Llados and Zapata, 1978b). There is, however, general agreement in
the literature that DA receptor blocking agents of the neuroleptic
type can block the inhibitory effects of exogenously administered
DA on chemoreceptor activity in the cat carotid body (Zapata, 1975,
1977; Nishi, 1977; Llados and Zapata, 1978a).
There is evidence to suggest that DA may influence responses
to chemoreceptor stimuli. Zapata (1975) has shown in the cat
carotid body in vitro that in preparations in which DA evokes
inhibition of chemoreceptor activity, the inhibitory effect of DA
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may partially or totally counteract the chemoreceptor stimulating
effects of simultaneously applied ACh or NaCN, while in preparations
in which DA has excitatory effects the stimulation produced by
simultaneously applied ACh or NaCN is additive. Nishi (1977) has
shown in the cat carotid body in situ that the inhibitory effects
of DA may counteract the stimulant effects of simultaneously applied
NaCN or of hypoxia.
Attempts have been made to study the importance of endogenous
catecholamines in the carotid body by observing the effects of
pharmacological depletion of catecholamines, using reserpine or
6-hydroxydopamine (6-OHDA), on chemoreceptor activity. It has been
variously reported that prolonged exposure to reserpine in cats
reduces chemoreceptor responses to ACh (Koppanyi and Cowan, 1962)
or to hypoxia (Cowan and Greene, 1965), completely abolishes chemo¬
receptor activity (Comroe, 1964) or has no effect on chemoreceptor
activity or responsiveness (Zapata, Hess, Bliss and Eyzaguirre, 1969;
Nishi, 1975). Attempts to deplete the carotid body of its catecholamine
content with 6-OHDA have met with varying degrees of success. It
has been found that chronic treatment with 6-OHDA causes a reduction
in catecholamine fluorescence in the rat carotid body (Lassman and
Bock, 1972; Hess, 1975) but other workers have found that neither
catecholamine fluorescence (Hansen and Ord, 1978) nor catecholamine
content (Hellstrom, 1977) are affected by chronic exposure to 6-OHDA
in this species. Zuazo and Zapata (1978) found that carotid chemo¬
receptor responses to NaCN and hypoxia in the cat were unchanged
up to seven hours after intracarotid injections of 6-OHDA but made
no estimate of the degree of catecho1 amine depletion, if any,
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produced by 6-OHDA in these experiments. Murphy and O'Regan (1977)
found that the chemoreceptor response to mild hypoxia in cats was
slightly potentiated 10-12 min after administration of 6-OHDA but
did not investigate the effects of chronic exposure to the drug and,
like Zuazo and Zapata, made no estimate of the degree of catecholamine
depletion produced by 6-OHDA in their experiments.
Clearly, exogenously applied catecholamines can influence
chemoreceptor activity although the effects of catecholamines,
especially DA, are complex. Results from studies of the effects
of pharmacological depletion of catecholamines on chemoreceptor
activity in the carotid body allow no clear conclusion as to the
role, if any, of catecholamines in the mechanism of generation of
afferent chemoreceptor activity. If, however, catecholamines do
play a role as chemical transmitters in the carotid body then
presumably they must be released from type I cells in order to have
any effect on chemoreceptor activity in the normally functioning
carotid body. It is important therefore to ascertain the conditions
under which catecholamines are released from type I cells.
Release of catecholamines
Several studies of the effects of hypoxia on the number and
density of DCVs in the type I cells of the carotid body have appeared
in the literature. Results from such studies have, however, been
inconclusive. it has been reported that the number of DCVs in type I
cells following hypoxia is either unchanged (Zapata, Hess, Bliss
and Eyzaguirre, 1969) or increased (Al-Lami and Murray, 1968) in the
cat, unchanged in the hamster (Chen et al, 1969), increased in the
rabbit (Moller, Mollgard and Sorensen, 197*0 and reduced in the rat
(Hoffman and Birrel, 1958; Blumcke, Rode and Niedorf, 1967). Results
such as these are difficult to interpret since the number of DCVs
may not reflect the amine content of the cell and a reduced number
of DCVs may be produced by pathological changes rather than a
specific effect of hypoxia.
Zapata, Hess, Bliss and Eyzaguirre (1969) measured the amounts
of DA, NA and ADR in the cat carotid body before and after chemo-
receptor stimulation by hypoxia both in vivo and in vitro (control
values are given in Table 1.1) but found no obvious difference in the
amounts of these substances under the different experimental conditions.
Mills and Slotkin (1975), however, found that the total NA plus ADR
content of the cat carotid body (control values are given in Table 1.1)
was reduced following hypoxia and that the extent of the reduction
was dependent on the magnitude and the duration of the hypoxic
stimulus. The effect of hypoxia on DA levels was not measured in
the latter study.
Hellstrom, Hanbauer and Costa (1976) measured catecholamine
levels in the rat carotid body under a variety of different experi¬
mental conditions using a highly sensitive gas chromatographic - mass
spectrometric assay method. They found that there was a significant
reduction in the DA content but no change in the NA content of
carotid bodies removed from rats exposed to hypoxia. This result
was obtained whether or not the carotid sinus nerve was intact. They
also found that DA depletion by hypoxia was partially relieved by
administration of atropine and that the muscarinic agonist metha-
choline, like hypoxia, caused a preferential reduction in DA levels.
These observations suggested to the authors that DA is released from
type I cells during hypoxia and that DA release may be triggered
by ACh acting on muscarinic receptors located on the membrane of the
type I cells. In this scheme ACh would be released from "intrinsic
cholinergic neurons" or from the type I cells themselves.
The finding that the DA content of the rat carotid body, but
not its NA content, is reduced by hypoxia has been confirmed by
Hanbauer and Hellstrom (1978) who further showed that this effect
is not due to a change in DA turnover and is best explained by an
increased release of DA. There is also evidence to suggest that DA
is released during chemoreceptor stimulation in the rabbit carotid
body (Gonzalez and Fidone, 1977)-
Although the NA content of the rat carotid body is not reduced
by hypoxia, it has been found that chronic section of the sinus
nerve causes an increase in the NA content of the carotid body in
this species (Hanbauer and Hellstrom, 1978). Other evidence also
suggests that the sinus nerve may have an influence on catecholamine
levels in the carotid body. Mills and Slotkin (1975) found that
cutting the sinus nerve attenuated the depletion of NA and ADR
produced in the cat carotid body by hypoxia (see above). It has
been found that electrical stimulation of the sinus nerve causes
depletion of DCVs in type I cells in the hamster carotid body and
that this effect is blocked by atropine (Yates, Chen and Duncan,1970).
Few conclusions can be drawn from this latter result since the dose
of atropine used in these experiments was 200 mg/kg, and at this
dose pronounced anaesthetic effects would be expected. Sampson,
Nicolayson and Jaffe (1975) reported that electrical stimulation of
the peripheral cut end of the sinus nerve resulted in an increase
in the intensity of forma 1dehyde-induced fluorescence intensity in
type I cells of the carotid body of normal cats and a reduction in
the fluorescence intensity in type I cells in cats pretreated with
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MK-486, a dopamine-g-hydroxy1ase inhibitor. The authors interpreted
these results as evidence suggesting that efferent discharge in the
sinus nerve stimulates the synthesis and release of catecholamines.
Role of catecholamines - hypotheses
A number of theories have been advanced in which DA is
considered to play an important role in the mechanism of chemo-
reception. Osborne and Butler (1975) have proposed a model which
suggests that DA is released from type I cells in the carotid body
and acts to inhibit activity in otherwise spontaneously active
sensory nerve endings- when the chemoreceptors are stimulated DA
secretion is reduced and consequently afferent nerve activity
increases. This hypothesis also suggests that a chemical trans¬
mitter, possibly ACh, is released from the sensory nerve endings and
acts on type I cells to further reduce DA secretion thus constituting
a positive feedback loop (see Figure 1.1).
FIGURE 1.1: Schematic flow diagram of carotid body chemoreceptor
during hypoxia (upper, dotted lines) and normoxia
(lower, solid lines) according to the hypothesis "of
Osborne and Butler (1975) (Taken from original paper -
Nature 254 pp. 701-703)
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The central feature of Osborne and Butler's hypothesis is that
increased chemosensory activity arises as a result of disinhibition
of spontaneously active nerve endings rather than excitation of
otherwise quiescent nerve endings. Krammer (1978) introduced an
hypothesis based on a similar idea. This author envisages a model
in which there are two varieties of type I cell - DA-containing
type IA cells and NA-containing type IB cells. It is suggested that
DA is continually released from type IA cells and acts on otherwise
active sensory nerve endings to suppress activity. When the chemo-
receptors are stimulated, NA is released from type IB cells to decrease
DA secretion and consequently cause disinhibition of afferent nerve
activity. Both Osborne and Butler's and Krammer's hypotheses
suggest that DA release decreases during chemoreceptor stimulation.
Evidence available at present, however, suggests that the DA content
of the carotid body is either unchanged or decreased by hypoxia
(see above) which does not support such an idea.
McDonald and Mitchell (1975) have proposed an alternative
hypothesis. According to them, the sensory nerve ending is itself
the chemoreceptor while type I cells are dopaminergic interneurons
in a local control mechanism. It is suggested that afferent nerve
endings are connected with type I cells by reciprocal synapses, i.e.
nerve ending and type I cell are both presynaptic and postsynaptic
to each other. Sensory nerve endings, when stimulated, release a
chemical transmitter which acts to promote DA release from type I
cells. DA, released in this way, then acts on the sensory nerve
ending to inhibit sensory activity thus forming a negative feedback
control system. According to this hypothesis, DA release increases
during chemoreceptor stimulation. Zapata (1975) has also suggested
that endogenous DA may modulate afferent chemoreceptor activity.
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The hypotheses discussed above suggest possible roles for
catecholamines, especially DA, in the mechanism of generation of
afferent chemoreceptor activity. The multiplicity of these hypotheses
is in some ways a measure of the difficulty involved in establishing
a role for catecholamines in the mechanism of carotid chemoreception.
The mammalian carotid body contains sufficient amounts of catechol amines
for them to subserve a role as chemical transmitters in this organ,
but if such a role exists it remains unknown at present.
5-HYDR0XYTRYPTAM1NE
In a histological study of human carotid body tumour, Costero
and Barosso-Miguel (1961) identified granule-containing cells,
distinct from type I cells, which they suggested might contain 5~HT.
No evidence for the presence of 5~HT in human carotid body tumours
was found in subsequent studies by fluorescence histochemistry
(Niemi and Ojala, 1964) or paper chromatography (Pryse-Davies, Dawson
and Westbury, 1964). Hamberger, Ritzen and Wersall (1966), however,
identified 5_HT containing cells in the normal human carotid body
by fluorescence microspectrophotometry.
Quantitative estimations of 5~HT content have been made for
cat and rat carotid bodies - the values obtained are shown in Table
1.2. Values obtained for DA content in these studies are also
included in the table for comparison.
There is evidence to suggest that 5~HT, like DA or NA, is
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stored in DCVs in type I cells in the carotid body in cats (Chiocchio
et al, 1967) and hamsters (Chen et al, 1969). Gronblad and Korkala
(1977) have suggested, however, that 5-HT is stored in interlobular
mast cells in the rat carotid body. Chiocchio et al (1967)
postulated that 5-HT might act as a chemical transmitter in the carotid
body.
TABLE 1.2: Summary of results from quantitative studies of 5~HT
"content in the carotid body (c.b.). Values for DA content
obtained in the same experiment are included for comparison
- see a 1 so Tab 1e 1.1
Author Date Species 5~HT DA Units
Ch i occh i o et al 1967 cat 6.9±0.3 4. 4 ± 0. *+ ug/g
Chiocchio et al 1971 cat 10" 260 ng/c.b.
Hellstrom 1977 rat 7-5 ± 1-4 28.9± 7.9 pmol/pair c.b.
* estimated value assuming cat c.b. weighs approximately 2 mg
(Jones, 1975).
Pharmacological studies
I.V. injection of 5"HT stimulates respiration in the dog
(Page, 1952). This phenomenon has been attributed to an action of
5-HT on carotid chemoreceptors (Douglas and Toh, 1952; Comroe and
Mortimer, 196*0, an action of 5~HT on the C.N.S. (Heymans and
Heuva1-Heymans, 1953), or to stimulation of cardio-pulmonary relfexes
(Schneider and Yonkman, 195*+). Schneider and Yonkman (195*+) found
that the effects of 5_HT on respiration were species-dependent, the
normal effect in dogs and rabbits being excitation of respiration
while in cats 5"HT has a bi phasic effect, i,e. an initial inhibition
followed by excitation of respiration. Ginzell and Kattegoda (195*+)
also found that the respiratory response to I.V. injection of 5-HT
in the cat consisted of an initial inhibitory and a secondary
excitatory phase and showed that the secondary excitation was
abolished by sinus nerve section.
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McCubbin, Green, Salmoiraghi and Page (1956) recorded
afferent chemoreceptor activity in the sinus nerve of the dog. They
found that intracarotid injection of 5"HT caused a marked stimulation
of chemoreceptor activity which suggests that the respiratory
stimulant effects of 5-HT in this species are due, at least in part,
to stimulation of carotid chemoreceptors. This view is supported by
the results of Black et al (1972) who found that 5~HT consistently
produced immediate hyperpnoea in dogs when the carotid sinus nerve
was intact but not when it was cut.
Studies of the effects of 5-HT on afferent chemoreceptor
activity in cats have yielded quite different results. Eyzaguirre
and Koyano (1965b) found that 5~HT normally caused a slight
depression of chemoreceptor activity in the cat carotid body in
vitro although in one experiment 5~HT was found to stimulate
activity. Black et al (1972) found that the effects of 5~HT on
chemoreceptor activity in the cat carotid body in situ were varied,
stimulation of activity occurring in some experiments while in others
5-HT caused depression of activity, or lacked effect.
More recently, Nishi (1975) reinvestigated the effects of
5~HT and also studied the effects of some antagonists of 5-HT on
chemoreceptor activity in the cat carotid body in situ. He found
that 5~HT caused a brief intense stimulation of chemoreceptor
activity followed by a depression or blockade of activity lasting
several seconds. Repeated injections of 5-HT at short intervals
led to progressively smaller responses, i.e. the preparation became
desensitized to the effects of 5-HT. This might be the reason why
previous workers found that chemoreceptor responses to 5"HT were
inconsistent in this species. Nishi also found that the effects of
5-HT on carotid sinus baroreceptor activity were qualitatively
similar to its effects on chemoreceptor activity which led him to
suggest that these effects were due to a non-specific action of
5~HT on sensory nerve endings and that 5"HT was unlikely to act as
a chemical transmitter in the carotid body. Lysergic acid
diethylamide (LSD), methysergide and gramine, which, although not
specific, are all antagonists of 5-HT, were found to block the
vascular response to 5-HT but not the chemoreceptor response which
suggests that the chemoreceptor response and the vascular response
are mediated by different receptor types. Low doses of LSD were
found to cause a marked stimulation of chemoreceptor activity.
The author, however, offers no explanation for this latter phenomenon.
It is not known whether or not 5~HT is released from cells in
the carotid body during chemoreceptor stimulation. The distribution
of enzymes concerned in 5~HT metabolism has apparently not been
studied although the carotid body is known to contain monoamineoxidase
(MAO) (Lee and Mattenheimer, 1964) which is an important enzyme in
the catabolism of monoamines such as 5-HT. There is, therefore,
little evidence in favour of the idea that 5-HT acts as a chemical
transmitter of sensory impulses in the carotid body. Nevertheless,
the evidence available at the present time suggests that the carotid
body contains small amounts of 5~HT and administration of 5"HT can
influence chemoreceptor activity. The possibility that endogenous
5~HT has a physiological role in the initiation or modulation of





Experiments were performed on anaesthetized cats or rabbits
(details of numbers, sex, weight etc of cats and rabbits are given
in Sectionslll and IV respectively). The method used was essentially
the same for experiments on animals of either species differing only
in some details as indicated below.
Anaesthesia
Cats were anaesthetized with sodium pentobarbitone (42 mg/kg
I.P.), supplemented every 1-2 hr during the experiment by 10% of
the initial dose administered I.V. Rabbits were anaesthetized with
sodium pentobarbitone (30 - 50 mg/kg) or urethane (400 mg/kg) and
a-chloralose (6 mg/kg of a 1% solution in 0.9% saline), administered
through an ear vein, with supplements as required.
Gene ra1
A cannula was inserted into the trachea low in the neck. Both
femoral arteries were cannulated, one catheter being connected to a
B.P. transducer (Bell and Howell, 4-442) and the other used for
withdrawing blood samples for subsequent gas analysis. The signal
from the transducer was displayed on a pen-recorder (Devices, M4) and
recorded on one channel of an FM tape recorder (Tandberg, 100;
frequency response d.c. to 1250 Hz). Arterial blood pH, p02 and
pCO2 were measured at hourly intervals using a Radiometer gas
monitor (BMS 3 with PHM 71 meter). A femoral vein was cannulated
and used for drug administration. Rectal temperature was monitored
and maintained at 38±0.5°C for cats, 39±0.5°C for rabbits, by a
heating pad.
The carotid bifurcation region was exposed and dissected free
of surrounding tissue. A cannula was inserted into the lingual
45
artery until its tip lay in the common carotid artery 1.5" 2.0 cm
caudal to the carotid bifurcation. This cannula was used for
intracarotid (l.C.) administration of drugs to the carotid body.
Figures 2.IB and 2.1A show diagrams of the gross anatomy in the
carotid bifurcation region of the cat and rabbit respectively.
Animals were artificially ventilated with room air by a
respiratory pump (S.R.I.), operating at 38 strokes/min for rabbits
or 25 strokes/min for cats, and gallamine triethiodide (3 mg/kg I.V.)
administered to paralyse spontaneous respiration. This treatment
also prevented muscle contraction, either spontaneous or in response
to close-arterial injections of ACh, from moving the nerve on the
recording electrodes.
In most experiments, end-tidal CO2 was continuously monitored
by an infra-red CO2 analyser (Med 1A; Grubb Parsons) and maintained
at about 5% by appropriate adjustment of the pump stroke volume.
Recording of sinus nerve activity
The sinus nerve, ipsilateral to the catheterized lingual
artery was identified and cut centrally. Exposed tissues were
covered with warm (37°C) mineral oil. The peripheral portion of the
cut sinus nerve was placed on a small moveable platform immersed
in the mineral oil so as to facilitate further dissection of the
nerve. The outer sheath of the nerve was partially removed and
small filaments were dissected from the main nerve trunk. Afferent
electrical activity in filaments of the nerve was recorded using
bipolar pi atinum-iridiurn electrodes, amplified by an a.c. amplifier
(Neurolog, Digitimer), displayed on an oscilloscope (Tektronix,
5103N) and recorded on one channel of the tape recorder. Chemo-
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receptor units were identified by their random pattern of discharge,
their increase in discharge frequency following injection of NaCN
(5 ug) into the ipsilateral common carotid artery, their increase
in discharge in response to hypoxia (breathing 10% or 5% 02 in
N2 or 100% N2), and by the inhibition of discharge in response to
hyperoxia (breathing 100% 02).
In all the experiments with cats, the ganglio-glomerular
nerves were cut in order to eliminate reflex effects of sympathetic
activity on carotid nerve discharge (Floyd and Neil, 1952;
Eyzaguirre and Lewin, 1961). A similar operation in rabbits
proved to be technically difficult since the ganglio-glomerular
nerve in the rabbit is not discrete, as are the corresponding nerves
in the cat, but joins the sinus nerve before reaching the carotid
sinus (see Figure 2.1A). It is therefore difficult to cut the
ganglio-glomerular nerve without damaging the sinus nerve.
Elimination of sympathetic effects was however accomplished in four
rabbits, without noticeable damage to the sinus nerve, by cutting
the ganglio-glomerular nerve in two animals and by removing the
superior cervical ganglion in another two.
Drug administration
Drugs used in the present study fall into two categories:
a) test drugs which were used to evoke a chemoreceptor response,
e^. ACh or DA, and
b) modifying drugs which were used to modify responses to test drugs,
e,g. atropine or a-f lupenthi xol .
Table 2.1 lists the drugs used in each category.
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Figure 2.1
The right carotid bifurcation of the rabbit (A) and the left
carotid bifurcation of the cat (B) and associated nerves.
Abbreviations for both A and B are : ap, ascending pharyngeal
artery; cb, carotid body; cs, carotid sinus; ec, external
carotid artery; fa, facial artery; gn, ganglion nodosum;
gg, gangliaglomerular nerves; ic, internal carotid artery;
la, lingual artery; occ, occipital artery; pX, pharyngeal
branch of X; scg, superior cervical ganglion; sla, superior
laryngeal artery; sin, superior laryngeal nerve; sn, sinus
nerve; sta, superior thyroid artery; sy, cervical sympathetic
trunk; IX, glossopharyngeal nerve; X, vagus nerve. Part B
of the figure is taken from Adams (1958).
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Table 2.1:










sodi urn n i tri te physostigmine
sodium nitroprusside propranolol
I.C. injections of test drugs were made in a volume of 0.1 ml
and modifying drugs in a volume of 0.1-0.2 ml and the catheter
(dead space = 0.1 ml) flushed with 0.2 ml of modified Locke solution
(composition given belcw) which had been bubbled with a 5% C02/95%
air gas mixture. Bubbling the Locke solution in this way prevented
a "flush response" which is sometimes observed following I.C.
injections of Locke solution (.Eyzagui rre and Nishi, 197*0. Injections
were made at the peak of the inspiratory phase of the respiratory
cycle and completed over one respiratory cycle. A period of 3~5 min
was allowed between injections of test drugs, unless otherwise
indicated in the text. I.V. injections of drugs were made in a
volume of 0.2- 1.0 ml and the catheter flushed with 0.5 ml 0.9%
(w/v) sal ine. In addition to test drugs, chemoreceptor responses
were obtained in some experiments to C02 or hypoxia. Chemoreceptor
responses to C02 were obtained by injecting 0.1-0.3 ml I.C. of
hypercapnic Locke solution (i.e. modi fied Locke solution which had
been bubbled for 2 min with 100% C02 (pC02 > 160 mm Hg, arithmetic
mean pH ± standard error = 5-85± 0.03)). In experiments performed
early in the present study, responses to hypoxia were obtained by
ventilating the lungs of the experimental animal with 100% N2 for
2 min. In later experiments a less severe stimulus of 5 or 10% 02
in N2 was used.
Control injections of modified Locke, i.e. 0.1 ml Locke
equilibrated with room air injected I.C. and the catheter flushed
with 0.2 ml Locke bubbled with 5% C02 in air, were made in every
experiment.
Data analysis
Data were analysed by the method of McQueen (1977) which may
be summarized as follows. Recordings of nerve activity were
selected for data analysis according to the following criteria:
a) the amplitude of the action potentials to be counted (chemo-
receptor units) was sufficiently different from that of other
nerve potentials that they could be clearly distinguished
throughout the course of an experiment, and
b) the popu1 ation of units being counted in a recording (maximum
6 but usually 1-3) remained constant throughout the course of
an experiment.
Individual units, which had a period of at least 7 msec between
successive spikes, were identified by the shape of the action
potential which was usually characteristic of a given unit and
remained consistent throughout the course of an experiment.
Many recordings of afferent activity were rejected because one or
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other of these criteria were not satisfied. This is particularly
true of recordings obtained from the rabbit sinus nerve where it
was found especially difficult to separate afferent chemoreceptor
activity in the nerve from other activity, e.g. baroreceptor activity.
Afferent activity in the rabbit sinus nerve is discussed further in
Appendix I.
The output of the tape channel on which action potentials
were recorded was fed into a pulse height discriminator, the upper
and lower levels at which the discriminator operated being
indicated by z-axis modulation. The analogue output, which had been
stored for 1 sec, was fed to a digital volt meter (Sch1umberger, A210)
coupled to a data transfer unit (Schlumberger, 3240) which drove an
Addo 5 punch.
Average discharge (x, counts/sec) in the 'control period1 prior
to administration of a test drug, generally 10-20 sec, was
computed (PDP8 computer, Digital Equipment Corporation) from the
punched tape. The average (x) and total counts (Ex) were calculated
for each response after its duration (t sec) had been determined
from a histogram of the response, displayed by the computer on an
x-y plotter (Complot, Houston Instruments). Responses to test
drugs were expressed as the absolute difference in discharge (AEx)
following drug administration where:
AEx = Ex (response) - Ex (control)
and
Ex (control) = x (control) x t
Data were expressed in this way since measurement of AEx takes into
account any variation in t as well as any change in x (see McQueen,
1977).
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The value of x (control) for the 10-20 sec period preceding
administration of a test drug was also used to calculate the overall
spontaneous discharge frequency in animals breathing room air before









where n was the number of injections of test drugs given before or
after administration of a modifying drug. In other words, overall
x - the average spontaneous chemoreceptor discharge frequency in
animals breathing room air - was the arithmetic mean of the values
of x (control) for all the test drugs administered under a particular
set of experimental conditions, i.e. before or after administration
of a modifying drug. Since 8-12 injections of test drugs were
normally given before and after administration of a modifying drug,
the values for spontaneous chemoreceptor discharge frequency in
animals breathing room air, quoted in Sections II! and IV, refer to
the average discharge frequency in a period of 30-45 min preceding
or following administration of a modifying drug. Where data were
available from more than one experiment values of overall x,
calculated as above, were pooled and expressed as the arithmetic
mean ± standard error.
Whenever possible, responses were obtained to a range of doses
of a test drug and AEx was plotted against logio dose. The range
of doses over which the relationship was approximately linear was
determined and a straight line was fitted to the points in the
linear portion of the dose-response curve using the method of least
squares. An estimate of the effect of a modifying drug on responses
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to test drugs was obtained by comparing the dose-response line
obtained before administration of the modifying drug to that
obtained after. A response in the central region of the control
dose-response line, of magnitude R, was selected arbitrarily and the
dose of test drug, , required to produce this response was calculated
using the equation for a straight line, y = mx + c where m is the
gradient and c is the intercept with the y-axis. The dose of a test
drug, D2, required to produce a response of magnitude R after
administration of a modifying drug was then calculated. The ratio,
D^/02 was called the dose-ratio and provided a quantitative measure
of the effect of a modifying drug on responses to test drugs. It
should be stressed that dose-ratios, calculated in this way, are not
equivalent to pharmacological dose-ratios obtained using isolated
tissues in vitro from which affinity constants may be calculated since
the concentration of a given drug in the carotid body is unknown but
are employed here only as a method of quantifying the effects of
modifying drugs on chemoreceptor responses to test drugs. Dose-
ratios were calculated only if the dose-response lines obtained
before and after administration of a modifying drug were approximately
para 1 lei .
When the same dose of a modifying drug was used in three or
more experiments, the dose-ratios from the different experiments
were pooled and data are presented as the geometric mean of the dose
ratios given by:
where ... Pn are the dose-ratios calculated in n experiments.
The median and the range (highest value minus lowest value) are also
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quoted to indicate the scatter of individual ratios about the mean value.
When the same dose of a modifying drug was used in only one or two
experiments, typical dose-response data from one or other experiment
is presented to illustrate the effect of the drug. This is especially
true in Section IV in which the effects of modifying drugs were
studied over a wide range of doses and consequently less data are
available for individual doses.
Linearly related dose-response data for test drugs was obtained
whenever possible. However, owing to the limited life-span of a given
recording it was considered expedient, in some cases, to administer
test drugs in single doses before and after administration of a
modifying drug. This situation arose in experiments in which it was
desirable to study the effect of several different test drugs before
and after administration of a modifying drug and insufficient time
was available to construct dose-response lines for all the test drugs.
The dose of test drug selected for such single dose studies was one
which, from experience, would be expected to produce a response which
was sub-maximal but well above the threshold dose required to produce
an effect. The usefulness of data derived from single dose studies of
this type was limited inasmuch as subtle changes in responsiveness
were difficult to detect and dose-ratios could not be calculated.
Nevertheless data of this type was considered a useful supplement
to linearly-related dose-response data obtained for other test drugs
in the same experiment.
Drugs
Drugs were prepared in modified Locke solution (NaCl, 6.0 g;
KC1, 0.42 g; CaCl2, 0.24 g; Tris base, 6.0 g; N-HC1, 39 ml;
distilled water to 1.0 1) excepting a~flupenthixol, which was
dissolved in 0.3% aqueous sodium chloride, and haloperidol, which was
dissolved in \% aqueous tartaric acid.
The drugs used were: sodium pentobarbitone (Abbott Laboratories);
gallamine triethiodide (May S Baker); acetylcholine iodide, sodium
cyanide, atropine sulphate, urethane (ethyl carbamate), a-chloralose,
sodium nitrite and physostigmine salicylate (all B.O.H.);
5-hydroxytryptamine creatinine sulphate, D-amphetamine sulphate,
pargyline hydrochloride and propranolol hydrochloride (all Sigma);
dopamine hydrochloride, bethanechol chloride, noradrenaline bitartrate
and methacholine bromide (all Koch-Light); benztropine mesylate and
mecamylamine hydrochloride (both M.S.D.); a(cis)-flupenthixol
dihydroch1 oride (Lundbeck & Co.); apomorphine hydrochloride
(Macfarlan Smith); haloperidol (Janssen); sodium nitroprusside
(Griffin S Tatlock); nomifensine hydrogen maleate (Hoechst);
phenoxybenzamine hydrochloride (S.K.F.); subery1dicholine di-iodide




THE EFFECTS OF DOPAMINE, 5-HYDROXYTRYPTAMINE
AND NORADRENALINE ON CHEMORECEPTOR ACTIVITY
IN THE CAT CAROTID BODY
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INTRODUCTION
DA is present in the mammalian carotid body and a number of
hypotheses have been proposed which suggest that DA acts as an
endogenous inhibitor of carotid chemoreceptor activity (see Section l).
The present experiments were performed in order to study the
inhibitory effects of DA on chemoreceptor activity in the cat
carotid body in situ, and also to examine the effects of drugs
which influence dopaminergic systems on chemoreceptor responses to
stimulants such as NaCN, ACh and hypoxia.
The carotid body also contains NA and 5-HT (see Section l).
Since drugs which modify dopaminergic systems may have non-specific
effects on noradrenergic and serotinergic systems, the opportunity
was taken to investigate the effects of NA and 5_HT on carotid
chemoreceptor activity in this species and to determine what effect
drugs which modify dopaminergic systems have on chemoreceptor
responses to NA and 5-HT.
RESULTS
Experiments were performed on 37 cats (22 male and 15 female)
weighing between 2.0 and A.O kg (mean weight ± standard error =
3.0 ± 0.7 kg). Forty-one recordings of afferent chemoreceptor
activity were obtained from 3^ of these animals. Animals were
anaesthetized with sodium pentobarbitone as described in Section II.
Responses to dopamine
Administration of DA (0.5-50 yg I.C.) caused an immediate,
short-1 ast i ng (5-^+5 sec) inhibition of chemoreceptor activity in all
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A B
oc-flupenthixol 0.2 mg/kg lc.
haloperidot 0.2 mg/kg i.v.
Figure 3.1
Chemoreceptor units from two experiments showing responses
to DA (2.5 |ig I.C.) before (A) and after (B) administration
of a-flupenthixol (0.2 mg /kg I.C.) (upper panels) and
haloperidol (0.2 mg /kg I.V.)(lower panels). Each panel
shows, from above downwards : B.P. (mm Hg), one second time
marks and injection marker. The smaller unit in the lower
panels is a baroreceptor unit.
58
Figure 3.2
Dose-response data for DA, from a recording of one
chemoreceptor unit, before (•—•) and after (x—x)
administration of a-flupenthixol (0.2 mg /kg I.C.). Doses
are plotted on a log10 scale and lines are fitted by the
method of least squares.
B
Figure 3.3
Dose-response data for DA (A) and 5-HT (B), from a recording
of two chemoreceptor units, obtained during artificial
ventilation of the experimental animal with air (•—•),
17.5 % 02 in N2 (■—■ ) and 15 % 02 in N2 (o-----o). Arterial
p02 was 92 mm Hg, 61 mm Hg and 45 mm Hg and pH was 7.33,
7.36 and 7.34 respectively. Doses are plotted on a logt0
scale and lines fitted to the data by the method of least
squares.
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the experiments (eg.see Figure 3-1A), the magnitude of the
inhibition being dose-dependent over the range 0.5 - 5 yg I.C. (see
Figure 3.2). There was a tendency for DA to cause a delayed or
secondary increase in discharge, especially at higher doses (10-50
yg I.C.) which curtailed the primary inhibition and gave inconsistent
responses. In view of this observation, the present study was
confined to low doses of DA (10 yg I.C.) with which secondary
excitatory effects were obtained only infrequently and which gave
more consistent inhibitory responses.
In three experiments the effect of hypoxia on the response to
DA was studied. It was found that the magnitude of the inhibitory
response to DA was inversely proportional to arterial p02, i.e. the
magnitude of the response was proportional to the background
frequency of spontaneous chemoreceptor activity against which the
inhibition was measured (see Figure 3-3A).
There was a slight increase in mean arterial B.P. which
commenced about 10 sec after an I.C. injection of high doses of DA
(>10 yg I.C.). With lower doses there was no obvious change in B.P.
Effects of dopamine antagonists
1 . ct-FI upenth i xol
a-Flupenthixol is a potent DA antagonist (Moller Nielsen,
Pedersen, Nymark, Franck, Boeck, Fjalland and Christensen, 1973;
Miller, Horn and Iversen, 197*0 which has very little anticholinergic
activity (Iversen, 1975). The effect of a-flupenthixol on chemo¬
receptor activity was studied in nine experiments.
Low doses of a-flupenthixol (0.05 mg/kg I.C.) reduced, and
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Figure 3.4
Dose-response data for NaCN (A) and ACh (B), from a recording
of two chemoreceptor units, before (• • ) and after (x x)
administration of a-flupenthixol (0.2 mg /kg I.C.). Doses
















0 L 5/1.6/1.0 6/l.C/l.6 3/1.8/1.1
3/1.3/1.1
A B C D
Figure 3.5
Pooled dose-ratio data showing the effects of a-flupenthixol,
in doses of 0.05 mg /kg I.C. (A), 0.2 mg /kg I.C. (B), 0.5
mg /kg I.C. (C) and 1.0 mg /kg I.C. (D), on chemoreceptor
responses to NaCN and ACh. Data are presented as the
geometric mean dose-ratio. The dashed line represents a
dose-ratio of one. The number of experiments (n), the median





Response of carotid chemoreceptors to 120 sec of hypoxia
(breathing 100% N2). The top panel (A) shows the response
before ( ) and after ( ) administration of a-flupenth-
ixol (0.2 mg /kg I.C.). The centre panel (B) shows the
response before ( ) and after ( ) administration of
apomorphine (0.2 mg /kg I.C.) and after ( ) subsequent
administration of a-flupenthixol (0.2 mg /kg I.C.). The
bottom panel (C) shows the response before ( ) and after
( ) administration of haloperidol (0.2 mg /kg I.V.).
Recordings were of two, two and one chemoreceptor units in
A, B and C respectively. Each panel shows from above down¬
wards : discharge frequency (averaged over 5 sec intervals),
time and period of hypoxia (horizontal black bar).
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of chemoreceptor activity (see Figures 3.1, 3.2). There was an
increased tendency for DA to produce excitatory effects following
administration of a-f1upenthixol, especially when high doses (0.5
or 1.0 mg/kg I.C. additional to 0.05 and 0.2 mg/kg I.C. respectively)
of this blocking drug were used (see Figure 3.1).
In order to make a quantitative estimate of the effects of
a-f1upenthixol on chemoreceptor responses to NaCN and ACh, dose-
response data were obtained before and after administration of
a-f1upenthixol (see Figure 3.*0 and dose-ratios (see Section ll)
calculated from the dose-response lines (see Figure 3-5). Low doses
of a-f1upenthixol (0.05 mg/kg I.C.) had no effect on responses to
NaCN while higher doses (0.2-1.0 mg/kg I.C.) caused potentiation
(see Figures 3-^, 3.5). Chemoreceptor responses to ACh were not
appreciably affected by low doses of a-flupenthixol (0.05 or 0.2 mg/
kg I.C.) but were reduced by higher doses (0.5 or 1.0 mg/kg I.C.)
(see Figures 3 - , 3-5). Unfortunately it was not possible to
calculate dose-ratios for DA since, after administration of
a-flupenthixol, the slope of the dose-response line became positive,
reflecting the tendency for DA to evoke excitatory responses under
these conditions (see Figure 3.2).
The rate of increase of spontaneous chemoreceptor discharge
during hypoxia (breathing 100% N2) was greatly increased following
administration of a-f1upenthixol although the maximum discharge
frequency reached was not appreciably different from control values
(see Figure 3.6A). The frequency of spontaneous discharge in
animals breathing room air was little affected by a-flupenthixol
except after high doses (1.0 mg/kg I.C.) when there was a slight
increase in frequency (see Table 3-1)
TABLE 3.1: Spontaneous chemoreceptor discharge frequency
(arithmetic mean (x) ±standard error; counts/
lec) in animals breathing room air, before "and
after administration of g-f1upenthixol
Dose of
No. of a-flupenthixol
experiments (mg/kg i.C.) x before x after
5 0.05 3.7 ± 1.3 4.3 ± 1-0
6 0.20 4.7 ± 0.8 5-9 ± 1.1
3 0 .50 3 .0 ±0.6 3.410.6
4 1.00 6.8 1 1.5 10.3 1 1.3
2. Haloperidol
Haloperidol blocks the action of DA at dopaminergic synapses
in the C.N.S. (Bunney, Walters, Roth and Aghajanian, 1973). The
effects of haloperidol, in cumulative doses of 0.2, 0.5 and 1.0
mg/kg I.V., on chemoreceptor activity were studied in one experiment
and the results obtained were qualitatively similar to those obtained
with a-f1upenthixol. The lowest dose (0.2 mg/kg I.V.) had little
effect, while higher doses (0.5 and 1.0 mg/kg I.V.) reduced, but did
not abolish, the inhibitory action of DA (see Figure 3.1), enhanced
the response to NaCN (see Figure 3-7A) and slightly reduced that to
ACh (see Figure 3 -7B). The rate of increase of spontaneous chemo¬
receptor discharge frequency during hypoxia (breathing 100% N2) was
slightly increased following administration of haloperidol although
the maximum discharge frequency reached was similar to control values
(see Figure 3.6C). Spontaneous discharge frequency in animals
breathing room air was 2.1 counts/sec before and 4.4 counts/sec
after 0.2 mg/kg I.V., 3.1 counts/sec after 0.5 mg/kg I.V. and 2.1
counts/sec after the final dose of 1.0 mg/kg I.V. of haloperidol.
Figure 3.7
Dose-response data for NaCN (A) and ACh (B), from a recording
of one chemoreceptor unit, before (• •) and after (X—x)
administration of haloperidol (1 mg /kg I.V.). Doses are
plotted on a log10 scale and lines fitted by the method of
least squares.
Figure 3.8
Dose-response data for NaCN (A) and ACh (B), from a recording
of three chemoreceptor units, before (• •) and after (x--x)
administration of apomorphine (0.2 mg /kg I.C.). Doses are
plotted on a log10 scale and lines fitted by the method of
least squares .
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Substances which mimic dopamine
1. Apomorphine
Apomorphine is a DA receptor agonist (Anden, Rubenson, Fuxe
and Hokfelt, 1967) which has been shown to mimic the effects of DA
at several sites (Ernst, 1969).
The effects of apomorphine, in cumulative doses of 0.05 and
0.2 mg/kg I.C., on chemoreceptor activity were studied in two
experiments. Apomorphine caused a depression of spontaneous
chemoreceptor activity lasting up to kS min, spontaneous discharge
frequency being 3.0 ±0.k counts/sec before and 1.0 ±0.1 counts/sec
after 0.05 mg/kg I.C. and 1.4 ± 0.5 counts/sec after the additional
dose of 0.2 mg/kg i.C. Dose-response data to NaCN and ACh were
obtained while spontaneous discharge frequency was still depressed.
Responses to both stimulants were slightly reduced (see Figure 3-8).
Although background discharge frequency was reduced following
administration of apomorphine, DA could still evoke an inhibitory
response. The rate of increase of spontaneous discharge frequency
during hypoxia was depressed following administration of apomorphine,
an effect which was reversed by subsequent administration of
a-flupenthixol (see Figure 3 -6B).
2. D-Amphetam? ne
D-Amphetamine causes release of DA from dopaminergic neurons
in the C.N.S. (Bunney, Aghajanian and Roth, 1973). The effects of
low doses (5-50 yg I.C.) of amphetamine on chemoreceptor activity
were studied in five experiments and the effects of a high dose

































The upper two panels (A) show chemoreceptor responses from
one experiment (four units) to low doses of DA and
amphetamine. The lower panel (B) shows the chemoreceptor
response, obtained in a second experiment (two units) to a
high dose of amphetamine (0.25 mg /kg I.C.). Each panel
shows, from above downwards : discharge frequency and mean
arterial B.P. The time bar refers to all three panels.
Injections of DA or amphetamine were made at the arrows.
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Figure 3.10
Panel A shows dose-response data for NaCN, from a recording
of one chemoreceptor unit, before (• •) and after (x x)
administration of benztropine (0.25 mg /kg I.C.) and after
(o o) subsequent administration of a-flupenthixol (0.5
mg /kg I.C.). Panel B shows dose-response data for hyperca-
pnic Locke solution, from a recording of one chemoreceptor
unit, before (•———•) and after (x x) administration of
benztropine (0.5 mg /kg I.C.). Panel C shows dose-response
data for DA, from a recording of one chemoreceptor unit,
before (• •) and after (x x) administration of benztrop¬
ine (0.25 mg /kg I.C.). Doses in A and C are plotted on a





















Pooled dose-ratio data showing the effect of benztropine in
doses of 0.25 mg /kg I.C. (A) and 0.5 mg /kg I.C. (B) on
chemoreceptor responses to ACh, NaCN and DA. Data are pres¬
ented as for Fig. 3.5.
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The chemoreceptor response to low doses of amphetamine was
qualitatively similar to that produced by low doses of DA, i.e.
inhibition (see Figure 3-9A). The inhibitory response to amphetamine,
however, was not as marked as that observed following low doses of
DA, did not appear to be dose-related, and was less consistent.
The higher dose of amphetamine (0.25 mg/kg I.C.) evoked a transient
stimulation of chemoreceptor activity and an increase in arterial
B.P. (see Figure 3 -9B).
Effects of dopamine uptake blockers
1. Benztropine
Benztropine is an anticholinergic agent which is, in addition,
a potent blocker of DA uptake (Coyle and Snyder, 1969; Horn, Coyle
and Snyder, 1971). The effect of cumulative doses of 0.25 and 0.5
mg/kg I.C. of benztropine on chemoreceptor activity was studied in
four experiments.
Benztropine enhanced DA-induced inhibition of chemoreceptor
activity (see Figure 3 -10C) and augmented responses to NaCN (see
Figure 3.1 OA). The chemoreceptor response to ACh was unaffected by
a dose of 0.25 mg/kg I.C. but was reduced following administration
of the additional dose of 0.5 mg/kg I.C. Dose ratios summarising
the effects of benztropine on chemoreceptor responses to DA, NaCN
and ACh are shown in Figure 3.11.
Mean arterial B.P. was reduced by approximately 15-20 per
cent following administration of an initial dose of 0.25 mg/kg I.C.
of benztropine but was not further modified by an additional dose
of 0.5 mg/kg I.C. The depressor response to ACh was also reduced
by benztropine.
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Figure 3.12
Response of carotid chemoreceptors to 120 sec of hypoxia
(breathing 5% 02 in N2 in A and C and 10% Oo in N2 in B).
The top panel (A) shows the response before( ) and
after ( ) administration of benztropine (0.25 mg /kg
I.C.). The centre panel (B) shows the response before ( )
and after ( ) administration of nomifensine (0.2 mg /kg
I.C.). The bottom panel (C) shows the response before ( )
and after ( ) administration of pargyline (2.5 mg /kg
I.C.). Recordings were of two, one and three chemoreceptor
units in A, B and C respectively. Each panel shows, from
above downwards : discharge frequency (averaged over 5 sec
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Dose-response data for NaCN (A) and DA (B) before (•—•) and
after (x--x) administration of nomifensine (0.4 mg /kg I.e.
in A and 0.1 mg /kg I.C. in B). Recordings were of three
and four chemoreceptor units in A and B respectively. Doses













Responses of carotid chemoreceptors (three units) to ACh
(50 fig I.C.) (A), DA (5 (ig I.C.) (B) and NA (10 jig I.C.KC)
before (left-hand panels) and after (right-hand panels)
administration of nomifensine (0.4 mg /kg I.C.). Each panel
shows, from above downwards : discharge frequency and mean
arterial B.P. Injections of ACh, DA or NA were made at the
arrows. The time bar refers to all six panels.
74
The chemoreceptor response to hypoxia (breathing 5% O2 in N2)
was increased following administration of benztropine (see Figure
3.12A). The response to I.C. injection of hypercapnic Locke
solution (0.1-0.3 ml) was also increased (see Figure 3• 1 0B) .
Spontaneous discharge frequency in animals breathing room air was
1.3±0.8 counts/sec before and 2.6±1.1 counts/sec after I.C.
injection of 0.25 mg/kg of benztropine and 2.4±0.3 counts/sec after
an additional dose of 0.5 mg/kg. Administration of a-flupenthixol
(0.5 mg/kg I.C.) subsequent to benztropine increased spontaneous
chemoreceptor discharge to 6.8 ± 1.8 counts/sec and further augmented
responses to NaCN (see Figure 3-1 OA) but did not further modify
responses to ACh.
2. Nomifensine
Nomifensine is a non-tricyclic antidepressant drug (Hoffmann,
1973) which, unlike benztropine, has little anticholinergic activity
(Hoffmann, 1977) and which is a potent blocker of DA uptake (Hunt,
Kannengeisser and Raynaud, 1974). Three experiments were performed
in which the effects of nomifensine in doses of 0.1 mg/kg I.C.,
cumulative doses of 0.1 and 0.2 mg/kg I.C. and cumulative doses of
0.1, 0.2 and 0.4 mg/kg I.C. on chemoreceptor activity were studied.
Nomifensine (0.1 -0.4 mg/kg I.C.) enhanced the chemoreceptor
response to DA (see Figure 3-13B). The lowest dose of nomifensine
(0.1 mg/kg I.C.) had no effect or slightly enhanced responses to
NaCN while higher doses (0.2 or 0.4 mg/kg I.C.) clearly augmented
responses (see Figure 3.13A). Neither the chemoreceptor response
nor the depressor response to ACh (single doses of 50 pg I.C.) were




Dose-response data for NaCN (A) and ACh (B), from a record¬
ing of three chemorecptor units, before (<•——•) and after
(*--x) administration of pargyline (5 mg /kg I.C.). Doses
are plotted on a log!0 scale and lines are fitted by the
method of least squares.
Figure 3.16
Dose-response data for DA (A) and hypercapnic Locke solution
(B), before (• •) and after (x--x) administration of pargyline
(2.5 mg /kg I.C. in A and 5 mg /kg I.C. in B). Data in A
and B are from recordings of two and one chemoreceptor units
respectively. Doses in A are plotted on a log10 scale.















Pooled dose-ratio data showing the effect of pargyline, in
doses of 2,5 mg /kg I.C. (A) and 5 mg /kg I.C. (B), on
chemoreceptor responses to ACh, NaCN and DA, Data are
presented as for Fig. 3,5,
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an increase in the chemoreceptor response to hypoxia (breathing 10%
02 in N2) following administration of nomifensine (see Figure 3 -12B).
The frequency of spontaneous discharge in animals breathing room air
was also increased (see Table 3.2).
TABLE 3-2: Frequency of spontaneous chemoreceptor
discharge in animals breathing room air
"(arithmetic mean (x) ±standard error) "before
and after administration of nomifensine.
Dose of
No. of nomifensine
experiments (mg/kg I.C.) x before x after
3 0.1 2.4 ± 1.2 6.9 ± 4.9
2 0.2 1.3 ± 0.7 2.3 ± 1.3
1 0.4 2.0 4.2
Mean arterial B.P. was increased by about 25 per cent following
administration of 0.1 mg/kg I.C. of nomifensine but was not further
mod i f i ed by an add i t i onal dose of 0. 2 mg/kg I.C. Mean B.P. fe 1 1 to
control or slightly below control levels following subsequent
administration of 0.4 mg/kg I.C.
Inhibition of monoamineoxidase (MAO)
Pargy1ine
Pargyline is a potent inhibitor of MAO (see Zeller and Hsu,
1973). The effects of cumulative doses of 2.5 and 5-0 mg/kg I.C. of
pargyline on chemoreceptor activity were studied in four experiments.
It was found that the inhibitory action of DA was enhanced by
pargyline (see Figure 3.16A). Responses to NaCN were, if anything,
slightly increased following administration of pargyline while responses
to ACh were unaffected or slightly reduced (see Figure 3.15). Dose
DA 2 5 pg
5-HT 1 0 pq
Figure 3.18
Responses of a chemoreceptor unit to DA (left-hand panels)
and 5-HT (right hand panels) before (A) and after (B)
administration of a-flupenthixol (0.05 mg /kg I.C.) and
after (C) subsequent administration of an additional dose
of 0.5 mg /kg I.C. of a-flupenthixol. Panel D shows the
effect of 0.1 ml I.C. of Locke solution (equilibrated with
5% C02 in air). Each panel shows, from above downwards :
action potentials and injection marker. The one sec timing



























Response of carotid chemoreceptors to 5-HT (5 fig I.C.)
before (left-hand panels) and after (right-hand panels)
administration of benztropine (A) and pargyline (B) and the
response to 5-HT (10 fig I.C.) before and after administrat-
tion of apomorphine (C). Recordings were of one, one and two
chemoreceptor units in A, B and C respectively. Each panel
shows, from above downwards : discharge frequency and mean
arterial B.P. Injections of 5-HT were made at the downward
pointing arrows. The time bar refers to all six panels.
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ratios summarising the effects of pargyline on chemoreceptor
responses to DA, NaCN and ACh are shown in Figure 3.17. There was
a slight rise in mean arterial B.P. of about 10 per cent following
administration of 2.5 mg/kg l.C. of pargyline but no further change
was observed after a subsequent dose of 5 mg/kg l.C.
Pargyline had no obvious effect on the chemoreceptor response
to hypoxia (see Figure 3 -13C) or on the response to hypercapnic Locke
solution (0.1 - 0.3 ml l.C.) (see Figure 3-16B). The frequency of
spontaneous chemoreceptor discharge in animals breathing room air
was 3.5 ± 2.A counts/sec before and 8.1 ±5.8 counts/sec after
administration of 2.5 mg/kg l.C. of pargyline and 11.3±8.0 counts/
sec after an additional dose of 5 mg/kg l.C.
Responses to 5-hydroxytryptam?ne
The effects of single doses (5 or 10 yg l.C.) of 5-HT,
injected at regular intervals (minimum 5 min) or of a range of
doses (0.5-5 yg l.C.) on chemoreceptor activity were studied in
14 experiments.
5-HT evoked a brief, intense burst of chemoreceptor activity
lasting up to 2 sec followed by a period of inhibition lasting up
to 10 sec (see Figure 3.18). In three experiments the effect of
hypoxia on the response to 5~HT was tested. It was found that the
magnitude of the inhibitory response to 5-HT increased when arterial
PO2 was lowered (see Figure 3-3). The magnitude of the initial
excitation was unaffected or slightly reduced by hypoxia.
There was a tendency for low doses (<0.5 mg/kg l.C.) of
a-f1upenthixol to reduce the excitatory effect of 5"HT on chemo¬





























Response of carotid chemoreceptors ( 1 unit ) to NA (10 |ig
I.C.) before (A) and after (B) administration of nomifensine
(0.2 mg /kg I.C.) and after (C) subsequent administration
of a-flupenthixol (0.2 mg /kg I.C.). Each panel shows,
from above downwards : discharge frequency and mean arterial
B.P. Injections of NA were made at the arrows. The time
bar refers to all three panels.
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The inhibitory effect of 5~HT was not appreciably affected until
high doses of a-f1upenthixol (>0.5 mg/kg I.C.) were administered,
when the response was abolished (see Figure 3-18). This finding
meant that results obtained following high doses of a-f1upenthixol
had to be interpreted cautiously because the drug was evidently no
longer acting selectively. The chemoreceptor response to 5-HT was
not, however, appreciably affected by benztropine or pargyline
(see Figures 3.19A, 3 -19 B) or when spontaneous discharge was
depressed by apomorphine (see Figure 3.19C).
Responses to noradrenaline
Chemoreceptor responses to single doses (5 or 10 yg I.C.) or
a range of doses (2.5-25 yg I.C.) of NA were obtained in seven
experiments. NA, in the doses studied, evoked an immediate, short-
lasting (1-20 sec) inhibition of chemoreceptor activity followed
by a secondary excitation (see Figures 3.1AC, 3-20, 3.21). The
initial inhibitory effect of NA was less marked than that produced
by DA and was less consistent, being observed in response to only
13 of a total of 21 injections. The secondary excitation had a
similar time course to the pressor response evoked by NA and it is
tempting to speculate that such excitation may be due to a reduction
in carotid body blood flow as a consequence of the vasoconstrictor
action of the drug.
Nomifensine (0.1 - 0.A mg/kg I.C.) enhanced both the initial
inhibition, when such was observed, and the secondary excitation
evoked by NA, and, on some occasions, potentiated the pressor
response (see Figures 3.1AC, 3.20). Administration of a-flupenthixol
(0.2 mg/kg I.C.) subsequent to nomifensine (consecutive doses of
20
counts/si
DA 5 uq i.c.
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Figure 3.21
Response of carotid chemoreceptors (2 units) to DA (left-hand
panels) and NA (right-hand panels) before (A) and after (B)
administration of PBA (5 mg /kg I.V.) and after (C) an
additional dose of PBA (5 mg /kg I.V.). Each panel shows,
from above downwards : discharge frequency and mean arterial
B.P. Injections of DA and NA were made at the arrows. The
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Figure 3.22
Dose-response data for NaCN, from a recording of two
chemoreceptor units, before (•——•) and after (o o) admini¬
stration of PBA (5+5 mg /kg I.V.) and after (x x)
subsequent administration of propranolol ( 2 mg /kg I.V.).
Doses are plotted on a log!0 scale and lines fitted by the
method of least squares.
Pooled dose-ratio data showing the effect of PBA, in doses
of 5 mg /kg I.V. (A) and 5 + 5 mg /kg I.V. (B), on chemo-
receptor responses to NaCN. The above data were obtained
from three recordings of chemoreceptor activity in two








0.1 and 0.2 mg/kg I.C.) blocked the inhibitory, but not the
excitatory, effects of NA (see Figure 3-20). This dose of
a-flupenthixol had little effect on the pressor response to NA
(see Figure 3.20).
Effect of phenoxybenzamine (PBA)
Two experiments were performed in which the effects of the
a-adrenergic blocking agent PBA on chemoreceptor activity were
investigated. The effects of an initial dose of 5 mg/kg I.V. of
PBA and a subsequent dose, also of 5 mg/kg I.V., were studied in
both experiments. A period of 30 min was allowed following
administration of PBA before responses to test substances were
obtained. Mean arterial B.P. fell by 20 - 30 per cent following
administration of the initial dose but was not further reduced by
the second dose.
The chemoreceptor response to NaCN was enhanced following
administration of PBA. This effect was not reversed by
administration of the B-adrenergic blocking agent propranolol
(2 mg/kg I.C.) (see Figure 3.22). Dose-ratios summarising the
effect of PBA on responses to NaCN are shown in Figure 3.23.
Inhibitory responses to NA and DA were little affected
following administration of the initial dose of PBA although the
secondary excitatory effects of NA were reduced. The inhibitory
response to NA was reduced, however, following administration of the
second dose of PBA (see Figure 3-21). DA still evoked an inhibition
of chemoreceptor activity following administration of the second dose
of PBA but the response became inconsistent (see Figure 3.21).
The pressor response to NA was abolished by PBA (see Figure 3.21).
Spontaneous chemoreceptor discharge frequency in animals
breathing room air was 5.0 ± 1.2 counts/sec before and 6.1 ± 1.9
counts/sec after an initial dose of 5 mg/kg I.V. of PBA and 11.0 ±
2.3 counts/sec after an additional dose of 5 mg/kg I.V.
DISCUSSION
The present results confirm that I.C. injection of low
doses of DA inhibits chemoreceptor activity in the cat carotid
body in situ (see also Black et al, 1976a; Nishi, 1977; Zapata,
1977; Llados and Zapata, 1978a; Zapata and Llados, 1978). It
is unlikely that the inhibitory effect is a consequence of a change
in carotid body blood flow since DA is also found to inhibit chemo¬
receptor activity in superfused preparations in vitro (Zapata,
1975) and during stagnant asphyxia in the carotid body in situ
(Sampson et al, 1976a). It appears that DA inhibits chemoreceptor
activity by a direct action on sensory nerve endings or on structures
presynaptic to sensory nerve endings in the carotid body.
The magnitude of the inhibitory response to DA was found to
be inversely proportional to arterial p02, i.e. proportional to the
background frequency of chemoreceptor discharge against which the
inhibition was measured. A similar result was obtained by Nishi
(1977). Sampson et al (1976a) found that there was no difference
in the chemoreceptor response to DA in animals breathing room air
or animals ventilated with hypoxic gas mixtures. The latter
authors, however, expressed their results as percentage changes in
average discharge frequency, whereas in the present study the
absolute difference in discharge, AZx, was measured (see Section II).
Since the magnitude of an inhibitory response, measured as AZx,
is proportional to the frequency of spontaneous discharge, this
meant that the effects of drugs which change the background frequency
of spontaneous chemoreceptor discharge on responses to DA had to be
interpreted cautiously.
High doses (>10 yg I.C.) and occasionally low doses (< 10
yg I.C.) of DA caused a delayed increase in discharge which reduced
the duration of the inhibitory response. Sampson (1972) and Sampson
et al (1976a, 1976b) obtained repeatable inhibitory responses to DA
in situ using doses of 2 - 5 yg I.C. which accords with the present
results at these doses. They found, however, that DA produced "only
a depression of impulse activity" (Sampson et al, 1976a) whereas
secondary excitations were observed, albeit infrequently, even with
low doses of DA in the present study. Llados and Zapata (1976a)
found that low doses of DA ( <: 5 yg I.C.) caused inhibition of
chemoreceptor activity and that on "certain occasions" this
inhibitory effect was followed by a secondary excitation which is
in complete agreement with the present results. Nishi (1977) found
that injection of small doses of DA (0.2-0.5 yg I.C.) evoked an
initial brief increase in chemoreceptor activity which preceded
the inhibitory effect. This phenomenon was not observed in the
present study. The above authors did not study the effects of
higher doses of DA which were found in the present investigation
to give delayed increases in discharge and inconsistent inhibitory
responses. The time course of the delayed increase in discharge
was similar to that of the slight pressor response observed
following administration of high doses of DA which suggests that
the two effects might be related. This delayed increase in discharge,
however, seems similar to that observed by Zapata (1975) in vitro
and it may be premature, therefore, to attribute the excitatory
effect observed in situ to circulatory changes. This view is
supported by the finding that the delayed excitatory effect produced
by DA in situ persists, even after the pressor response to DA is
blocked by administration of dibenamine (Llados and Zapata, 1978a).
The present investigation, however, was concerned mainly with the
inhibitory effect of DA and the mechanism of the delayed excitatory
effect was not studied.
Following administration of a-f1upenthixol (0.2-1.0 mg/kg I.C.)
the inhibitory response of the carotid chemoreceptors to DA was
abolished and an excitatory response was observed. Similar results
were obtained with another DA antagonist, haloperidol. These results
are in agreement with those obtained by other workers who used
haloperidol and trifluperidol (Nishi, 1977) or haloperidol, spiro¬
peridol, fluphenazine and chlorpromazine (Llados and Zapata, 1978a)
to block the DA inhibitory response.
In the present experiments, administration of DA blockers had
little effect on spontaneous discharge frequency in animals breathing
room air. Zapata (1975) found that spiroperidol had little effect
on spontaneous chemoreceptor discharge frequency in vitro. Nishi
(1977) and Llados and Zapata (1978a), however, found that
administration of DA blockers caused a marked increase in discharge
frequency in situ. This discrepency in results is difficult to
explain since the experimental method used by these workers was very
similar to that used in the present study save that in the present
experiments gallamine was used to paralyse spontaneous respiration.
It is possible that gallamine prevented an increase in discharge
following administration of DA blockers although previous work has
shown that gallamine itself, in the doses used in the present study,
has little effect on chemoreceptor activity in the cat carotid body
(McQueen, 1977). A slight increase in the frequency of spontaneous
discharge was observed following administration of a high dose of
a-flupenthixol (1 mg/kg l.C.) in the present experiments but at this
dose the inhibitory effect of 5-HT was also blocked, indicating that
the drug was no longer acting selectively against DA, which it was
assumed to be at lower doses.
If the theories of Osborne and Butler (1975) or Krammer (1978)
are correct (see Section l) and DA is released from type I cells to
suppress activity in otherwise spontaneously active sensory nerve
ends then abolition of the inhibitory effect of DA would be expected
to precipitate a marked increase in chemoreceptor activity. While
the results obtained by Nishi (1977) and by Llados and Zapata (1978a),
discussed above, may be interpreted in favour of such an hypothesis,
the results obtained in the present study and by Zapata (1975) are
not in accord with such an idea. Osborne and Butler also suggest
that a transmitter, possibly ACh, is released from sensory nerve
ends and acts to suppress the release of DA from type I cells, thereby
causing an increase in chemoreceptor discharge. If this is the case
then ACh should no longer cause excitation when the inhibitory
effect of DA is blocked. It was found in the present study that the
response to ACh was little affected by doses of a-flupenthixol
sufficient to block the inhibitory effects of DA. High doses of
a-f 1 upenthixol (^0.5 mg/kg l.C.) did reduce the response to ACh
but, at these doses, it was not certain whether a-flupenthixol was
acting selectively against DA (see above). Similar results were
obtained with haloperidol. Nishi (1977) found that the chemoreceptor
response to ACh was unchanged or enhanced by haloperidol. These
results do not support the theory advanced by Osborne and Butler.
As well as blocking the inhibitory response to DA, a-flupenthixol
potentiated chemoreceptor response to NaCN and increased the rate of
increase of chemoreceptor discharge during hypoxia. Similar results
were obtained using haloperidol and Nishi (1977) has also reported
that haloperidol causes potentiation of responses to chemoreceptor
stimuli. These results are compatible with suggestions that endogenous
DA may, through an inhibitory action, modulate chemosensory activity
(McDonald and Mitchell, 1975; Zapata, 1975). This conclusion relies
on the assumption that potentiation of responses to chemoreceptor
stimuli was a consequence of blockade of an inhibitory effect of
endogenous DA. Such an assumption is not unwarranted, however,
since DA is stored in the carotid body and released during hypoxia
(see Section l) and DA can inhibit chemoreceptor activity. The
chemoreceptor response to ACh was not, however, appreciably
affected by a-flupenthixol or haloperidol. It may be that ACh
increases afferent chemoreceptor activity by a direct action on the
unmyelinated, terminal portion of the sensory nerves, as Douglas
(195*0 suggested, and that the dopaminergic mechanism operates at a
point which is peripheral to this site of action, e^g. at synapses
between type I cells and sensory nerve endings. If this is the case
then drugs which modify the action of endogenous DA would not be
expected to have much effect on responses to ACh.
In addition to studying the effects of DA-blocking drugs,
experiments were performed to study the activity of the carotid
chemoreceptors during prolonged stimulation of the DA inhibitory
receptor. Inhibitory responses to DA injections were short-1asting,
and although the use of DA infusion to give a sustained inhibition
was considered, this was rejected because of the possibility of
causing delayed increases in discharge. Instead, the DA agonist
apomorphine was used and gave a long-lasting inhibition of chemo-
receptor activity without any apparent excitatory effects. Nishi
(1977) and Llados and Zapata (1978a) obtained a similar result with
apomorphine. Responses to NaCN and ACh were slightly reduced by
apomorphine and the response to hypoxia was depressed. Nishi (1977)
found that responses to both NaCN and hypoxia were reduced by
administration of doses of apomorphine similar to those used in the
present study although responses to the nicotinic stimulant DMPP
were not. It seems then that chemoreceptor responses to hypoxia
and NaCN may be reduced by apomorphine. If the depressant effects
of apomorphine are due to an action on the DA inhibitory receptor
then these results support the idea that endogenous DA has an
inhibitory effect on chemoreceptor activity. The inhibitory
effects of apomorphine were prevented by administration of
a-flupenthixol, an observation which provides indirect evidence
that DA and apomorphine were acting at the same site(s).
As an alternative to studying the effects of injections of
DA or apomorphine, it was decided to study the effects of amphetamine
in the hope that this drug, by releasing DA from endogenous stores,
would give a better indication of the action of endogenous DA. If
endogenous DA acts as an inhibitory modulator of chemoreceptor
activity, as the above results suggest, then one might expect
amphetamine to inhibit chemoreceptor activity. Low doses of
amphetamine (5 - 50 tig I.C.) did inhibit chemoreceptor activity but
the response was inconsistent and did not appear to be dose-related,
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while a high dose of amphetamine (0.25 mg/kg I.C.) caused stimulation
of activity. These results are puzzling if endogenous DA is an
inhibitory modulator of chemoreceptor activity. It is possible
that DA stores in the carotid body are resistant to the DA-releasing
action of amphetamine. If this is the case then the inhibitory
effect of low doses of amphetamine might have been due to a slight
agonist action of amphetamine on DA inhibitory receptors. The
stimulant effect of the high dose of amphetamine is difficult to
explain however. Llados and Zapata (1978a) found that doses of
amphetamine up to 2 mg I.C. "did not induce inhibition" of chemo¬
receptor activity but do not mention whether or not they observed
any stimulant effects. It may be that the stimulant effect of
amphetamine observed in the present study was unrelated to the DA-
releasing action of the drug. Nevertheless, since DA may cause
excitation of chemoreceptor activity as well as inhibition (see
above), the possibility that the stimulant effect of amphetamine
was a consequence of release of endogenous DA cannot be ruled out.
If DA acts as a modulator of afferent chemoreceptor activity
then the most likely place for such a mechanism to operate is at
synapses between sensory nerve endings and type I cells. Ultra-
structural studies of the innervation of the carotid body have shown
that type I cells are in synaptic contact with nerve endings (see
Biscoe, 1971). There is, however, a dispute as to whether the nerves
forming these synaptic connections are sensory as claimed
by De Castro (1928) or whether they are part of an efferent pathway
(Biscoe, Lall and Sampson, 1969)- Current evidence suggests that
the majority of the fibres are sensory (Hess and Zapata, 1972; Nishi
and Stensaas, 197*+; Osborne and Butler, 1975; Mitchell and McDonald,
1975; Kondo, 1976) although the synaptic connections between the
sensory nerves and type I cells may be reciprocal (Verna, 1973;
Butler and Osborne, 1975; Mitchell and McDonald, 1975). If DA is
released from type I cells at these synapses and acts on sensory
nerve ends then it is likely that there is a mechanism for
inactivation of released transmitter. This could be accomplished
by enzymatic degradation, by cellular uptake, by diffusion of DA
away from the synapse or by a combination of these processes. Lee
and Mattenheimer (1965) demonstrated the presence of MAO in the
carotid body of the bullock. Since DA is a substrate for MAO it is
possible that this enzyme is involved in the inactivation mechanism
for DA released from type I cells. It was found, however, that
pargyline, a MAO inhibitor, had little effect on chemoreceptor
responses to NaCN, ACh, hypoxia or hypercapnic Locke solution.
Inhibitory responses to DA were enhanced following administration
of pargyline although this may, in part, have been due to the
increased background discharge frequency against which the inhibition
was measured. If endogenous DA modifies responses to chemoreceptor
stimuli as the results from experiments with DA receptor blocking
agents suggest (at least for NaCN and hypoxia), then the results
from experiments with pargyline suggest that MAO may contribute, but
is not very important to the inactivation mechanism for DA in the
region of the synapse at which the presumptive dopaminergic mechanism
operates. The increased response to injected DA may have been due
in part, to blockade of MAO at a site which is remote from the
synapse between sensory nerve ends and type I cells. It is possible
that another enzyme or enzymes, such as catechol-0-methyltransferase
(COMT) is of importance in the inactivation of DA in the synaptic
region. So far as I am aware, however, the distribution of COMT
in the carotid body or the effects of COMT inhibitors on chemo-
receptor activity have not been studied.
Cellular uptake is an important mechanism for the inactivation
of released neurotransmitter and for control of release in adrenergic
nerves and also in dopaminergic neurons in the C.N.S. (see Iversen,
197*0. Type I cells in the carotid body are not neurons, however,
and Mills et al (1978) have suggested that these cells may have no
mechanism for catecholamine uptake. Kobayashi's (1975) autoradiographic
studies, however, showed that DA was taken up into some, though not
all, type I cells in the mouse carotid body and Lishajko (1970) has
demonstrated uptake of tritiated DA into isolated granules of human
carotid body tumour. If cellular uptake is important as an
inactivation mechanism for DA released during chemoreceptor stimula¬
tion then drugs which block DA uptake might be expected to enhance
the effects of endogenously released DA. Alternatively if DA
uptake is not important then one would not expect drugs which block
DA uptake to have any appreciable effect on chemoreceptor activity,
unless by a non-specific action. Hence, if DA acts as an inhibitory
modulator of chemoreceptor activity, drugs which block DA uptake
would be expected to depress responses to chemoreceptor stimuli or
to have no effect, depending on whether or not uptake was an
important inactivation mechanism. In contrast to expected results,
however, benztropine and nomifensine, both potent inhibitors of DA
uptake, potentiated chemoreceptor responses to NaCN and hypoxia.
Benztropine also potentiated the response to hypercapnic Locke
solution. If these effects were due to blockade of DA uptake at
the synapse between type I cells and sensory nerve endings,then the
results suggest that endogenous DA has an excitatory effect on
chemoreceptor activity. That both benztropine and nomifensine blocked
DA uptake is evidenced by the observation that both caused a marked
potentiation of the inhibitory response to injected DA. Chemo¬
receptor responses to ACh were unaffected by either nomifensine or
low doses of benztropine. It may be, however, as suggested above,
that ACh stimulates afferent chemoreceptor activity by a direct
action on the terminal, unmyelinated portion of the sensory nerve
and so acts at a point which is central to that at which a dopaminergic
mechanism operates. The higher dose of benztropine reduced responses
to ACh but this is not surprising since benztropine, as well as
blocking DA uptake, has anticholinergic properties.
The above suggestion that endogenous DA may have an
excitatory effect on chemoreceptor activity does not invalidate
the earlier suggestion that endogenous DA has an inhibitory effect.
It may be that endogenous DA has both an inhibitory and an
excitatory effect on chemoreceptor activity. Zapata (1977) proposed
such a dual role for endogenous DA and Llados and Zapata (1978a)
have suggested that even in a preparation in which the response to
injected DA is inhibitory, "excitation could result in response to
liberation of endogenous DA ... if there is different accessibility
to the two types of DA receptors", i.e. exc i tatory and inhibitory DA
receptors. It may be that there are both excitatory and inhibitory
receptors for DA in the carotid body and that the juxtaposition of
the receptors on the sensory nerve end is such that the inhibitory
receptors are freely accessible to injected DA and the excitatory
receptors are less so, while the excitatory receptors are more
accessible than the inhibitory receptors to endogenous DA. Such a
situation might occur if the excitatory receptors are located on
the sensory nerve end, mainly in the region where this is apposed
to a type I cell, i.e. in the synaptic cleft, and the inhibitory
receptors are located on the periphery of the synaptic region and
on the extrasynaptic region of the sensory nerve end. Under normal
conditions DA release would be minimal and affect mainly the
excitatory receptors - hence blockade of the inhibitory receptors
with a-f1upenthixol has little effect on resting chemoreceptor
activity. When the chemoreceptors are stimulated, DA release
increases and the number of excitatory receptors activated
increases but the number of inhibitory receptors activated increases
also. Blocking the inhibitory receptors under these conditions would
tend to increase chemoreceptor activity and hence a-f1upenthixol
potentiates responses to chemoreceptor stimuli. DA uptake blockers
increase the amount of DA acting at both inhibitory and excitatory
receptors but since excitatory receptors predominate at the site of
DA release, chemoreceptor responses to stimulants are potentiated.
Administration of a-flupenthixol subsequent to benztropine caused
a marked potentiation of responses to NaCN which would be expected
if the above were the case. This interpretation also explains why
high doses of DA caused a delayed increase in discharge and even
low doses stimulate chemoreceptor discharge following administration
of a-f1upenthixol. In addition this could also explain why high
doses of amphetamine caused a stimulation of chemoreceptor discharge.
Kebabian and Calne (1979) have suggested that at least two
distinct types of DA receptor, designated D1 and D2, are present in
the mammalian C.N.S. The possibility that the excitatory and
inhibitory DA receptors in the carotid body correspond to the central
D1 and D2 receptors proposed by these authors is discussed further
in Section V.
From a consideration of the above, a 'self-modulating' mechanism
for the action of endogenous DA is proposed, i.e. DA is released from
type I cells and acts on excitatory receptors on the sensory nerve
end but the excitatory effect of DA on chemoreceptor activity is
limited by the presence of inhibitory receptors which are less
accessible to endogenous DA than the excitatory receptors but which
are activated when the amount of DA released has reached a sufficient
level. This conclusion, however, relies on the assumption that DA
uptake blockers potentiated responses to chemoreceptor stimuli by
blocking cellular uptake of DA at the synapse between type I cells
and sensory nerve endings and a 1 so that drugs which blocked the inhibitory
effect of injected DA potentiated responses to chemoreceptor stimuli
by blocking an inhibitory action of endogenous DA. It may be
worthwhile considering other possible interpretations of results
from experiments with drugs which block the DA inhibitory receptor
or prevent uptake. It is possible, for example, that the effects
of these drugs were a consequence of changes in carotid body blood
flow or an action on a noradrenergic or serotinergic mechanism since
the carotid body contains both NA and 5"HT (see Section l).
B1 ood f 1 ow
An increase in carotid body blood flow would be expected to
decrease, and a reduced flow to increase, the frequency of
spontaneous chemoreceptor discharge in animals breathing room air
(see Torrance, 1968). Neither a-flupenthixol nor haloperidol
had any appreciable effects on resting discharge frequency. It is
unlikely that the effects of these drugs are attributable to flow
changes. Both benztropine and nomifensine, however, increased
resting discharge frequency and it is possible therefore that these
drugs reduced carotid body blood flow. If this occurred, it is
unlikely to have resulted from an effect on the general circulation
since benztropine caused a slight decrease, and nomifensine (0.1 and
0.2 mg/kg I.C.) caused a slight increase, in arterial B.P. The
drugs may, however, have had a particular effect on carotid body
blood flow. If carotid body flow was reduced, however, the dose of
stimulant drugs reaching the chemoreceptors would also be reduced
since a smaller amount of carotid blood would enter the carotid body
and drugs were injected into the carotid artery. Nevertheless, if
decreased flow reduced O2 availability to the chemoreceptors (but
see Torrance, 1968) responses to NaCN and CO2 could still be
potentiated since the effects of both stimulants are interactive
with hypoxia, i.e.the chemoreceptor response is greater when 02
levels are reduced (Lahiri, 1977). This argument does not apply to
ACh, however, since the chemoreceptor response to ACh is additive
with hypoxia, i.e. the magnitude of the response to ACh is not
dependent on 02 levels (Lahiri, 1977). Since chemoreceptor
responses to ACh were not appreciably affected by nomifensine or
by low doses of benztropine it is unlikely that the dose of ACh
reaching the chemoreceptors was changed. Hence, blood flow through
the carotid body was probably little affected by the DA uptake blockers.
An explanation of the effects of benztropine and nomifensine based
on flow changes is, therefore, untenable.
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NA
a-Flupenthixol, though more selective for DA receptors, may
also block a-adrenergic receptors (Moller Nielsen et al, 1973) and
benztropine and nomifensine can block NA uptake (Horn, Coyle and
Snyder, 1971; Hoffmann, 1977). It is possible, therefore, that the
observed effects of these drugs are a consequence of their action on
a noradrenergic rather than a dopaminergic mechanism.
I.C. injection of NA caused a brief inhibition of chemo-
receptor activity followed by excitation. This result is in good
agreement with results obtained by other workers (Sampson, 1972;
Sampson et al, 1976a, 1976b; Llados and Zapata, 1978b; see also
Section l). The time course of the delayed excitatory effect was
similar to the time course of the pressor response to NA and was
probably due to reduced blood flow through the carotid body as a
consequence of vascular changes (see Section l). Llados and Zapata
(1978b) found that I.C. injection of NA did not always produce an
inhibitory response and attributed this effect, when observed, to
a 'flush response1 or to a weak action of NA on DA inhibitory
receptors. Great care was taken in the present experiments to
avoid 'flush responses' (see Section !l) and it is unlikely that
this phenomenon accounts for the inhibitory effect of NA observed
in these experiments. In agreement with Llados and Zapata, however,
it was found that NA did not always produce an inhibitory effect.
The inhibitory response to NA was prevented by administration
of a high dose of the a-adrenergic blocking agent PBA (5+5 mg/kg
I.V.) but not by a lower dose (5 rng/kg I.V.) although the pressor
response was blocked by either dose. Also, the lower dose of PBA
had little effect on resting chemoreceptor discharge frequency but
100
the higher dose caused an increase in frequency. Similar results
were obtained by Llados and Zapata (1978b) who suggested that blockade
of the inhibitory response to NA was an indirect effect resulting
from the hypotension produced by high doses of PBA. It was found
in the present experiments, however, that although administration
of the lower dose of PBA caused a 20 - 30 per cent reduction in B.P.,
the inhibitory response to NA was not affected while increasing the
dose of PBA blocked the inhibitory response to NA without further
modifying B.P. It seems unlikely, therefore, that blockade of the
NA inhibitory response by the higher dose of PBA was due to the
development of hypotension.
Chemoreceptor responses to NaCN were potentiated following
administration of PBA. Since high doses of PBA blocked the
inhibitory response of the chemoreceptors to NA and since a-flupenthixol
also blocked this effect, it is possible that potentiation of chemo¬
receptor responses to NaCN following administration of a-f1upenthixol
was a consequence of blockade of a-adrenergic receptors rather than
DA receptors and that this is also the mechanism for the potentiating
effect of PBA. These results then, might be interpreted in favour
of the idea that a-adrenergic receptors mediate inhibition of
chemoreceptor activity in vivo (see Section l). If this is the case,
however, it is difficult to explain the effects of benztropine and
nomifensine on the chemoreceptor response to NaCN. Nomifensine
potentiated the chemoreceptor response to injected NA. It is
possible that nomifensine and benztropine block cellular uptake of
NA, released during chemoreceptor stimulation, and that endogenous
NA stimulates afferent chemoreceptor activity by a B-adrenergic
action. This is unlikely, however, since propranolol, a B-adrenergic
antagonist, did not reverse the potentiation of responses to NaCN
caused by PBA and 3-adrenergic blockers do not otherwise have any
appreciable effect on chemoreceptor activity (Llados and Zapata,
1978b; see also Section l). In any case, it is unlikely that the
inhibitory effect of NA is mediated by a-adrenergic receptors
since the low dose of PBA which blocked the pressor response to
NA, had little effect on NA-induced inhibition of chemoreceptor
activity.
From the above it may be seen that it is difficult to explain
the effects of DA antagonists or uptake blockers in terms of any
non-specific effects they may have on a noradrenergic mechanism.
It is possible, however, that the effects of NA and PBA were a
consequence of non-specific effects of these substances on a
dopaminergic mechanism. It may be, as Llados and Zapata suggest
(see above), that the inhibitory effect of NA is due to a weak
agonist action of NA on DA inhibitory receptors. Also, PBA has
been shown to enhance the release of DA from rat brain slices during
electrical stimulation (Howd and Horita, 1975) and it is possible
that the drug may also increase the release of DA from type I
cells in the carotid body during chemoreceptor stimulation which,
if endogenous DA stimulates chemoreceptor activity, would be
expected to cause potentiation of responses to chemoreceptor stimuli.
The lack of drugs which act specifically on either noradrenergic or
dopaminergic mechanisms make this a difficult problem to study.
An indication of the effects, if any, of endogenous NA on chemo¬
receptor activity might be obtained by studying the effects of the
catecholamine uptake blocker desipramine, which is about one
thousand times more potent for blocking NA than DA uptake (Foster,
1967), on chemoreceptor activity. This experiment, however, was not
performed in the present study.
5-HT
The effects of 5-HT and of some antagonists of 5-HT on chemo¬
receptor activity in the cat carotid body were the subject of a
recent study by Nishi (1975) (see Section l). The results obtained
with 5~HT in the present study were similar to those obtained by
Nishi. The excitatory effect of 5-HT was blocked by low doses of
a-f1upenthixol but the inhibitory response was not affected until
high doses of a-f 1 upenthixol (>0.5 mg/kg I.C.) were administered.
This result is not surprising since a-f1upenthixol, although a
potent DA antagonist, also antagonizes the effects of 5~HT in the
C.N.S., being only slightly more selective for DA (Straughan and
Dray, 1976). The chemoreceptor response to 5~HT was not appreciably
affected by benztropine however, and it is unlikely that the effects
of DA antagonists or uptake blockers on chemoreceptor activity were
due to a non-specific effect on a serotinergic mechanism.
Surprisingly, responses to 5-HT were unaffected by pargyline although
5-HT is a good substrate for MAO. This is further evidence that
MAO activity in the cat carotid body is low. Starlinger (1977)
attributed this low MAO activity in the cat carotid body to the
presence of an endogenous inhibitor of the enzyme.
Summary
From a consideration of the above it can be seen that the
effects of DA antagonists or uptake blockers on chemoreceptor
activity cannot be satisfactorily explained in terms of changes in
carotid body blood flow or any non-specific actions they may have on
a serotinergic mechanism. It is possible that potentiation of
responses to chemoreceptor stimuli following administration of
a-f1upenthixol is due to blockade of a-adrenergic receptors although
it seems more likely that this is due to blockade of DA inhibitory
receptors and, in any case, the potentiating effect of DA uptake
blockers on responses to chemoreceptor stimuli is difficult to
explain in terms of a noradrenergic mechanism. Further experiments
are required to elucidate the role, if any, of NA in the carotid
chemoreceptors. The most satisfactory explanation of the results
is that DA has both excitatory and inhibitory effects on carotid
chemoreceptor activity mediated by at least two distinct DA
receptors in the manner described above. This does not mean to say
that the type I cells in the carotid body are the chemoreceptors and
that DA-induced increase of chemoreceptor activity is the sole
mechanism for stimulation of afferent chemoreceptor activity, although
this is a possibi1ity.
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SECTION IV
THE EFFECTS OF ACETYLCHOLINE, DOPAMINE AND
5-HYDROXYTRYPTAMINE ON CHEMORECEPTOR ACTIVITY
IN THE RABBIT CAROTID BODY
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INTRODUCTION
The present electrophysiological investigation was undertaken
to examine the effects of ACh on carotid chemosensory activity in the
rabb i t.
ACh has been shown to stimulate carotid chemoreceptor activity
in the cat and dog and it has been suggested that this substance
may act as a sensory transmitter in the carotid body (see Section I).
It was therefore of interest to determine the effects of ACh on
carotid chemosensory activity in the rabbit since at the time the
present investigation was instituted, there were no reports available
in the literature concerning the effects of ACh or of drugs which
affect the cholinergic system on chemoreceptor activity in this species.
The opportunity was taken to investigate the effects of DA and
5_HT on the activity of rabbit carotid chemoreceptors since reports
of the effects of these substances on chemoreceptor activity in the
cat and dog suggest that their effects are species-specific (see
Sect ion I).
RESULTS
Experiments were performed on 86 rabbits (six female New
Zealand Whites, 7^ male New Zealand Whites and six male Californian
rabbits) weighing between 2.0 and ^4.0 kg (mean weight ± standard
error = 2.9±0.1 kg). Thirty-two recordings of afferent chemo¬
receptor activity (three single and 29 multiple units) were obtained
in 26 of these animals (all male; 2h New Zealand White and two
Californian rabbits), i.e.recordings of chemoreceptor activity were
obtained in approximately 30 per cent of the experimental animals.







Recording of chemoreceptor activity obtained from a rabbit
illustrating responses of the units to ACh (A), DA (B) and
NaCN (C). Panels show, from above downwards : action
potentials, B.P (mm Hg) and injection marker. The time
bar refers to all three panels.
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Figure 4.2
Dose-response data for ACh (A % B) and NaCN (C & D) obtained
from four experiments. Panels A and C show data obtained
from experiments in which the ganglioglomerular nerve was
intact and panels B and D show data from experiments in which
this nerve was eliminated. Data in A, B, C and D were from
recordings of three, two, three and two chemoreceptor units
respectively. Doses are plotted on a log10 scale and lines
fitted to the data by the method of least squares.
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Ill) where recordings of chemoreceptor activity were obtained in
approximately 90 per cent of the experimental animals. Possible
reasons for the low success rate in rabbits and a discussion of non-
chemoreceptor afferent activity in the rabbit sinus nerve are given
in Appendix I.
Animals were anaesthetized with either sodium pentobarbitone
or urethane and a-chloralose as described in Section II.
Responses to acetylcholine
In all the experiments in which recordings of chemoreceptor
activity were obtained, including two experiments in which the
superior cervical ganglion was extirpated and two in which the
ganglio-g1omeru1 ar sympathetic nerve was cut, injections of ACh
(1 - 250 yg I.C.) caused an immediate, short-1 ast i ng (<30 sec)
inhibition of chemoreceptor activity. A typical response to an
I.C. injection of ACh is illustrated in Figure 4.1A. Figure
A.2A, B, shows dose-response data for ACh in two experiments,
one in which the ganglio-glomerular nerve was intact and one in
which it was sectioned. There was an approximately linear relation¬
ship between log^g dose and response (AEx) over the range 5~ 100 yg
I.C. (see Figure A.2). Doses in this range, which always caused
inhibition of chemoreceptor activity in the rabbit, are comparable
to doses which stimulate chemoreceptor activity in the cat (McQueen,
1977). In some experiments, the inhibition observed following
administration of high doses of ACh (>50 yg I.C.) was preceded by
a slight (2-3 times control discharge), transient period of
stimulation lasting less than one second (see Figure A.AC).
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Figure 4.3
Panels A and B show chemoreceptor units from an experiment
illustrating the response to ACh (10 jig I.C.) before (A)
(B) administration of gallamine
C shows dose-response data from
before (o o) and after (x—x)
(6 mg /kg I.V.). Panels A and
(3 mg /kg I.V.)
a second experiment
administration of





downwards : action potentials and injection marker. The time
bar refers to both A and B. In C doses were plotted on a
log10 scale and lines were fitted by the method of least
squares.
110
Response to sodium cyanide
NaCN increased carotid chemosensory activity in all the experi¬
ments in which recordings of chemoreceptor activity were obtained
including the four experiments in which connections between the
superior cervical ganglion and the carotid body were eliminated.
The threshold dose for stimulation was about 2.5 Vg I.C. and a
maximum response was elicited by 25 ug I.C. The effective dose-
range is comparable to that for exciting carotid chemoreceptors in
the cat (McQueen, 1977). Figure 4.2C, D, shows dose response data
for NaCN in two experiments, one in which the ganglio-glomerular
nerve was intact and one in which this nerve had been cut, illustrating
the approximately linear relationship between log1Q dose and response
(AEx) over this range. A typical neurogram illustrating the
response of rabbit carotid chemoreceptors to NaCN is shown in
Figure k.1C) .
Effects of Gallamine
It has been found that neuromuscular blocking agents such as
gallamine and D-TC depress the stimulant effect of ACh on chemo¬
receptor activity in the cat carotid body in vitro (Eyzaguirre and
Zapata, 1965b). In all the experiments performed in the present
study, gallamine triethiodide (3 mg/kg I.V.) was administered to
paralyse spontaneous respiration and minimise muscular movement
in the vicinity of the recording electrodes (see Section II). Two
experiments were performed in order to ascertain whether low doses
of gallamine had any effect on the response of the rabbit carotid
chemoreceptors to ACh or NaCN. Gallamine (3-6 mg/kg I.V.) had



















Panels A and B show dose-response data for NaCN (A) and ACh
(B) , before (•——•) and after (x x) administration of
mecamylamine ( 0.5 mg /kg I.C.). Doses are plotted on a
log10 scale and lines fitted by the method of least squares.
Panels C and D show the chemoreceptor response to a high
dose (50 (J.g I.C.) of ACh, before (C) and after (D)
administration of mecamylamine (0.5 mg /kg I.C.). The
chemoreceptor recording shown in C and D is from the same
experiment as the data shown in A and B. Panels C and D
show from above downwards : action potentials and injection
marker. The time bar refers to panels C and D.
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It was not possible to obtain linearly related dose-response data
for ACh before and after administration of gallamine since injection
of high doses of ACh (>25 yg I.C.) prior to administration of
gallamine usually resulted in loss of the recording due to muscular
movement causing displacement of the nerve from the recording
electrodes. The inhibition of chemoreceptor activity produced by
small doses of ACh (5 or 10 yg I.C.) was not, however, appreciably
affected by gallamine (see Figure 4.3A, B).
Effects of mecamylamine
Mecamylamine is a potent ganglion blocking drug (Stone,
Torchiana, Navarro and Beyer, 1956; Bennet, Tyler and Zaimis,
1957) which can reduce or abolish the increase in chemoreceptor
activity evoked by ACh in the cat carotid body in vitro (Eyzaguirre
and Zapata, 1968b) or in vivo (Sampson, 1971; Nishi and Eyzaguirre,
1971).
In the present experiments with mecamylamine, the appropriate
volume of dextran solution (2.5% dextran, 5% glucose in distilled
water) required to maintain B.P. at the control level was administered
I.V. This treatment prevented the fall in B.P. which would other¬
wise have accompanied administration of this ganglion blocking,
drug making interpretation of results difficult. The effects of
mecamylamine on carotid chemoreceptor activity were investigated in
four experiments.
Mecamylamine (0.5~ 5 mg/kg I .V. or 0.25 - 0.50 mg/kg I.C.) did
not reduce the inhibitory chemoreceptor response to ACh but caused
a slight potentiation of responses in some experiments (see Figure

















Response of carotid chemoreceptors (two units) to 120 sec of
hypoxia (breathing 5% 02 in N2) before ( ) and after ( )
administration of mecamylamine (1.0 mg /kg I.V.). Panels
show, from above downwards : discharge frequency (averaged




















Response of carotid chemoreceptors (three units) to 90 sec
of hypoxia (breathing 5% 02 in N2) before ( ) and after
( ) administration of atropine (0.5 mg /kg I.e.). Panels
show, from above downwards : discharge frequency (averaged
over 5 sec intervals), time and period of hypoxia (horizontal
black bar).
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abolished by mecamylamine (see Figure 4.4C,D). The response of the
carotid chemoreceptors to NaCN, especially the higher doses, was
reduced but not abolished by mecamylamine (see Figure 4.4A).
Mecamylamine also caused a slight reduction in the chemoreceptor
response to hypoxia (see Figure 4.5). There was no obvious change
in the frequency of spontaneous discharge in animals breathing room
air following I.V. injection of mecamylamine (1-5 mg/kg) but there
was a reduced frequency of discharge following close-arterial
administration of the drug (0.5 mg/kg I.C.) (see Table 4.1).
TABLE 4.1: Spontaneous chemoreceptor discharge frequency (x,
"counts/sec) in animals breathing room air, before and
after administration of mecamylamine. In experiments
marked *, progressively larger doses of mecamylamine
were administered. In these cases the dose included






mecamy1 amine x before x after
R63 3 1 mg/kg I • V. 6.7 7.6
R42" 3 2 mg/kg I .V. 21.9 19.0
R37 6 5 mg/kg I .V. 19.8 24.3
R61* 1 0.5 mg/kg I • C. 3.0 0.6
Effect of atropine
The effect of atropine on chemoreceptor activity was studied
in nine experiments. There was considerable variation in the dose
of atropine required to block the vasodepressor action of ACh. Low
doses of atropine (cumulative doses of 1 and 2 mg/kg I.V.) had no
consistent effect on either the depressor response or the inhibition
of chemoreceptor activity produced by ACh. The mean dose-ratio
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Figure 4.7
Response of carotid chemoreceptors (three units) to ACh
(10 jig I.C.) before (A) and after (B) administration of
atropine (10 mg /kg IV.). Panels show from above
downwards : discharge frequency, injection marker, mean
B.P. (mm Hg) and time.
Figure 4.8
Dose-response data for ACh (A), BCh (B) and NaCN (C), from a
recording of three chemoreceptor units, before (•———•) and
after (x x) administration of atropine (1.0 mg /kg I.C.).
Doses are plotted on a log10 scale and lines fitted by the
method of least squares.
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tendency for these low doses of atropine to reduce the inhibitory
effect of ACh although the high value of the range associated with
each mean dose-ratio illustrates the variability of this effect.
TABLE 4.2: Geometric mean dose-ratios (d.r.) for the effects of
atropine on chemoreceptor responses to ACh. The number
of experiments (n) , the median (m) and range of valI ues
(r) associated wi th each ratio are included in the tab I e
Dose of atropine d.r. n m r
1 mg/kg I.V. 1.7 4 1.9 4. 0
2 mg/kg I.V. 2.2 3 1.9 5.8
5 mg/kg I.V. 5-7 3 9.2 19.A
Higher doses of atropine (5 mg/kg I.V. additional to the 1 and 2 mg/
kg I.V. doses or 10 mg/kg I.V.) sufficient to block the depressor
effects of ACh reduced, but did not abolish, the inhibition of
chemoreceptor activity produced by ACh (see Figure 4.7) although,
as with the lower doses of atropine, the magnitude of the effect
varied considerably between experiments. Administration of atropine
close-arterial to the carotid body (1 mg/kg I.C.), however, greatly
reduced the chemoreceptor response to ACh (see Figure 4.8A).
Chemoreceptor responses to NaCN were not appreciably altered
fol1owing I.V. administration of atropine (1-10 mg/kg I.V.).
Sufficient data was available to calculate the geometric mean dose-
ratio for the 1 and 2 mg/kg I.V. doses of atropine on the response
to NaCN giving values of 1.4 (number of experiments = 4, median =
1.2, range = 2.6) and 1.0 (number of experiments = 3, median = 0.9,
range = 1.1) respectively. There was a slight reduction in the






Panels A and B show dose-response data for NaCN (A) and ACh
(B), from a recording of four chemoreceptor units, before
(•——•) and after (x x) administration of physostigmine
(0.1 mg /kg I.C.). Doses are plotted on a log10 scale and
lines fitted by the method of least squares. Panel C shows
the response to hypoxia (breathing 5% 02 in N"2), in the same
experiment, before ( ) and after ( ) administration
of physostigmine (0,1 mg /kg I.C.). Panel C shows from
above downwards : discharge frequency, time and period of
hypoxia (horizontal black bar).
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(1 mg/kg I.C.) (see Figure 4.8c). The chemoreceptor response to
hypoxia did not appear to be affected by atropine (see Figure 4.6)
nor was there any obvious change in the frequency of chemoreceptor
discharge in animals breathing room air (see Table 4.3).
TABLE 4.3: Spontaneous chemoreceptor discharge frequency (x,
counts/sec - values quoted as arithmetic mean ±
"standard error) in animals breathing room air~before
and after administration of atropine. Doses marked *
were from the same experiment, 0.3 mg/kg I.C. being
administered subsequent to 10 mg/kg I,V.
No. of Dose of
experiments atropine x before x after
5 1 mg/kg I .V. 19.2 ± 4.3 15.1 ±3.3
4 2 mg/kg I .V. 16.5± 5.3 9.4 ± 4.5
3 5 mg/kg 1 .V. 16.7 ± 4.0 18.1 ± 2.5
1 10 mg/kg 1 .v.* 0.6 0.4
1 0.5 mg/kg 1 .v.* 0.6 0.9
2 1.0 mg/kg 1 .V. 21.4 ± 2.4 17.0 ± 1.6
Effects of physostigmine (eserine)
Physostigmine is a potent anticholinesterase drug which is
effective against both acetylcholinesterase and pseudocholinesterase
(see Koelle and Gilman, 1949). The effects of physostigmine on
carotid chemoreceptor activity were studied in three rabbits. In
each of these animals the ganglio-glomerular nerve remained intact.
Administration of cumulative doses of 0.1 and 0.2 mg/kg I.C.
of physostigmine greatly potentiated ACh-induced inhibition of
chemoreceptor activity (see Figure 4.9B) . There was no increase in
the tendency for ACh to produce excitatory effects following
administration of physostigmine. The excitatory response to NaCN
became less consistent following administration of physostigmine
making the effects of the drug difficult to interpret (see Figure
4.9A). There was, however, no consistent change in the magnitude
of responses to NaCN following administration of physostigmine.
The chemoreceptor response to hypoxia was not appreciably altered
by physostigmine (see Figure 4.90). Physostigmine sometimes
increased and sometimes decreased the frequency of spontaneous
discharge in animals breathing room air but had no consistent effect
(see Table 4.4).
TABLE 4.4: Spontaneous chemoreceptor discharge frequency (x) in
animals breathing room air, before and after
administration of cumulative doses of 0.1 and 0.25




un i ts Control
x (counts/sec):
after after
0.1 mg/kg I.C. 0.2 mg/kg I.C.
R76 3 25.6 20.0
R77 4 21 .1 36.7 12.6
R85 6 oo 92.7 77.9
Response to subery1dicholine (SDCh)
SDCh is a potent nicotinic agonist which has been shown to
stimulate the carotid chemoreceptors of the cat (Anichkov and
Belen'kii, 1963; Dardymov and Ger, 1964; McQueen, 1974). The
effects of SDCh on carotid chemoreceptor activity in the rabbit was
studied in four experiments. SDCh (10-100 yg I.C.) had no effect
or caused a slight inhibition of chemoreceptor activity in this






































Responses of carotid chemoreceptors, from a recording of
three units, to ACh, BCh, SDCh and MCh. Panels show, from
above downwards : discharge frequency and mean B.P. Inject¬
ions were made at the arrows. The time bar refers to all
four panels.
121
Response to bethanechol (BCh)
BCh is a muscarinic cholinomimetic substance which is free
of nicotinic actions (Molitor, 1936). Injections of single doses of
BCh (50 or 100 yg I.C.) caused inhibition of chemoreceptor activity
in each of the five rabbits in which its action was investigated
(see Figure 4.10). The relationship between logjo dose and response
was studied in one experiment and was found to be linear in the
range 25-100 yg I.C. (see Figure 4.8b). Unlike the response to
ACh, the inhibition of chemoreceptor activity produced by BCh was
not preceded by stimulation at high doses (i.e. 50 - 100 yg I.C.). The
chemoreceptor response to BCh was greatly reduced following close-
arterial administration of atropine (1 mg/kg I.C.) (see Figure 4.8b).
Response to methacholine (MCh)
MCh is a potent cholinergic agonist which exhibits predominantly
muscarinic cholinomimetic effects (Simonaert, 1932; Hunt and *■?
Renshaw, 1934) although it can stimulate carotid chemoreceptors in
the cat by a weak nicotinic cholinomimetic action (McQueen, 1978;
see Sect ion I) .
The effect of MCh on carotid chemoreceptor activity in the
rabbit was studied in three experiments. Injections of single doses
of MCh (5, 10 or 25 yg I.C.) caused an inhibition of chemoreceptor
activity which was qualitatively similar to that produced by ACh or
BCh (see Figure 4.10).
There was considerable variation between experiments in the
relative potencies of ACh, BCh and MCh in their ability to produce
inhibition of chemoreceptor activity and insufficient data are
available to make a quantitative estimate of their relative potency.
Figure 4.11
Dose-response data for DA, from a recording of one chemorecep-
tor unit, before (•——•) and after (x x) administration of
gallamine (3.0 mg /kg I.V.). Doses are plotted on a log10
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Data from two experiments showing the response of carotid
chemoreceptors to DA before (a) and after (b) administration
of mecamylamine (A) and atropine (B)'. Recordings were of
three chemoreceptor units in both experiments. Panels show,
from above downwards : discharge frequency and time.












































Data from two experiments showing the response of carotid
chemoreceptors to DA before (a) and after (b) administration
of physostigmine. Recordings were of three units in A and
four units in B. Panels show from above downwards : discharge
frequency and time. Injections of DA were made at the upward
pointing arrows.
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Qualitatively, however, on a molar basis, the order of potency was
MCh ^ ACh > BCh.
Responses to dopamine
The effect of DA on carotid chemoreceptor activity was studied
in 22 experiments. Injections of DA (0.5-10 yg I.C.) caused an
immediate, short-1asting (<30 sec) depression of chemoreceptor
activity in all the experiments. Figure 4.1B shows a typical response
of rabbit carotid chemoreceptors to DA. The present study was
restricted to low doses of DA since it had been found in experiments
with cats that higher doses of DA tend to produce secondary excitations
which curtail the primary inhibition and give inconsistent responses
(see Section III). In some experiments, however, the inhibitory
response of the rabbit chemoreceptors to DA was followed by a slight
secondary excitation even at these low doses. This phenomenon was
uncommon, occurring in response to only 12 of a total of 50
injections of DA.
The relationship between the inhibitory response to DA and
log10 dose was studied in eight experiments and was found to be
approximately linear over the range 0.5 "5 yg I.C. Gallamine
(3-6 mg/kg I.V.) slightly potentiated the inhibitory response to
DA (see Figure A.11). There was no apparent change in the response
to single doses of DA (5 or 10 yg I.C.) following administration
of mecamylamine (0.5 - 5 mg/kg I.V. or 0.25-0.5 mg/kg I.C.) (see
Figure 4.12A) or low doses of atropine (1-10 mg/kg I.V.). There
was, however, a slight reduction in the response to DA following
close-arterial administration of atropine (1.0 mg/kg I.C.) (see
Figure 4.12B). The effects of physostigmine on the response to DA
Figure 4.14
Dose-response data for NaCN (A) and ACh (B), obtained from
a recording of three chemoreceptor units, before (• •) and
after (x—x) administration of a-flupenthixol (0.25 mg /'kg
I.V.). Doses are plotted on a log10 scale and lines fitted
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Figure 4.15
Response of carotid chemoreceptors (four units) to DA before
(A) and after (B) administration of a-flupenthixol. Panels
show, from above downwards : discharge frequency and time.





Chemoreceptor units from an experiment showing the response
to D-amphetamine (10 (ig I.C.) before (A) and after (B)
administration of a-flupenthixol (0.5 mg /kg I.V.). Panels
show, from above downwards : action potentials and injection
marker. The time bar refers to both panels.
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were studied in two experiments. The results obtained are difficult
to interpret, however, because of the changes in spontaneous
discharge frequency which occurred following administration of
physostigmine. In one experiment there was no change in the
numerical value (A£x) of the response to DA (see Figure 4.13A)
while in the second this was increased (see Figure 4.13B). In both
experiments the duration of the response to DA was increased which
suggests that physostigmine may slightly potentiate the effects of DA.
Effects of a-f1upenthixol
The effect of a-f 1 upenthixol (0.25-0.5 mg/kg I .V. or 0.25-
0.5 mg/kg I.C.) on chemoreceptor activity was studied in seven
rabbits. The inhibitory action of DA on carotid chemosensory
TABLE b.k: Spontaneous chemoreceptor discharge frequency (x,
counts/sec - presented as arithmetic mean± standard
Trror) in animals breathing room air before and after
administration of a4H upenthixol
No. of Dose of
experiments a-f1upenthixol x before x after
2 0.25 mg/kg I .V. 26.5± 2.7 20.9 ±0.8
k 0.50 mg/kg I .V. 15-3 ± 6.6 16.2±6.9
1 0.25 mg/kg I.C. 19-9 27.6
2 0.50 mg/kg I.C. 26.3 ± 6.5 30.7±6.i4
activity was reduced or abolished following administration of
a-f1upenthixol and there was an increased tendency for DA to
produce delayed excitatory effects (see Figure ^.15). The
inhibitory action of ACh on chemosensory activity was little
affected by a-f1upenthixol while the excitatory response to NaCN
was potentiated (see Figure ^.14). There was no obvious change in
5 sec
Figure 4.17
Chemoreceptor units from an experiment showing responses to
5-HT (5 jig I . C. ) (A, B <k C) and DA (0.5 jig I.C.)(D, E Ik F)
before (A k D) and after (B k E) administration of gallamine
(3.0 mg /kg I.V.) and after (C k F) subsequent administration
of a-flupenthixol (0.5 mg /kg I.V.). Panels show, from above
downwards : action potentials and injection marker. The time
bar refers to all six panels.
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the frequency of spontaneous chemoreceptor discharge following
administration of oi-f 1 upenthixol (see Table 4.4).
Response to D-amphetamine
The effect of D-amphetamine on chemoreceptor activity in the
rabbit was studied in one experiment. Injection of a single dose of
D-amphetamine (10 yg I.C.) caused an immediate depression of chemo¬
receptor activity which was greatly reduced by administration of
a-f1upenthixol (0.5 mg/kg l.C.) (see Figure 4.16).
Responses to 5~hydroxytryptamine
The effect of 5"HT on carotid chemoreceptor activity was
studied in 11 experiments. Injection of 5-HT (0.25-10 yg l.C.)
caused an intense but transient (<2 sec) stimulation of chemo¬
receptor activity followed by a period of inhibition (2-25 sec)
(see Figure 4.17). Both the excitatory and inhibitory components
of the response were subject to considerable variation in any
experiment making an accurate assessment of the effects of blocking
drugs difficult. Gallamine (3-6 mg/kg I.V.) did not appear to
modify the response to 5-HT (see Figure 4.17), nor did the cholinergic
antagonists mecamylamine or atropine. Doses of a-f1upenthixol which
greatly reduced the inhibitory effects of DA had little effect on
responses to 5-HT (see Figure 4.17).
Responses to vasodilator substances
1. Sodiurn nitrite
Sodium nitrite is a potent vasodilator which acts directly
on vascular smooth muscle (Weiss, Wilkins and Haynes, 1937).






















Response of carotid chemoreceptors (three units) to ACh and
sodium nitroprusside. Panels show from above downwards :
discharge frequency and mean B.P. Injections were made at
the arrows. The time bar refers to both panels.
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or caused a slight inhibition of chemoreceptor activity. The
magnitude of the inhibition did not appear to be dose-related and
was only slightly greater than that produced by an equal volume
(0.1 ml) of Locke solution. The effectiveness of sodium nitrite
as a vasodilator in the rabbit is uncertain, however, since
injection of sodium nitrite had very little effect on arterial B.P.
2. Sodium nitroprusside
Sodium nitroprusside, like sodium nitrite, is a potent
vasodilator which acts directly on vascular smooth muscle (Johnson,
1929). Injection of sodium nitroprusside (10- 50 ug I.C.) caused
a short-1asting (4 - 7 sec) inhibition of chemoreceptor activity,
which did not appear to be dose-related, and evoked a marked
depressor response (see Figure 4.23). In some experiments sodium
nitroprusside caused a delayed increase in chemoreceptor activity
which was dose-dependent.
DISCUSSION
Although the first reported recordings of afferent impulse
activity in the sinus nerve were obtained using rabbits as the
experimental animal (see Bronk and Stella, 1932) there have, since
that time, been few electrophysiological studies of afferent chemo¬
receptor activity in this species - cats or, less frequently, dogs
being the preferred species for such experiments. It is therefore
worthwhile to briefly discuss the advantages and disadvantages of
using rabbits as experimental animals in this type of study. The
greatest advantage is that of cost, since rabbits, for experimental
purposes, may be obtained more cheaply than cats or dogs. A second
advantage is that the sinus nerve of the rabbit is not embedded
in muscle or connective tissue as is the corresponding nerve in the
cat or dog and is consequently more easily accessible by surgery.
These advantages are, however, offset by the disadvantage that a low
success rate, at least for recording chemoreceptor activity, may be
expected and hence a larger number of animals and, perhaps more
important, a greater amount of time must be expended in order to
obtain useful data. This disadvantage does not apply to experiments
in which it is desirable to study afferent baroreceptor activity
which is relatively easy to record from the rabbit sinus nerve (see
Appendix I) making this species particularly suitable for such a
study. Rabbits were chosen as experimental animals in the present
investigation partly for financial reasons and partly due to the
fact that a study of the effects of ACh, DA and 5~HT on afferent
chemoreceptor activity in this species had not previously been
performed.
The results show that ACh and DA both inhibit chemoreceptor
activity while 5-HT causes excitation followed by inhibition of
activity in anaesthetized rabbits. The responses of the rabbit
carotid chemoreceptors to DA and 5_HT were qualitatively similar to
the corresponding responses of cat carotid chemoreceptors (see
Section III). The inhibitory response to ACh, however, was
unexpected, being in complete contrast to the stimulant action
obtained in other species (see Section l). Experiments were
performed to investigate the mechanism whereby ACh inhibits chemo¬
receptor activity. The results obtained are discussed below.
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Vascular effects
Sampson and Vidruk (1977) found that ACh caused depolarisation
of the d.c. potential recorded from the sinus nerve of the rabbit
carotid body in vitro. Since this response is characteristic of
substances which stimulate chemoreceptor discharge in this
preparation, e.g. NaCN, the possibility that the inhibition of chemo¬
receptor activity produced by ACh in the rabbit carotid body in situ
was due to a vascular effect must be considered. Inhibition of
chemoreceptor discharge could have resulted from an action of ACh on
vascular smooth muscle, although the short latency to onset of the
effect argues against this, at least for the early part of the
response. Vasodilatation of the carotid body vasculature would
increase blood flow into the glomus and might thereby be expected
to reduce spontaneous chemoreceptor discharge before any tendency
for discharge to increase secondary to the delayed fall in B.P.
caused by circulation of the ACh, although autoregulation of blood
flow which can occur in the rabbit carotid body (McCloskey, 1968)
complicates this speculation. It was found that administration of
doses of atropine (5 or 10 mg/kg I.V.) sufficient to block the ACh-
induced fall in systemic B.P. reduced, but did not abolish, the
chemoreceptor response to ACh. The vascular explanation therefore
seems unlikely, providing that the carotid body vasculature
responsiveness to ACh is similar to that of the peripheral vasculature.
This may or may not be the case. Also, it is possible that the high
local concentration of ACh following I.C. injection was sufficient
to overcome the antagonistic effect of atropine in the region of the
carotid sinus. It was found, however, that l.C. administration of
the vasodilators sodium nitrite and sodium nitroprusside had little
effect on chemoreceptor activity. It is questionable whether sodium
nitrite is an effective vasodilator agent in rabbits in the doses used
in the present study since administration of this substance had very
little effect on systemic B.P. Sodium nitroprusside, however,
caused a marked fall in B.P., presumably due to its vasodilator
action, but had little effect on chemoreceptor activity. The delayed
increase in discharge observed following administration of sodium
nitroprusside in some experiments was probably due to production of
cyanide ions during the conversion of nitroprusside to thiocyanate.
These results with atropine and sodium nitroprusside indicate that
although vasodilatation may explain a small part of the inhibition
of chemoreceptor activity evoked by ACh, it is not responsible for
the greater part of the effect. This view is supported by the
recent finding that ACh inhibits afferent chemoreceptor activity
in the superfused rabbit carotid body in vitro (Monti-Bloch and
Eyzaguirre, 1977)- In view of these observations it seems doubtful
whether results obtained by measuring d.c.potential changes in the
sinus nerve, such as those of Sampson and Vidruk (above), may be
compared meaningfully with results obtained by measuring afferent
chemoreceptor activity.
Very recently, Matsumoto, Nagao, Ibi and Nakajima (1979) found
that I.C. injections of ACh evoked reflex bradycardia in rabbits,
an effect which the authors assumed was due to stimulation, by ACh,
of carotid chemoreceptors. The authors did not, however, check to
see whether this response was abolished by section of the sinus
nerve. In the light of the present results it seems unlikely that
the reflex bradycardia observed by these workers was due to
stimulation of carotid chemoreceptors. In fact, the opposite result
would be expected, i.e. ACh, by inhibiting afferent chemoreceptor
activity, would be expected, if anything, to cause a slight tachycardia
by transiently depressing any tonic inhibitory influence of afferent
chemoreceptor activity on heart rate. It is not clear, however,
whether a short-lasting depression of chemoreceptor activity in
rabbits, such as that produced by I.C. injection of ACh, is reflected
in reflex adjustments of heart rate, vasomotor tone or respiration.
Results obtained in this laboratory (A. Morris, unpublished observations)
suggest that this is.not the case and Wiemer (1962) has reported that
the carotid chemoreceptors do not participate in the respiratory
response to I.V. injections of ACh in rabbits. The bradycardia
observed by Matsumoto et al (above) following I.C. injection of ACh
was probably due to an action of ACh on the C.N.S.
Characterization of the cholinergic receptors
Experiments were performed in an attempt to identify the
cholinergic receptors responsible for the effects of ACh on
chemosensory activity. High doses of ACh caused a transient
stimulation of the chemoreceptors in some experiments, an effect
which preceded the inhibition. This excitation appeared to be
attributable to a nicotinic action of ACh since it was blocked by
mecamy1 amine. Monti-Bloch and Eyzaguirre (1977) found that nicotine
stimulated the chemoreceptors in the rabbit carotid body in vitro,
an effect which was blocked by D-TC. In the present experiments
SDCh was used as a nicotinic agonist rather than nicotine since it
has been reported that in cats, repeated administration of the latter
substance leads to blockade of the nicotinic receptor whereas SDCh
evokes consistent excitatory chemoreceptor responses without develop-
ment of tachyphylaxis (Anichkov and Belen'kii, 1963; Dardymov and
Ger, 1964) . It was found, however, that SDCh had no consistent
effect on chernoreceptor activity in the rabbit. Since the excitatory
effect of ACh was mediated by a nicotinic mechanism, one would
expect SDCh to evoke a similar, albeit slight, excitatory response.
It is not clear why this did not occur. In any event, since the
excitatory effect of ACh was slight and was only observed following
injections of high doses, it is unlikely to have much physiological
significance.
The inhibitory action of ACh was evidently mediated by a
muscarinic mechanism since the muscarinic agonists BCh and MCh also
caused inhibition of chemoreceptor activity. SDCh sometimes evoked
a slight inhibition of chemoreceptor activity but this was probably
due to a weak action on muscarinic receptors. ACh-induced inhibition
of chemoreceptor activity was blocked by administration of the
muscarinic antagonist atropine, though relatively high doses were
needed. Interpretation of data derived from experiments involving
the use of atropine in rabbits is complicated by the presence of
an atropinase enzyme in some rabbits (Ambache, 1955), a fact which
might account for the large variation in the dose of atropine
required to block the vasodepressor action of ACh. This might also
be the reason why high doses of atropine were required to block
ACh- or BCh-induced inhibition of chemoreceptor activity. Alternatively
it may be that the muscarinic receptors mediating the inhibition of
chemoreceptor activity are 'atypical1, perhaps being similar to
those in the adrenal medulla (Henderson and Ungar, 1977), or in
sympathetic ganglia (Hilton, 1977), which are also fairly resistant
to atropine blockade. A better understanding of the mechanism by
which ACh inhibits chemoreceptor activity in the rabbit might be
gained by studying the effects of a non-esteratic muscarinic blocking
agent of similar potency to atropine, e.g. trieye 1 amol (Barlowe, 1955), .
on the responsiveness of rabbit carotid chemoreceptors to ACh since
such a drug would be resistant to the action of atropinase (atropine
esterase). Unfortunately, it was not possible to perform this
experiment during the present investigation.
ACh-DA interaction
It has been suggested that ACh may release DA in the rat carotid
body via a muscarinic mechanism (Hellstrom, Hanbauer and Costa, 1976).
Since it was found that I.C. injection of DA caused inhibition of
rabbit chemosensory activity, and DA is present in the rabbit carotid
body (Dearnaley et al, 1968), the possibility that ACh-induced
inhibition of chemoreceptor activity was secondary to DA release
became attractive. This is unlikely to be the case, however, since
a-f1upenthixol, in doses sufficient to block the inhibitory response
to exogenous DA, did not reduce the inhibitory response evoked by ACh.
Although it was found in the present experiments that
injections of DA inhibit chemoreceptor activity in the rabbit, the
response being similar to that observed in cats (see Section III),
it should be noted that Monti-Bloch and Eyzaguirre (1977) reported
that DA increases chemoreceptor discharge in the superfused rabbit
carotid body in vitro. A possible explanation for the difference
between the present results, obtained in the carotid body in situ,
and those obtained in the in vitro preparation is that vascular
effects are responsible for the inhibition observed in situ; such
vascular changes should not affect activity in the superfused
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preparation. However, vascular effects are unlikely to account for
DA-induced inhibition of chemoreceptor activity in cats (see Section
III) and by analogy it is unlikely that inhibition of chemoreceptor
activity in rabbits is secondary to vascular effects of DA,
particularly since the latency to onset of the effect is so short
(<2 sec). Zapata (1975) found that DA produced excitation of
chemoreceptor activity in the cat carotid body in vitro following
desensitization of DA inhibitory receptors (see Section I). It is
possible that the excitatory chemoreceptor response to DA in the
rabbit carotid body in vitro, observed by Monti-Bloch and Eyzaguirre,
was due to desensitization of DA inhibitory receptors. It was found
in the present experiments that, on certain occasions, DA produced
a delayed excitation which followed the inhibitory effect. Also,
DA tended to cause excitation of chemoreceptor activity following
administration of a-f1upenthixol. It may be that there are both
inhibitory and excitatory receptors for DA in the rabbit carotid
body and that endogenous DA in this species has a similar physiological
role to that suggested for cats in Section III. Injection of D-
amphetamine (10 yg I.C.) caused inhibition of chemoreceptor activity,
an effect which was blocked by a-f1upenthixol. In terms of the
original rationale for using amphetamine, i.e. to release DA (see
Section III), this result could be interpreted as suggesting that
endogenous DA has an inhibitory action on chemoreceptor activity.
It was found in cats, however, that although low doses of amphetamine
inhibit chemoreceptor activity, high doses cause stimulation of
activity (see Section III). It may be that in rabbits, as in cats,
inhibition of chemoreceptor activity produced by low doses of
amphetamine is due to an agonist action on DA inhibitory receptors
rather than secondary to release of endogenous DA. It would be
interesting to determine the effects of high doses of amphetamine on
chemosensory activity in the rabbit and to study the effects of DA-
uptake blockers on responses to chemoreceptor stimulants to see if
such treatments have a similar effect on chemosensory activity in
rabbits as in cats. The response of the rabbit carotid chemoreceptors
to NaCN was potentiated by a-f1upenthixol, which supports the idea
that endogenous DA is released during chemoreceptor stimulation and
has an inhibitory effect on afferent chemoreceptor activity. Whether
endogenous DA also has an excitatory effect on chemoreceptor activity
in this species remains to be established but the similarities in
the responsiveness of the rabbit carotid chemoreceptors to DA to
that of the cat carotid chemoreceptors suggests that this might be
the case.
The inhibitory response to DA was slightly reduced by a high
dose of atropine (1 mg/kg I.C.) and the duration of the response
was increased following administration of physostigmine (0.1-0.25
mg/kg I.C.). This might be taken to mean that DA-induced inhibition
of chemoreceptor activity was secondary to ACh release. It is
possible, however, that the effects of physostigmine on the response
to DA were brought about indirectly by flow changes arising from
enhanced cholinergic transmission in the superior cervical ganglion,
since the ganglio-g1omeru1ar nerve was intact during experiments
with this anticholinesterase drug. This might also explain the
variability of responses to NaCN following administration of
physostigmine. The reduced inhibitory response to DA following
administration of atropine may have been due to a non-specific
action of the high dose of atropine required to produce this effect.
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Nevertheless, on the basis of the above results, the possibility
that DA causes release of ACh in the rabbit carotid body cannot be
precluded. The present experiments were designed primarily to
study the inhibitory effects of ACh on rabbit carotid chemoreceptor
activity and most of the data relating to the effects of cholinergic
antagonists on responses to DA are of a qualitative rather than a
quantitative nature. A quantitative study of the effects of cholinergic
antagonists on responses to DA is required to clarify this point.
The response of the rabbit chemoreceptors to 5~HT was very
similar to the response of the cat carotid chemoreceptors to this
substance (see Section III). It is unlikely that either the
excitatory or the inhibitory effects of 5~HT were secondary to
release of ACh since responses to 5~HT were not appreciably affected
by cholinergic blocking agents. The possibility that ACh might
release 5~HT in the rabbit carotid body was not investigated in the
present study.
Physiological significance
It is difficult to reconcile the present finding that ACh
inhibits rabbit chemosensory activity with the hypothesis that ACh
is an excitatory transmitter in the chemosensory mechanism (see
Section I). The nicotinic action of ACh in exciting chemoreceptor
nerve endings in cats and dogs may be non-specific, i.e.a direct
action on the unmyelinated, terminal portion of the sensory nerve
which can be blocked pharmacologically without affecting the response
to physiological stimuli (see Section I). It could be that whereas
non-specific excitation of chemosensory afferents is observed in
the cat and dog, it is not obtained, except transiently following
high doses of ACh, in the rabbit, i.e. the threshold for non-specific
excitation by ACh is higher in the rabbit than in cats or dogs.
If this is the case, and ACh has nothing to do with transmission
of afferent chemosensory impulses, it is difficult to explain why
mecamylamine reduced chemoreceptor responses to NaCN and hypoxia.
It could be argued that any tendency for injected ACh to cause
stimulation of afferent activity in rabbits is masked by the in¬
hibitory effects of the drug. The arrangement of cholinergic
receptors on the sensory nerve end may be such that the inhibition-
mediating muscarinic receptors are more accessible to injected ACh
than the excitation-mediating nicotinic receptors while the nicotinic
receptors are more accessible to endogenously released ACh than the
muscarinic receptors. In this scheme mecamylamine might be expected
to reduce the chemoreceptor response to NaCN or hypoxia by
antagonising the excitatory action of endogenously released ACh even
though the response to injected ACh was inhibitory. This argument
is very similar to that proposed in Section III to explain the
effects of DA and drugs which modify dopaminergic systems on chemo¬
receptor activity in the cat. Whereas in the cat and rabbit DA
tended to produce excitatory effects when the inhibitory effects
of DA were blocked, however, ACh did not produce excitatory responses
in the rabbit when its inhibitory action was blocked by atropine.
Further, physostigmine, which would be expected to enhance the
effects of endogenously released ACh, did not increase the magnitude
of chemoreceptor responses to NaCN and had little effect on responses
to hypoxia. It seems unlikely, therefore, that endogenous ACh has
an excitatory effect on afferent chemoreceptor activity. The
suggestion that ACh-induced excitation of chemoreceptor activity
is due to a non-specific action of the drug and that this effect
has a high threshold in the rabbit (above) seems a more appropriate
explanation of results. The inhibitory effect of mecamylamine on
chemoreceptor responses to NaCN and hypoxia is unlikely to be due to
the nicotinic receptor blocking properties of the drug but may be
due to a non-specific action. This possibility is explored further
in Section V.
The question must now be asked what role, if any, does ACh-
play in the chemosensory mechanism? It may well be that the inhibition
evoked by ACh in rabbits is either indirectly mediated or else non¬
specific and lacking physiological significance, but it seems worth
exploring the possibility that these findings with exogenous ACh in
rabbits, free from the masking excitatory effects of the drug,
provide a clue regarding the physiological role of ACh in the carotid
body. If endogenous ACh has an inhibitory action on afferent chemo¬
receptor activity, physostigmine, which enhanced the inhibitory
response to injected ACh, might be expected to reduce responses to
chemoreceptor stimuli and high doses of atropine, which blocked the
inhibitory response, might be expected to cause potentiation of
responses to stimulants. This was not found to be the case, in fact,
responses to NaCN were reduced following administration of high
doses of atropine. It is unlikely, therefore, that ACh is important
to an intrinsic mechanism of control of chemoreceptor discharge
frequency. There is, however, the possibility that ACh is important
to an extrinsic control mechanism. In all the experiments performed
in the present study, the sinus nerve was cut in order to facilitate
dissection of the nerve and obtain recordings of afferent activity.
This procedure, however, obviates the influence of any descending,
i.e. efferent pathway which might travel in the sinus nerve. There is
evidence for an efferent pathway in the sinus nerve to the cat
carotid body (Biscoe and Sampson, 1968) and stimulation of this
pathway inhibits chemosensory activity (Neil and O'Regan, 1969;
Belmonte and Eyzaguirre, 197*0 . it has been shown that efferent
inhibition can be reduced by administration of atropine (Goodman,
1975; Willshaw, 1976; Sampson, Aminoff, Jaffe and Vidruk, 1976b)
or ct-adrenergic blocking agents (Sampson, 1975; Sampson, Aminoff,
Jaffe and Vidruk, 1976b). It has been proposed that the efferent
pathway is part of an inhibitory feedback system which involves
release of ACh, or some other substance with muscarine-1ike properties,
from efferent nerve ends which acts on type I cells to release
catecholamines which in turn mediate the inhibitory effect by an
a-adrenergic mechanism (Sampson, 1972). It is not known whether the
rabbit carotid body receives an efferent innervation. Nevertheless,
the possibility exists that the inhibitory effect of ACh on chemo¬
sensory activity in rabbits might result from an action on muscarinic
receptors involved in such a pathway. On the basis of the present
results it seems unlikely that the inhibitory effect of ACh is
secondary to DA release but the possibility that the effect is
secondary to release of NA or ADR cannot be precluded since the
effects of these substances on chemoreceptor activity in this species
have not been studied. In this scheme ACh would be a transmitter
at efferent nerve endings in the carotid body, acting either
directly or through release of another substance(s) which modulates
or regulates chemoreceptor activity rather than an excitatory trans¬
mitter at afferent synapses between type I cells and sensory nerve
endings.
SECTION V
GENERAL DISCUSSION AND CONCLUSIONS
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The results presented in this thesis suggest two important
conclus ions,
a) endogenous DA may have an excitatory effect on chemoreceptor
activity in the mammalian carotid body, and
b) ACh is unlikely to act as an excitatory transmitter at
carotid chemoreceptors but might act as a transmitter in an
inhibitory efferent pathway.
The possibility that DA has an excitatory effect on carotid
chemoreceptor activity in the cat even though, under normal
circumstances, injected DA evokes inhibition of activity may explain
the apparent species differences in the response to injected DA
observed in cats and rabbits and that observed in dogs (see Section l).
The different responses to injected DA, i.e. excitation in dogs and
inhibition in cats and rabbits, may, as Llados and Zapata (1978a)
suggest, be due to a difference in the accessibility of the
excitatory receptors to injected DA. Very recently, Bisgard, Mitchell
and Herbert (1979) showed that I.C. injection of low doses of DA
(usually <10 pg) inhibited carotid chemoreceptor activity in dogs
and that DA produced an excitatory response, such as that observed
by Black et al (1972) in this species, only when higher doses of DA
(^10 pg I.C.) were administered. Bisgard et al also found that the
inhibitory effects of DA in dogs were blocked by haloperidol which
suggests that the receptor mediating chemosensory inhibition in the
dog is the same or a similar type to that mediating chemosensory
inhibition in the cat and rabbit. It seems that injection of DA can
cause inhibition and/or excitation in cats and dogs (and probably
also in rabbits) depending on the dose of DA administered. Under
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normal circumstances, the excitatory effect of DA on chemoreceptor
activity in the cat is delayed and is preceded by inhibition
(Zapata, 1975, 1977; Nishi, 1977; Llados and Zapata, 1978a;
Zapata and Llados, 1978; see also Section III of this thesis).
According to Bisgard et al, the opposite is true in dogs, i.e. DA
causes excitation followed by inhibition. This may be due to a
difference in the accessibility to injected DA of excitatory and
inhibitory receptors.
There is evidence that at least two types of DA receptor are
present in the mammalian C.N.S., one of which is linked to the
enzyme adenylate cyclase (designated D1) and the other (designated
D2) which is not (see Kebabian and Calne, 1979). The pharmacological
characteristics of the receptor mediating the inhibitory effects of
DA on carotid chemoreceptor activity, i.e.stimulation by apomorphine
and inhibition by a-f1upenthixol or haloperidol, seem similar to
the non-adenylate cyclase linked receptor found in the C.N.S. and
may therefore be of the same or a similar type to the D2 receptor
(Kebabian and Calne, 1979). It is tempting to associate the excitation-
mediating receptor in the carotid body with the D1 receptor,
especially since cAMP stimulates afferent chemoreceptor activity in
cats (Joels and Neil, 1968). a-Flupenthixol antagonises, although
not specifically, the D1 receptor in the C.N.S. (see Kebabian and
Calne, 1979), however, and this is clearly not the case for the DA
receptor mediating chemoreceptor stimulation in cats and rabbits.
Nevertheless it might be interesting to study the effects of
phosphodiesterase (which metabolises cAMP) inhibitors on chemo¬
receptor activity and the effects of cholera toxin which is a non¬
specific activator of adenylate cyclase (see Gill, 1977).
The excitatory effect of DA on chemoreceptor activity in the
dog was blocked by D-TC but not by gallamine (Bisgard et al, 1979)-
The receptor mediating this effect might be similar therefore to the
receptor mediating DA-induced depolarization of neurone in the
molluscan nervous system which is also blocked by D-TC (Ascher, 1972).
LSD is a specific ligand for the depolarization-mediating DA
receptor in the mollusc (Drummond, Bucher and Levi tan, 1978) and
Nishi (1975) has found that LSD stimulates carotid chemoreceptor
activity in the cat carotid body in vivo. Nishi offered no explanation
for the effect of LSD on chemoreceptor activity (see Section I) but
it may be that this effect was due to an action of LSD on excitation-
mediating DA receptors. These results cannot be considered as
direct evidence that the receptor mediating the excitatory effect
of DA on chemosensory activity in cats and dogs (and probably also
in rabbits) and the receptor mediating depolarization of neurone
in the molluscan nervous system are of the same type but they are
certainly suggestive. It is not known whether D-TC blocks the
excitatory effects of DA on chemoreceptor activity in cats and rabbits.
It has been found, however, that D-TC inhibits chemoreceptor activity
in the cat carotid body in vitro (Eyzaguirre and Koyano, 1965b) and
this has been considered as evidence in favour of the 'ACh hypothesis'
of carotid chemoreception (see Section I). It is possible, however,
that this effect of D-TC was due to blockade of DA excitatory receptors
rather than cholinergic receptors. Indeed, in view of the fact
that ACh is unlikely to act as an excitatory transmitter in the
carotid body (see Section IV), this seems a more probable explanation.
It is not entirely surprising that D-TC should act as an antagonist
at DA receptors since the chemical structure of D-TC is, in some
Figure 5.1
Schematic diagrams of the molecular structure of D-TC and DA.
The regions of the D-TC molecule enlosed in the dotted lines
can be seen to be structurally similar to DA.
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respects, similar to that of DA (see Figure 5.1). It was found in
the present study that mecamylamine slightly inhibited the response
of rabbit carotid chemoreceptors to NaCN and hypoxia even though, in
this species, ACh itself causes inhibition of chemoreceptor activity.
Those authors who reported that mecamylamine inhibits responses of
cat carotid chemoreceptors to NaCN and hypoxia found that much
higher doses of mecamylamine were required to produce this effect
than to block responses to ACh (see Section 1) which might be taken
to indicate that the effect was unlikely to be due to the nicotinic
blocking action of the drug. As well as blocking cholinergic
nicotinic receptors, however, mecamylamine inhibits release of DA
from neurons, in the C.N.S. (Ahtee and Kaakkola, 1978). It is
possible that this drug inhibits release of DA from type I cells in
the carotid body. It could be that some drugs, better known for
their effects on cholinergic systems, bring about their effects on
chemoreceptor activity by non-specific actions on a dopaminergic
mechanism. This suggestion, though speculative, could help to
explain some of the anomalies in the literature regarding the effects
of cholinergic agonists and antagonists on carotid chemoreceptor
activity. It would be interesting to determine whether D-TC blocked
the excitatory effects of DA in cats and rabbits. This could be
done by studying the effects of D-TC on responses to DA in animals
pretreated with haloperidol or a-f1upenthixol. It would also be
interesting to determine whether D-TC or mecamylamine reverse the
potentiating effects of DA-uptake blockers on responses to chemo¬
receptor stimulants. The possibility that D-TC is an antagonist
at a novel DA receptor, i.e. the chemoreceptor excitation/mol 1 uscan
neuron depolarization mediating receptor, could have interesting
implications in terms of the development of new drugs effective as
agonists or antagonists at this receptor.
In view of the evidence presented in Section IV it seems highly
unlikely that ACh is an excitatory transmitter of sensory impulses
in the carotid body. The excitatory effect of ACh on chemosensory
activity in cats and dogs appears to be due to a non-specific action
of ACh on sensory nerve ends, an interpretation which agrees well
with results presented in Section III where it was found that ACh-
induced stimulation of chemoreceptor activity in the cat is not
appreciably affected by a-f1upenthixol (except at high doses) or
nomifensine, and is slightly reduced by benztropine even though
responses to NaCN and hypoxia were potentiated by these substances.
The most likely physiological role for ACh in the carotid body is as
a transmitter in an inhibitory efferent pathway (see Section IV).
The mechanism of efferent inhibition in cats appears to have two
components - a vascular and a non-vascular component (0'Regan, 1977).
Increased efferent activity in the sinus nerve in cats causes
increased glomerular blood flow and, as a consequence, afferent
chemoreceptor activity is reduced (Neil and O'Regan, 1969, 1971).
This is the vascular component and a number of authors are of the
opinion that this is the sole mechanism of efferent inhibition
(Goodman, 1973; Belmonte and Eyzaguirre, 197*+; McCloskey, 1975)-
There is, however, evidence that efferent inhibition may be demon¬
strated during total abolition of carotid body blood flow (O'Regan,
197*0 ind icating that a non-vascular component also exists though
this is probably less important physiologically, at least in cats,
than the vascular component (O'Regan, 1977). ACh-induced inhibition
of chemoreceptor activity in rabbits did not appear to be mediated
by a vascular mechanism (see Section IV). If the inhibitory action
of ACh was due to an action on muscarinic receptors involved in an
efferent inhibitory pathway then this would suggest that efferent
inhibition in the rabbit has a strong non-vascular component.
Rabbits, therefore, might prove to be useful experimental animals
for studying non-vascular mechanisms of efferent inhibition. This
is pure speculation, of course, since the inhibitory effect of ACh
on rabbit chemosensory activity may have nothing to do with efferent
inhibition. It must be established, by recording from the central
cut end of the sinus nerve, whether the rabbit carotid body receives
an efferent innervation and if so, what influence this pathway has
on chemoreceptor activity before any correlation between the
inhibitory effects of ACh on chemosensory activity and efferent
inhibitory mechanisms may be made.
The possibility that DA acts as a sensory transmitter in the
carotid body must now be considered, i.e. that the chemoreceptor
elements in the carotid body are presynaptic to sensory nerve endings
and increased afferent activity occurs as a consequence of increased
DA release from type I cells in response to chemoreceptor stimuli.
In favour of this idea is evidence which suggests that the carotid
body stores DA which is released in response to chemoreceptor stimuli
(see Section l). Also, the results presented in this thesis suggest
that endogenous DA has an excitatory effect on carotid chemoreceptor
activity. Studies of the effects of pharmacological depletion of
catecholamines, by reserpine or 6-OHDA, on carotid chemoreceptor
activity have produced equivocal results (see Section l). Zapata
et al (1969) obtained recordings of carotid chemoreceptor activity
in cats following chronic exposure of the animals to reserpine.
Under these conditions the DA content of the carotid body was reduced
by up to 90 per cent. Without knowing what percentage of the total
amount of DA stored in the carotid body is required to maintain
normal function, however, few conclusions can be drawn from this
result. Antonaccio and Smith (197*0 found that the response of
atrial muscle to sympathetic nerve stimulation was unimpaired
following 90 per cent depletion of NA stores by reserpine.
Conceivably, 10 per cent of the total DA content of the carotid
body could be sufficient to maintain its function as a sensory
transmitter. There are, however, a number of reasons why it is
unlikely that DA is an excitatory transmitter of afferent chemo-
receptor activity. For the dopaminergic mechanism described above
to operate, sensory nerve ends must be apposed to type I cells. It
has been found, however, that chemoreceptor activity may be recorded
from regenerated axons of the sinus nerve which terminate in
neuromas containing no type I cells (Mitchell, Sinha and McDonald,
1972; Mitchell and McDonald, 1975) or from regenerating afferent
fibres which are not in contact with type I cells (Bingmann,
Kienecker and Knoche, 1977) although other authors have found that
afferent fibres must be in contact with type I cells before afferent
activity may be recorded (Verna, Roumy and Leitner, 1975; Zapata,
Stensaas and Eyzaguirre, 1969). The carotid body may be functionally
reinnervated with vagal (De Castro, 1951) or superior laryngeal
nerve fibres (Zapata, Hess and Eyzaguirre, 1969) which does not
support the case for DA as a sensory transmitter unless it is assumed
that vagal and superior laryngeal nerve endings have excitatory DA
receptors, an assumption for which there is no evidence whatsoever.
In any case, doses of D-TC sufficient to abolish the excitatory
effects of injected DA on chemosensory activity in the dog reduce,
but do not abolish, chemoreceptor responses to NaCN and hypoxia
(Bisgard et al, 1979) which suggests that although endogenous DA
may have a stimulant effect on chemoreceptor activity in vivo, this
is not the sole mechanism by which afferent chemoreceptor discharge
is initiated. It may be that the sensory nerve ends are themselves
the chemoreceptors, as Biscoe (1971) suggests, and that DA modulates
activity in the nerve endings. A model for the relationship
between sensory nerve endings and type I cells, based on this idea,
would be similar to that proposed by McDonald and Mitchell (1975)
(see Section l) save that instead of type I cells acting as inhibitory
interneurons, the present results suggest that the type I cells act
as excitatory interneurons, i.e. as endogenous 'amplifiers' of afferent
chemoreceptor activity. In this scheme increased activity in the
sensory nerve would be accompanied by increased release of DA. The
DA then acts on excitatory receptors on the sensory nerve ending to
boost activity. During strong chemoreceptor stimulation, eg. in
response to NaCN, large amounts of DA are released, some of which
flows out of the synapse and acts on inhibitory receptors which are
located on the sensory nerve ending on the periphery of the synaptic
region. Activation of inhibitory receptors in this manner limits
the excitatory effects of DA. DA release would be in response to a
direct effect of chemoreceptor stimulants on type I cells or
secondary to release of an unidentified substance, itself released
from the sensory nerve endings. This scheme has the physiological
advantage that, for a stimulus of a given strength, the frequency of
discharge of individual chemoreceptor units could be controlled by
the relative numbers of excitatory and inhibitory receptors for DA
——► = major action
- --► = minor actionJ end
> = major action^ n,
---> = minor actionJ ^ inj
a = exitatory DA receptor
• = inhibitory DA receptor
Figure 5.2
Schematic diagram of proposed control mechanisms of afferent
chemoreceptor discharge. Most of the endogenous DA (DAend )
released acts ( ► ) at excitatory DA receptors but some acts
( -♦») at inhibitory receptors. Injected DA (DAmj ) acts
( o) mainly at inhibitory receptors but some may act ( i>)
at excitatory receptors. Possible efferent pathways . (eff.1,2
and 3) are also included in the diagram. Eff.l and eff.2
represent possible non-vascular pathways in which ACh acts
either on the sensory nerve end (s.n.e.) or type I cell (Tl)
and eff.3 represents the vascular pathway - release of ACh
causing vasodilatation and consequently increased carotid
body blood flow.
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on sensory nerve endings which would allow a measure of differentiation
between the chemoreceptors at the peripheral level. A schematic
diagram illustrating the mechanism described above is given in Figure
5-2. Figure 5.2 also includes representations, based on the suggestions
of O'Regan (1977), of possible interactions of a cholinergic, non¬
vascular, inhibitory efferent pathway with the proposed dopaminergic
mechanism.
Research in the field of carotid chemoreceptors has placed
considerable emphasis on the chemoreceptor stimulant effects of ACh
and, especially in recent years, the inhibitory effects of DA. On
the basis of the results obtained in the present study it is concluded
that although these effects may be important, the opposite effects,
i.e. inhibition in the case of ACh and excitation in the case of DA,
are of greater importance to the chemoreceptive mechanism in vivo.
Perhaps a re-evaluation of data derived from experiments designed to
study the carotid body chemoreceptors, especially those involving the
use of pharmacological substances, in these terms may be of value in
reaching a better understanding of the mechanism by which chemo¬
receptor activity is initiated.
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APPENDIX I
AFFERENT ACTIVITY IN THE RABBIT SINUS NERVE
158
1 . Chemoreceptor activity
Recordings of chemoreceptor activity were obtained from the
sinus nerves of only about 30 per cent of the rabbits used in the
present study. It is unlikely that this low success rate was due to
surgical incompetance since recordings of chemoreceptor activity
were obtained in about 90 per cent of experiments on cats in which
similar surgical procedures were used. The criteria adopted to
identify afferent chemoreceptor activity,
a) random frequency of discharge,
b) increased activity in response to NaCN,
c) increased activity in response to hypoxia, and
d) decreased activity in response to hyperoxia,
were the same for both cats and rabbits and seem adequate. No
recordings were obtained which satisfied criteria (c) and (d) which
did not also satisfy (a) and (b). Changing the strain of rabbits
or the anaesthetic used in the experiments did not increase the
success rate in obtaining recordings of chemoreceptor activity. Two
possible explanations for the low success rate are, firstly, that
due to a peculiarity of carotid body chemoreceptors in some rabbits,
the sinus nerve must be intact for normal function or, secondly, the
fibres conducting afferent chemoreceptor activity in rabbits are more
fragile than the corresponding fibres in cats and are therefore
more liable to be damaged during fine dissection of the nerve. The
first possibility seems unlikely. The second possibility is feasible,
however, since it has been shown that afferent chemoreceptor activity
in the rabbit sinus nerve is conveyed by slow-conducting, small
diameter (<2 ym) myelinated fibres (Laurent and Barres, 1964) . The
A B
Figure A . 1
Two recordings of baroreceptor activity showing fast (A) and
slow (B) baroreceptor activity in the rabbit sinus nerve. The
two recordings were obtained from different filaments of one






Recording of unidentified aperiodic activity in the rabbit
sinus nerve obtained from an animal breathing room air (A),
5% 02 in N2 (B) or 100% 02 (C). Panels show, from above
downwards : action potentials, B.P. and one second time marks.
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fibres which conduct afferent chemoreceptor activity in the cat are
composed of two-thirds fast-conducting A-fibres (about 3" 5 vm
diameter) and one-third c-fibres (Fidone and Sato, 1969)• It is
possible that most recordings of chemoreceptor activity in the cat
are obtained from the more robust A-fibres while in the rabbit the
smaller diameter, slow-conducting fibres are more fragile and are
subject to damage during dissection of the nerve.
2. Baroreceptor activity
Afferent baroreceptor activity was recognised by its character¬
istic pattern of discharge, i.e.periodic discharge at a frequency
dependent on B.P. and synchronized with pulse pressure. Small
filaments of the sinus nerve displaying baroreceptor activity were
obtained in almost every experiment but were usually discarded in
favour of other filaments in the hope that these would contain chemo¬
receptor activity.
Baroreceptor activity seemed to be of two types - high frequency
or fast activity and low frequency or slow activity (see Figure A.1).
Fast activity was characterized by a continuous train of impulses
at a frequency which fluctuated in time with pulsatile changes in
B.P. (see Figure A.1A) while slow activity was characterized by
discrete bursts of activity synchronized with pulse pressure (see
Figure A.IB). Both types of baroreceptor activity could be recorded
from filaments of the same sinus nerve.
3. Non-chemoreceptor aperiodic activity
In most experiments recordings of non-chemoreceptor aperiodic
activity were obtained. This type of activity was characterized by
a random or near random pattern of discharge. The frequency of
aperiodic activity was not appreciably altered during exposure of
the experimental animal to hypoxia or hyperoxia (see Figure A.2) or
by I.C. injection of ACh, NaCN, DA or 5~HT. Recordings of normal
chemoreceptor and baroreceptor activity could be obtained from
nerves in which non-chemoreceptor aperiodic activity was observed.
In view of the fact that non-chemoreceptor aperiodic activity was
not observed in cats and, as pointed out above, the success rate in
obtaining recordings of afferent chemoreceptor activity in rabbits
was low it is possible that non-chemoreceptor aperiodic activity
arose from chemoreceptors which had ceased to function normally.
The source of non-chemoreceptor aperiodic activity in the rabbit
sinus nerve was not established in the present study.
b. Phasic activity
On some occasions, a fourth type of activity was observed in
small filaments of the rabbit sinus nerve. This activity, which was
observed less frequently than the types of activity described in
1-3 above, was phasic activity and was characterised by brief bursts
of impulses occurring apparently at random. The source of this





[From the Proceedings of the Physiological Society, 22-23 April 1977
Journal of Physiology, 270, 73-74P]
The effect of a-flupenthixol on the response of carotid chemo-
receptors to acetylcholine, sodium cyanide and dopamine in the cat
By R. J. Docherty and D. S. McQueen. Department of Pharmacology,
University of Edinburgh, Edinburgh EH8 9JZ
Dopamine (DA) may modulate sensory activity of cat carotid chemo-
receptors (Zapata, 1975; Osborne & Butler, 1975). If the theory advanced















Fig. 1. Response of a chemoreceptor unit before (mean spontaneous dis¬
charge 2-8 ±0-1 c.p.s.) and after (2-7 ±0-1 c.p.s.) a-flupenthixol. Panels
show: action potentials; counter output; B.p.; 1 sec and injection markers.
suppressed by the continuous release of DA, then block of the DA receptor
should substantially increase spontaneous chemoreceptor activity and
also, according to the theory, markedly reduce the response to ACh. We
used a-flupenthixol, a potent inhibitor of DA in the c.n.s. (Iversen, 1975)
to block the inhibitory effect of DA.
Experiments were performed on eight pentobarbitone-anaesthetized




artificially ventilated and a gallamine (3 mg/kg) administered. Chemo-
receptor activity was recorded from the peripheral end of a sectioned sinus
nerve and stimulants injected into the ipsilateral carotid artery. The
results showed that a-flupenthixol (0-2 mg/kg i.a.) abolished the inhibitory
effect of DA while the response to NaCN was augmented and that to
ACh slightly reduced. (Fig. 1).
Providing that exogenous DA is acting at the same site(s) as endogenous
DA, the results suggest that while there may be some tonic inhibition of
sensory activity by DA, this is not substantial. It is also unlikely that
ACh or NaCN act to any appreciable extent by inhibiting DA release.
This work was supported by an M.R.C. project grant.
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[From the Proceedings of the Physiological Society, 6-7 January 1978
Journal of Physiology, 277, 64—OOP]
Inhibitory effects of acetylcholine and dopamine on rabbit carotid chemo-
receptors
By R. J. Docherty and D. S. McQueen. Department of Pharmacology, University
of Edinburgh, 1 Oeorge Square, Edinburgh E11S 9JZ
During experiments in pentobarbitone-anaesthetized rabbits we observed that
intracarotid (i.c.J injection of acetylcholine (ACh, 5-250 fig) caused an immediate
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Fig. 1. Recording of chemoreceptor activity obtained from a rabbit, illustrating
responses to ACh, DA and NaCN. Panels show: action potentials, b.p.; 1 sec and
injection markers.
inhibition of respiration, whereas NaCN (1-25 fig i.e.) markedly stimulated respira¬
tion. Cutting the ipsilateral sinus nerve abolished the response to NaCN and greatly
reduced the inhibitory action ofACh. The possibility that ACh was inhibiting chemo-




ACh (.r> 250 /ill, I.e.) caused ;i dose dependent inhibit ion of discharge (Fig. I). Willi
doses greater than 100 //g the inhibition was preceded by a slight transient increase in
discharge. Atropine (1 -;» mg/kg i.v.) slightly reduced t he response to ACli. Dopamine
(DA, 10//g i.e.) also inhibited chemoreeeptor activity. To determine whether the
ACh-induced inhibition was secondary to 1)A release, we administered the DA
antagonist a-flupenthixol (O-25-O-o mg/kg r.v.). DA-induced inhibition was abolished,
wliereas that caused by ACh was only slightly reduced.
In contrast to other species where ACh increases chemosensory activity, and lias
been proposed as an excitatory transmitter (see review by Biscoe, 1071), our evi¬
dence shows that ACh has an inhibitory effect on rabbit chemoreccptors, implying
that endogenous ACh is unlikely to be an excitatory transmitter in this species.
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INHIBITORY ACTION OF DOPAMINE ON CAT
CAROTID CHEMORECEPTORS
By R. J. DOCHERTY and D. S. McQUEEN
From the Department of Pharmacology, University of Edinburgh,
1, George Square, Edinburgh EH8 9JZ
(.Received 8 September 1977)
summary
1. The influence of some drugs which affect the dopaminergic system was studied
on chemosensory responses to dopamine (DA), acetylcholine (ACh), sodium cyanide
(NaCN) and hypoxia during experiments on pentobarbitone anaesthetized cats in
which chemoreceptor activity was recorded from the peripheral end of a sectioned
sinus nerve.
2. Spontaneous chemosensory activity was inhibited in a dose-dependent manner
by DA (0-5-5 yg, i.a.). Higher doses (10-50 yg) caused a delayed increase in discharge
and were associated with inconsistent inhibitory responses.
3. The DA antagonist a-flupenthixol (0-2 mg/kg, i.a.) blocked the inhibitory
response to DA without affecting either the spontaneous discharge frequency or the
response to ACh. The effect of NaCN was potentiated, and during hypoxia chemo¬
receptor activity increased more rapidly, although the maximum frequency attained
was not appreciably different from control values. Similar results were obtained with
haloperidol (0-5 and 1-0 mg/kg, i.v.).
4. Higher doses of a-flupenthixol (0-5-1-0 mg/kg, i.a.) increased spontaneous
chemoreceptor activity, but this was regarded as a non-specific effect of the drug
since at these doses the inhibitory effect of 5-hydroxytryptamine (5-HT) was also
abolished.
5. The animals were exposed to alternate periods of hypoxia and hyperoxia
following administration of the tyrosine hydroxylase inhibitor a-methyl p-tyrosine
(AMPT, 0-2-10 mg/kg, i.a.). The inhibitory response previously evoked by amphet¬
amine was abolished, and electron microscopic studies showed a great reduction in
the number of dense-cored granules, both of which suggested that DA levels in the
carotid body had been substantially reduced. Responses to NaCN and hypoxia were
slightly potentiated following AMPT, but neither spontaneous activity nor the
response to ACh was affected.
6. Apomorphine (0-05-0-2 mg/kg, i.a.) inhibited the chemoreceptor discharge for
up to 45 min, an effect which was antagonized by a-flupenthixol (0-2 mg/kg, i.a.),
implying it resulted from DA receptor stimulation. Although responses to NaCN,
hypoxia and higher doses of ACh were reduced following administration of apo¬
morphine, the reduction was not very marked.
7. These results are not compatible with the theory of Osborne & Butler (1975),
that in normoxia DA is tonically released in the carotid body and suppresses spon¬
taneous chemosensory activity.
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8. It is concluded that DA modulates chemosensory activity by influencing the
rate of increase in discharge, without affecting maximum discharge frequency. The
mechanism whereby DA is released in response to increased chemosensory activity
remains to be established.
INTRODUCTION
A new theory of carotid body chemoreceptor activity has recently been advanced
(Butler & Osborne, 1975; Osborne & Butler, 1975). This proposes that in normoxic
conditions dopamine (DA), which is known to be present in the cat carotid body
(Chiocchio, Biscardi & Tramazzani, 1966; Zapata, Hess, Bliss & Eyzaguirre, 1969),
is tonically released from Type 1 cells and suppresses the spontaneous discharge of
afferent nerve endings; in hypoxic conditions DA release is attenuated and conse¬
quently afferent nerve activity increases.
The present pharmacological study was undertaken to test this theory by investi¬
gating the response of cat carotid chemoreceptors to acetylcholine (ACh), sodium
cyanide (NaCN), DA, and hypoxia, before and after administering drugs which
influence the dopaminergic system. A preliminary report on some of the results has
been made to the Physiological Society (Dochertv & McQueen, 1977).
METHODS
The experimental details have previously been described fully (McQueen, 1977) and only a
brief summary follows. Experiments were performed on cats of either sex weighing between
2-0 and 4-4 kg (mean weight 2-9 kg) which were anaesthetized with sodium pentobarbitone
(42 mg/kg, i.p.), supplemented approximately every 1-5-2 hr during the experiment by 10%
of the initial dose administered i.v. Blood pressure was recorded from a femoral artery, the
bladder drained at regular intervals and the rectal temperature maintained at 38 ± 0-5 °C.
A sinus nerve was cut centrally and electrical activity from single or multiple chemoreceptor
units was recorded from filaments of the peripheral nerve. The ganglioglomerular nerves were
cut in order to eliminate the influence on chemoreceptor discharge of reflex changes in sympa¬
thetic nerve activity (Floyd & Neil, 1952; Eyzaguirre & Lewin, 1961). The animals were artifici¬
ally ventilated either with air, 5% 02 in 95% N2 (hypoxic stimulus), or 100% 02 (hyperoxia).
They were paralysed by gallamine triethiodide (3 mg/kg i.v.).
Drug solutions (0.1 ml.) were injected into the common carotid artery ipsilateral to the sinus
nerve from which activity was being recorded and washed in with 0-2 ml. modified Locke
solution which had been bubbled with 5 % C02 in air in a water-bath at 37 °C (solution Pcc>2
32 mmHg; Po, 132 mmHg; pH7-0). Injections were made over a 2 sec period commencing at the
peak of the inspiratory phase of the respiratory cycle.
Nerve activity was recorded on magnetic tape (d.c. to 1250 Hz) and subsequently analysed to
provide data concerning the change in integrated discharge (AZx) following drug administra¬
tion. Responses were plotted against log10 dose and straight lines fitted by the method of least-
squares to data obtained before and after the test procedures. A response in the central region
of the control dose-response line was selected arbitrarily and the dose of stimulant required to
match this response following drug administration was calculated from the post-drug dose-
response line. The ratio of the dose required after drug administration to that required in the
control state is the dose ratio. Dose ratios obtained from different experiments were pooled and
data presented as the mean dose ratio ± s.E. of mean. These ratios provided a quantitative
estimate of the effect of a drug on chemoreceptor responses to ACh and NaCN. Control values
were determined by calculating the average discharge in the 20 sec period preceding the test
stimulus. All the individual values were pooled to provide a mean control + s.E. of the mean for
spontaneous chemoreceptor activity which could be compared with that obtained following
administration of one of the drugs being studied. Inhibitory responses were calculated by
determining the integrated discharge (Z.r) observed during the response period (t sec), defined
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as the time from onset of inhibition until return to control average discharge (x c.p.s.). The
inhibition was then expressed as:
— AEx = EiX—(x.t).
Drugs. Drugs were prepared in modified Locke solution (NaCl 6-0 g; KC1 0-42 g; CaCl2,
0-24 g; Tris base, 6-0 g; normal HC1 39 ml.; distilled water to 1 1.) excepting a-flupenthixol and
a-methyl-tyrosine which were dissolved in 0-9 % aqueous sodium chloride, and haloperidol
which was dissolved in 1 % aqueous tartaric acid.
The drugs used were: sodium pentobarbitone (Abbott Laboratories), gallamine triethiodide
(May & Baker), acetylcholine iodide, sodium cyanide (B.D.H.), dopamine hydrochloride (Koch
Light), a(cis)-flupenthixol dihydrochloride (Lundbeck & Co.), apomorphine hydrochloride
(Macfarlan Smith), haloperidol (Janssen), 5-hydroxytryptamine creatinine sulphate, d-amphet-
amine sulphate (Sigma), dl-a-methyl-p-tyrosine (Labkemi A.B.).
Fig. 1. Dose-response lines showingthe inhibitory effect of low doses of DA (plotted on
a log10 scale) on a single chemoreceptor unit before (0-—0) and after ( x x ) ad¬
ministering a-flupenthixol (0-2 mg/kg, i.a.). The average spontaneous discharge was
2-5 ± 0-3 c.p.s. before and 2-8 ± 0-3 c.p.s. after a-flupenthixol. Straight lines were fitted
to the data by the method of least-squares.
results
Experiments were performed on fifteen cats from which a total of seventeen re¬
cordings (eight single, nine multiple units) of chemoreceptor activity were obtained.
Dopamine
DA reduced spontaneous discharge frequency in all fifteen experiments, the magni¬
tude of the inhibition being dose-dependent over the range 0-5-5 pg i.a. (see Fig. 1)
and the effect lasting for 5-45 sec. Higher doses (10-50 pg i.a.) caused a delayed or
secondary increase in discharge which curtailed the primary inhibition and gave
inconsistent responses. A secondary increase in chemoreceptor discharge was also
observed by Zapata (1975) in his experiments with DA on the carotid body in vitro,
so it was unlikely that this delayedeffect was attributable to vascular changes. Zapata
also reported that frequent administration of DA (dose unspecified) caused inhibitory
responses to be converted to biphasic responses. In view of his findings and our
observations with high doses of DA, we confined our studies to low doses of DA
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administered infrequently and obtained consistent responses to both DA and the
chemoreceptor stimulants.
Early in experiments ungassed Locke solution caused a very slight inhibition of
spontaneous chemoreceptor activity, but later it caused an inhibition similar to that
evoked by low doses of DA. It was therefore necessary to use Locke solution which
DA 2-5 y/g 5-HT 10 ug
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Fig. 2. Responses of a single chemoreceptor unit to DA and to 5-HT before and
after a-flupenthixol. A, control, B, after 0-05 mg/kg a-flupenthixol, i.a. and C, after
an additional 0-5 mg/kg. D shows the effect of 0-3 ml. Locke solution, i.a. Injection
periods are represented by the horizontal bar below each panel and 1 sec timing
marks are shown below D.
had been bubbled with 5 % C02 in air to wash in drug solutions (the gassed solu¬
tion did not cause any appreciable inhibition, even during long experiments; see
Fig. 2). There was a slight increase in mean b.p. which commenced about 10 sec after
an i.a. injection of high doses ofDA ( > 10 fig). With lower doses there was no obvious
change in mean b.p.
171
DOPAMINE ON CHEMORECEPTORS 429
cc-Flupenthixol
a-Flupenthixol is a potent DA antagonist (Moller Nielsen, Pedersen, Nymark,
Franck, Boeck, Fjalland & Christensen, 1973; Miller, Horn & Iversen, 1974) which
acts post-synaptically (House & Ginsborg, 1976) and has very little anticholinergic
activity (Iversen, 1975). We used it to reduce the inhibitory action of DA and, while
responses to DA were suppressed, investigated the effects ofACh, NaCN and hypoxia.
Dose ratios showing the influence of a-flupenthixol on the responses were calculated
from the central region of AS.r dose-response lines and the results obtained from
ten experiments are summarized in Fig. 3. Responses to DA could not be expressed
in the same way because after a-flupenthixol the slope of the DA dose-response line
became negative, reflecting the tendency for DA to evoke excitatory responses under























Fig. 3. Pooled dose ratio data showing the effect of various doses of a-flupenthixol on
chemoreceptor responses to ACh and NaCN. Data are presented as mean dose ratios
+ s.e. of the mean, and the dashed line represents a dose ratio of 1.
Low doses of a-flupenthixol (0-05 mg/kg, i.a.) reduced the inhibitory action of DA
and showed up a small delayed increase in discharge (see Fig. 2), without appreciably
affecting either spontaneous chemoreceptor activity or the responses to ACh and
NaCN (Figs. 2 and 3). A dose of 0-2 mg/kg, i.a. abolished the inhibitory effect of DA
(see Fig. 1), potentiated the response to NaCN, and was without much effect on the
spontaneous discharge frequency or the response to ACh. Higher doses of antagonist
(0-5 or 1-0 mg/kg, i.a., additional to 0-05 and 0-2 mg/kg respectively) resulted in
DA causing a brief period of excitation, and whereas responses to NaCN were still
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potentiated, those to ACh were slightly inhibited. There was also a tendency for
spontaneous activity to increase, particularly after the 1 mg/kg dose.
Following administration of a-flupenthixol the rate of increase of chemoreceptor
discharge during hypoxia was much greater than in the control, although the
maximum frequency reached was not appreciably different in the two states (see
Fig. 4J5).
It has been reported that besides inhibiting the depressive action of DA in the
c.N.s., a-flupenthixol also antagonizes the depressive effect of 5-HT, being only
slightly more selective against DA (Straughan & Dray, 1976). Accordingly, in the
present study responses to both DA and 5-HT were obtained before and after ad¬
ministering a-flupenthixol so that the specificity of the antagonist on chemosensory
responses could be assessed. 5-HT caused a slight increase in discharge on injection
followed by a period of inhibition similar to that evoked by DA (see also Nishi,
1975). There was a tendency for low doses of a-flupenthixol to reduce the excitatory
action of 5-HT, although this was not consistent. The inhibitory effect was not
affected until doses of 0-5 mg/kg or more were used, when the response was abolished
(Fig. 2). This findingmeant that results obtained following high doses of a-flupenthixol
(^ 0-5 mg/kg, i.a.) had to be interpreted cautiously because the drug was evidently
no longer acting selectively.
The dopamine antagonist haloperidol in cumulative doses of 0-2, 0-5 and 1-0 mg/kg,
i.v. was studied in one experiment and the results obtained were similar to those
obtained with a-flupenthixol. The lowest dose was without much effect, but the
higher two reduced, but did not abolish, the inhibitory action of DA while potentia¬
ting the response to NaCN and inhibiting that to ACh. Spontaneous discharge
frequency was 2.1 + 0-2 c.p.s. before and 3-1 + 0-4 after 0-5 mg/kg, and 2-1 + 0-3
c.p.s. after the additional 1 mg/kg dose of haloperidol.
cc-Methyl p-tyrosine (AMPT)
As an alternative to using receptor antagonists to interfere with the actions of
endogenous DA, attempts were made to increase the turnover of DA in the presence
of AMPT, a drug which blocks the biosynthesis of catecholamines by inhibiting
tyrosine hydroxylase. The animals were exposed to two ten min periods of hypoxia
separated by a ten min period of hyperoxia over the course of 30 min and they were
then returned to breathing room air. This was done before and after administering
AMPT in doses of 0-2, 1-0 and 10 mg/kg, i.a. Results from three experiments showed
that the low dose slightly potentiated the responses to NaCN and hypoxia, an
example of this can be seen in Fig. 4A ; higher doses caused a further small increase.
Responses to ACh were only very slightly potentiated, even after the highest dose of
AMPT. Spontaneous chemoreceptor activity averaged 1-3 + 0-1 c.p.s. before and 1-3 +
0-2 c.p.s. after AMPT, 0-2 mg/kg. The corresponding values for 10 mg/kg, i.a. were
1-3 + 0-1 and 1-5 + 0-1 c.p.s. Electronmicroscopy revealed that depletion of dense-cored
granules occurred following the 1 mg/kg dose, as compared with untreated carotid
bodies exposed to alternating periods of hypoxia and hyperoxia (K. Bell, R. J.
Docherty & D. S. McQueen, unpublished observations).
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Time (sec)
Fig. 4. The upper panel A shows the response of a single chemoreceptor unit (dis¬
charge averaged over 5 sec intervals) to 120 sec of hypoxia, represented by the hori¬
zontal black bar, before ( ) and after ( ) AMPT 0-2 (mg/kg, i.a.).
The centre panel B illustrates the response to hypoxia obtained from a recording
containing two chemoreceptor units before ( ) and after ( ) administering a-
flupenthixol (0-2 mg/kg, i.a.).
In the lower panel C the response of another two chemoreceptor units to hypoxia
is shown before ( ) and after ( ) apomorphine (0-2 mg/kg, i.a.). Administration
of a-flupenthixol (0-2 mg/kg, i.a.) reversed the inhibition caused by apomorphine and
potentiated the response to hypoxia ( ).
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~d-Amphetamine
Amphetamine causes release of DA (Bunney, Aghajanian, & Roth, 1973) and
10 fig was injected i.a. before and after treating the animal with AMPT in two
experiments. This dose of amphetamine caused a slight inhibition of chemoreceptor
discharge in the control state (although not as marked as that observed following low
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Fig. 5. Dose-response lines, from a recording of chemoreceptor activity (three units),
illustrating the influence of apomorphine on responses evoked by ACh and NaCN. Doses
are plotted on a log10 scale and straight lines, fitted to the data by the method of
least squares, show: control response (#—0), responses after apomorphine, 0-05mg/kg,
i.a. ( x—.— x ), and after a further dose of 0-2 mg/kg, i.a. (A A)-
Mean control discharge frequencies were 3-8 + 0-4 c.p.s. before apomorphine and
0-9 + 0-1 and 1-7 + 0-2 after 0-05 and 0-2 mg/kg apomorphine respectively.
Apomorphine
Apomorphine was used in two experiments to provide a long-lasting stimulation
of the DA receptor. It was studied in cumulative doses of 0-05 and 0-2 mg/kg, i.a.
and caused an inhibition of spontaneous chemoreceptor activity which persisted for
up to 45 min. This allowed sufficient time to obtain dose-response data for ACh and
NaCN. Although background discharge frequency was reduced, DA could still evoke
an inhibitory response. Similar results were obtained in both experiments, dose-
response linesj from one of them being shown in Fig. 5 where it can be seen that
responses to NaCN were slightly inhibited as were responses to ACh, particularly at
the higher doses. The rate of increase of discharge during hypoxia was reduced
following apomorphine, an effect which was reversed by a-flupenthixol (see Fig. 4C).
discussion
The present results confirm that DA inhibits chemosensory activity following close-
arterial injection to the cat carotid body (see also Black, Comroe & Jacobs, 1972;
Sampson, 1972; Zapata, 1975). This inhibitory effect of DA is primarily a direct
175
DOPAMINE ON CHEMORECEPTORS 433
action on the chemoreceptors and not a consequence of vascular changes (Zapata,
1975; Sampson, Aminoff, Jaffe & Vidruk, 1976a; Sampson & Vidruk, 1977). Higher
doses of DA caused a delayed increase in discharge which greatly reduced the dura¬
tion of the inhibitory response. This increase seems similar to that observed in vitro
by Zapata (1975) which was unaffected by dopaminergic or a-adrenergic blockers.
The cause of the delayed increase was not investigated in the present study and
remains to be determined.
Recently Sampson & Vidruk (1977) obtained reproducible DC potential changes
with DA, even when administered every 3-4 min (dose unspecified), using the in
vitro carotid body preparation, and they contrasted their results with Zapata's
finding that frequent administration of DA reduced the chemoreceptor inhibitory
response. However, whether results obtained using the mass receptor potential can
be compared meaningfully with those using chemosensory discharge frequency has
yet to be established. Sampson (1972) and Sampson et al. (1976a) apparently ob¬
tained repeatable inhibitory responses to DA in vivo using doses of 2-5 fig, which
accords with our results at these doses, but they did not study the higher doses
which we foundgave delayed increases in discharge and inconsistent inhibitory effects.
If Osborne & Butler's theory is correct (see Introduction), chemoreceptor activity
should increase when the inhibitory action of DA is blocked because spontaneous de¬
polarization of sensory nerve endings would no longer be suppressed. Furthermore,
according to their theory ACh is released from sensory nerve endings in the carotid
body and acts to suppress the release of DA from Type 1 cells, thereby causing an
increase in chemoreceptor discharge. In a situation where the inhibitory effect of DA
has been blocked, ACh should no longer cause excitation. Our results show that
blocking the inhibitory effect of DA with a-flupenthixol (0-2mg/kg, i.a.) did not affect
either spontaneous chemoreceptor activity or the response to ACh. Higher doses
(e.g. ^ 0-5 mg/kg, i.a.) did cause spontaneous activity to increase and reduced the
responses to ACh, but at this dose inhibitory responses to 5-HT were also blocked,
implying that the drug was not acting selectively against DA, which we assumed it
was at lower doses. It should be noted that a-flupenthixol has weak a-adrenergic
blocking actions (Moller Nielsen et'al. 1973). After a-flupenthixol, 0-2 mg/kg, re¬
sponses to NaCN were potentiated and the increase in discharge during hypoxia was
much more rapid. Similar results were obtained with another DA antagonist,
haloperidol.
In addition to the experiments with DA antagonists, we also studied the response
of the chemoreceptors during prolonged DA receptor stimulation. Inhibitory re¬
sponses to DA injections were short-lasting, and although the use of DA infusion to
give a sustained inhibition was considered, this was rejected because of the possibility
of causing secondary increases in discharge. Instead the DA agonist apomorphine
(Bunney et al. 1973) was used and gave a long-lasting inhibition of spontan¬
eous chemosensory activity. Responses to NaCN and hypoxia were reduced by
apomorphine, as were those to ACh, but to a lesser extent. These results showed that
the responsiveness of the chemoreceptors to stimulants was only slightly reduced by
prolonged DA receptor stimulation. The inhibitory effect of apomorphine was
prevented by a-flupenthixol, an observation which provides indirect evidence that
apomorphine and DA were acting at the same site(s).
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We also tried a different approach to testing the theory, the objective being to
reduce endogenous DA levels in the carotid body using AMPT. Hypoxia reduces the
DA content of the carotid body, both when the sinus nerve is intact (Sampson,
Nicolaysen & Jaffe, 1975) and when denervated (Hellstrom, Hanbauer & Costa,
1976), and the presence of the tyrosine hydroxylase inhibitor AMPT (Moore &
Dominic, 1971) should reduce DA biosynthesis during and after hypoxia. In our
experiments AMPT was administered and the animals subjected to alternate periods
of hypoxia and hyperoxia (the latter because according to Osborne & Butler's theory
DA turnover should be greatest when the oxygen tension is higher than normal). The
results indicated that AMPT treatment slightly potentiated the response to NaCN
but had little effect on either spontaneous activity or the response to ACh. To test
for DA depletion we studied the inhibitory effect of d-amphetamine, which was
presumed to reflect DA release (Bunnev et al. 1973) and which was reduced or
abolished by AMPT. We also assessed, qualitatively, the reduction by AMPT in
the dense-cored vesicle content of Type 1 cells, where DA is thought to be stored
(Chen & Yates, 1969; Kobayashi, 1971;see also the review by Biscoe, 1971). Although
Zapata et al. (1969) reported that prolonged hypoxia in cats had no effect on either
the dense-cored vesicles or the catecholamine levels in the carotid body, more recent
studies by Hellstrom et al. (1976) have shown that 15 min of hypoxia (5% 02 in N2)
selectively reduced the DA content in the rat carotid body.
We have interpreted the results as showing that DA levels in the carotid body were
greatly reduced by the catecholamine-synthesis inhibitor AMPT, although other
interpretations are possible. For example, structural changes in the Type 1 cells may
reflect changes in the amount of complexing substances rather than DA content,
and noradrenaline in the cat carotid body (Chiocchio et al. 1966) may also be affected
by hypoxia (Mills & Slotkin, 1975; cf. Zapata et al. 1969), AMPT and amphetamine.
However, responses to stimulants following the combination of AMPT and hypoxia/
hyperoxia were in good agreement with results obtained using the DA antagonist
a-flupenthixol, which adds further support to the interpretation that AMPT was
reducing DA levels.
In summary, the present results demonstrate that responsiveness of the chemo-
receptors to stimulants was only slightly affected when the dopaminergic system was
influenced by blocking drugs (a-flupenthixol or haloperidol), a biosynthesis inhibitor
(AAIPT), or a long-acting DA agonist (apomorphine). These findings do not support
the theory of Osborne & Butler (1975) that DA is tonically released in the carotid
body to suppress chemosensory activity. There is also evidence in the literature
which is at variance with this theory. For example, reserpine treatment does not
modify the response to chemoreceptor stimulants, even though DA levels in the
carotid body are substantially reduced (Eyzaguirre & Zapata, 1968; Zapata et al.
1969; Nishi, 1975). Also, Zapata (1975) found that the DA antagonist spiroperidol did
not increase spontaneous chemosensory activity in vitro and he concluded that 'a
continuous release of DA to maintain tonic inhibition of chemosensory fibres is not
very probable'.
Our results are, however, compatible with suggestions that DA may, through its
inhibitory action, modulate chemosensory activity (Mitchell & McDonald, 1975;
Zapata, 1975). We consider that increased afferent activity causes a release of DA
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which reduces the sensitivity of the sensory nerves; this does not preclude the
possibility that stimulants (e.g. hypoxia) also cause a direct release of DA from
storage sites. In this scheme DA release would be minimal in the normal resting
state, which explains why a-flupenthixol and AMPT had no appreciable effect on
spontaneous discharge frequency. Responses to ACh injections last for only 1-2 sec
(not very physiological) which may not be long enough to allow any DA released by
the increased activity to exert an inhibitory influence, thus explaining why responses
to ACh were not greatly affected by the DA inhibitors. Responses to NaCN and to
hypoxia are longer-lasting (4-10 sec for NaCN) and were evidently suppressed by
DA, since they wete potentiated following a-flupenthixol or AMPT. We conclude,
therefore, that DA modulates an increase in chemosensory activity by influencing the
rate of increase in discharge, but not the maximum discharge frequency. The
mechanism whereby DA is released in response to increased chemosensory activity
remains to be established, but may involve reciprocal synapses, possibly utilizing
ACh (Hess & Zapata, 1972; McDonald & Mitchell, 1975), or release from Type 1
cells by increased efferent activity in the sinus nerve (Biscoe & Stehbens, 1967;
Biscoe, Lall & Sampson, 1970; Neil & O'Regan, 1971; Sampson, 1972; Sampson,
Aminoff, Jaffe & Vidruk, 19766), although the physiological importance of the latter
pathway has been questioned (McCloskey, 1975; Mitchell & McDonald, 1975).
This work was supported by a project grant from the Medical Research Council. R. J.
Docherty is in receipt of an M.R.C. Research Studentship. We are grateful to Lundbeck & Co.
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SUMMARY
1. Intracarotid (i.e.) injection of either acetylcholine (ACh) or dopamine in¬
hibited spontaneous chemosensory activity recorded from the peripheral cut end of
the sinus nerve in the anaesthetized rabbit.
2. High doses of ACh ( ^ 50 /tg i.e.) evoked a slight increase in discharge which
preceded the inhibition. This excitation was attributable to a nicotinic action of the
drug since it was abolished by mecamylamine.
3. The muscarinic agonist bethanechol inhibited chemoreceptor activity, an effect
which was blocked by high doses of atropine, as was the inhibition caused by ACh.
Dopamine-induced inhibition was unaffected by atropine.
4. Atropine, in doses sufficient to abolish the vasodepressor effect of ACh, only
slightly reduced the inhibitory action of ACh on the chemoreceptors. Also, the
vasodilators sodium nitrite and sodium nitroprusside did not appreciably alter
chemosensory discharge. It seems unlikely, therefore, that the inhibitory response
to ACh is secondary to vascular changes.
5. The inhibitory response to dopamine, but not that to ACh, was blocked by the
dopamine antagonist a-flupenthixol. This implies that inhibition of chemosensory
activity evoked by exogenous ACh was not secondary to dopamine release.
6. The implications of the results are discussed, particularly with regard to the
possible physiological role of ACh as a modulator of carotid chemosensory activity.
INTRODUCTION
The present electrophysiological investigation was undertaken to examine the
effects of acetylcholine (ACh) and dopamine on carotid chemosensory activity in
the rabbit. It is well known that ACh stimulates arterial chemoreceptors in the eat
(e.g. see Anichkov & Belen'kii, 1963; Schweitzer & Wright, 1938) and dog (e.g.
Hevmans, Bouckaert, Farber & Hsu, 1936), but there do not appear to be any
reports concerning the effects of ACh, or other drugs which affect the cholinergic
system, on the activity of rabbit carotid body chemoreceptors.
Dopamine seems to have species-dependent effects on the carotid chemoreceptors,
stimulating sensory activity in dogs (Jacobs & Comroe, 1968), but inhibiting it in cats
(Black, Comroe & Jacobs, 1972; Sampson, 1972; Zapata, 1975; Docherty & McQueen,
1978a). We were interested in determining what effect dopamine has on chemosen-
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sory activity in the rabbit, particularly since it is present in the carotid body of this
species (Dearnaley, Fillenz & Woods, 1968). A preliminary account of some of this
work has been presented to the Physiological Society (Docherty & McQueen, 19786).
METHODS
Experiments were performed on male rabbits (New Zealand White or Californian) weighing
between 2-5 and 3-5 kg (mean weight = 2-9 kg).
Anaesthesia. Animals were anaesthetized with sodium pentobarbitone (30-50 mg/kg) or
urethane (400 mg/kg) and a-chloralose (6 ml./kg of a 1 % solution in saline), administered
through an ear vein, with supplements as required (Korner, Uther & White, 1968).
General. A cannula was inserted in the trachea low in the neck. Blood pressure was measured
via a pressure transducer (Bell & Howell, 4-422) from a cannulated femoral artery, displayed
on a pen recorder (Devices, M4), and recorded by an FM tape recorder (Tandberg, 100; frequency
response d.c. to 1250 Hz). Arterial blood pH, P0t, and P0o2 were measured at hourly intervals
using a Radiometer gas monitor (BMS 3 with PHM 71 meter). A femoral vein was cannulated
and used for drug administration. Rectal temperature was monitored and maintained at
39 ± 0-5 °C by a heating pad.
The carotid bifurcation region was exposed and dissected free from surrounding tissue. A
cannula was inserted into the lingual artery and advanced until its tip lay in the common
carotid artery approximately 1-5 cm caudal to the carotid bifurcation. This cannula was used
for close-arterial administration of drugs to the cartoid body.
Recording sinus nerve activity. The animal was artificially ventilated with room air by a
respiratory pump (S.R.I.) operating at 38 strokes/min and gallamine triethiodide (3 mg/kg
I.v.) was administered to paralyse spontaneous respiration. This dose had no appreciable effect
on chemoreceptor responses to ACh or dopamine. In most experiments end-tidal C02 was
continuously monitored by an infra-red CO, analyser (Med 1A; Grubb Parsons) and the stroke
volume of the pump adjusted to maintain end-tidal CO, at 5%. The carotid sinus nerve ipsilateral
to the catheterized lingual artery was cut centrally and activity in the nerve was recorded as
described previously (McQueen, 1977). Chemoreceptor units were identified by their random
pattern of discharge, their increase in discharge frequency following injection of sodium cyanide
(5 fig) into the ipsilateral common carotid artery, their increase in discharge in response to
hypoxia (breathing 5% oxygen in nitrogen), and by the inhibition of discharge in response to
hyperoxia (breathing 100% oxygen).
Drug administration. Intracarotid (i.e.) injections of drugs were made in a volume of 0-1 ml.
and the catheter (dead space = 0-1 ml.) flushed with 0'2 ml. modified Locke solution at 37 °C
which had been bubbled with a 5% carbon dioxide/95% air gas mixture. Injections were made
at the peak of the inspiratory phase of the respiratory cycle and completed over one respiratory
cycle, i.v. injections of drugs were made in a volume of 0-2-1-0 ml. and the catheter flushed with
0-5 ml. saline. In experiments with mecamylamine, the appropriate volume of dextran solution
(2-5% dextran, 5% glucose in distilled water) required to maintain blood pressure at the control
level, was administered i.v. This treatment prevented the sustained fall in blood pressure which
would otherwise have accompanied administration of this ganglion blocking drug.
Data analysis. Action potentials were counted and data analysed as previously described
(McQueen, 1977). Responses to drugs were expressed as the absolute difference in discharge
following drug administration where
\Ex = Sa: (response) — Ex (control)
and
Ex (control) = x (control) x t,
AZa; = absolute difference in discharge,
Ex = total discharge,
x = average discharge (counts per second),
t = response duration (sec).
Drugs. Drugs were prepared in modified Locke solution (NaCl 6-0 g; KC1 0-42 g; CaCl2 0-24 g;
Tris base 6-0 g; n-HCI 39 ml.; distilled water to 11.; pH = 7-41 at 37 °C), excepting a-flupen-
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thixol which was prepared in 0-9% (w/v) sodium chloride solution. Doses referred to are those
of the salts.
The drugs used in this investigation were: pentobarbitone sodium, gallamine triethiodide
(May & Baker); acetylcholine iodide, sodium cyanide, atropine sulphate; urethane (ethyl
carbamate), a-chloralose, sodium nitrite (B.D.H.); bethanechol chloride, dopamine hydro¬
chloride (Koch-Light); sodium nitroprusside (Griffin & Tatlock); mecamylamine hydrochloride
(M.S.D.); 5-hydroxytryptamine creatinine sulphate (Labkemi A. B.); suberyldicholine di-iodide
(kindly supplied by Dr A. Ungar, Department of Pharmacology, University of Edinburgh).
RESULTS
Experiments were performed on twenty-one rabbits from which twenty-three











Fig. i. Dose-response data for sodium cyanide, NaCN (O—O) and acetylcholine,
ACh (0 0) in one experiment (three chemoreceptor units). In this and subsequent
Figures doses (fig i.e.) are plotted on a log10 scale and responses expressed as AE®
unless otherwise indicated (see Methods section). Lines were fitted to the data by the
method of least squares.
Responses to cholinergic agonists
Acetylcholine. Injections of ACh (1-250 fig i.e.) caused an immediate, short-lasting
(1-30 sec) inhibition of chemoreceptor activity in all the experiments, including two
in which the ipsilateral superior cervical ganglion had been removed. There was an
approximately linear relationship between log10 dose and response (AEx) over the
range 5-100 yg i.e. (see Fig. 1). Doses in this range, which always caused inhibition
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of chemoreceptor activity in the rabbit (either anaesthetic), are comparable to doses
which stimulate chemoreceptor activity in the cat (McQueen, 1977). With high doses
of ACh ( ^ 50 fig i.e.), the inhibition was preceded by a slight (2-3 times control
discharge), transient period of stimulation lasting less than 1 sec (see Fig. 2).
Mecamylamine. Mecamylamine is a potent ganglion blocking drug (Stone, Tor-
chiana, Navarro & Beyer, 1956; Bennet, Tyler & Zaimis, 1957), which can block the
increase in chemoreceptor activity evoked by ACh in the cat carotid body, both in
vitro (Eyzaguirre & Zapata, 1968) and in vivo (Sampson, 1971; McQueen, 1977).
Fig. 2. Chemoreeeptor units from an experiment showing the early part of the response
to a high dose of ACh (50 fig i.e.), before (A) and after (B) administration of mecamyl¬
amine (0-5 mg/kg i.e.). Panels show from above downwards: action potentials, 1 sec
time markers, injection marker.
The inhibition of chemoreceptor activity evoked by ACh in rabbits was either
unaffected or potentiated following the administration ofmecamylamine (1-5 mg/kg
i.v. or 0-25-0-5 mg/kg i.e.). The transient stimulation seen with high doess of ACh
was, however, abolished (Fig. 2).
Suber-yldicholine (SDCh). SDCh is a potent nicotinic agonist which has been shown
to stimulate the carotid chemoreceptors of the cat (Anichkov & Belen'kii, 1963;
Dardymov & Ger, 1964; McQueen, 1974). Intracarotid injection of SDCh (10-50 pg)
in the rabbit had no consistent effect on carotid chemoreceptor activity.
Atropine. Atropine, in doses (1-10 mg/kg i.v.) sufficient to block the depressor
effects of ACh, caused only a slight reduction in the inhibition of chemoreceptor
activity produced by ACh (see Fig. 3). There was a large variation in the dose of
atropine required to block the vascular effects of ACh in different animals. However,
administration of atropine close-arterial to the carotid body (1 mg/kg i.e.) caused
a substantial reduction in the chemoreceptor response to ACh (Fig. 4A).
Bethanechol. Bethanechol is a muscarinic agonist which is relatively free ofnicotinic
actions (Molitor, 1936). i.e. injection of bethanechol (10-100 pg) produced a dose-
related inhibition of chemoreceptor activity which was greatly reduced by admini¬
stration of atropine (1 mg/kg i.e.; see Fig. 4B). Unlike the response to ACh, the
inhibition was not preceded by a stimulant effect at high doses.
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Responses to sodium cyanide
Sodium cyanide increased carotid chemosensorv activity in all the experiments,
including the two in which the ipsilateral superior cervical ganglion had been
extirpated. The threshold dose of stimulation was about 2-5 /jg i.e. and a maximum
response was elicited by 25 /tg i.e. The effective dose range is comparable to that for
stimulation of carotid chemoreceptors in the cat (McQueen, 1977). Fig. 1 shows
0 L. 1 1 1 1 1 I I i
0 10 20 30 40 50 60 70
Time (sec)
Fig. 3. Response of carotid chemoreceptors (three units) to ACh (10 /ig i.e.) before (A)
and after (B) administration of atropine (10 mg/kg i.v.). Panels show from above down¬
wards: discharge frequency (counts/sec), injection marker, mean blood pressure
(mmHg), time (sec).
dose-response data for sodium cyanide, illustrating the approximately linear re¬
lationship between log10 dose and the response (NZx) over this range.
The chemoreceptor response to sodium cyanide was not appreciably affected by
administration of either atropine or mecamylamine, although in some experiments
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there was a slight reduction in the response to sodium cyanide in the presence of
mecamylamine (see Figs. 5A, B).
Response to dopamine and 5-hydroxytryptamine
Dopamine. The effect of dopamine on carotid chemoreceptor activity was studied
in sixteen experiments. A single injection (5-10/<g i.e.) caused an immediate, short-
lasting (5-20 sec) inhibition of chemoreceptor activity in every experiment (see
Fig. 7). The inhibition was sometimes followed by excitation, a phenomenon which
has also been observed in cats (Zapata, 1975, 1977; Docherty & McQueen, 1978a).
The chemoreceptor response to dopamine was unaltered by mecamylamine (0-5—
5 mg/kg I.v. or 0-25-0-5 mg/kg I.e.) or atropine (1-5 mg/kg i.v. or 1 mg/kg i.e.).
a.-Flupenthixol. a-FIupenthixoI is a potent dopamine antagonist (Moller Nielsen,
Pederson, Nymark, Franck, Boeck, Fjalland & Christensen, 1973) which has been
shown to block the inhibitory action of dopamine on carotid chemosensory discharge
in the cat (Docherty & McQueen, 1978a). Administration of a-flupenthixol (0-25-
1 mg/kg i.v. or 0-25-0-5 mg/kg i.e.) in rabbits blocked the inhibitory action of
dopamine on carotid chemosensory activity (see Fig. 6A) but did not reduce the
inhibitory response to ACh (see Fig. 6B). The excitatory response to sodium cyanide
was potentiated by a-flupenthixol (Fig. 5C).
5-Hydroxytryptamine (5-HT). The effect of 5-HT on carotid chemosensory activity
was studied in eight experiments. Intracarotid injection of 5-HT (5-10 pg) caused
an intense but transient stimulation of chemoreceptor activity followed by a period of
relative inhibition (5-15 sec; see Fig. 7). Both the excitatory and inhibitory com¬
ponents of the response were subject to considerable variation in any experiment,
making an accurate assessment of the effects of blocking drugs difficult. The response
did not appear to be modified by either mecamylamine or atropine. Low doses of
a-flupenthixol (0-25-0-5 mg/kg i.v.) had little effect on the chemoreceptor response to
5-HT although responses to dopamine were blocked. Higher doses of a-flupenthixol
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(0-25-0-5 mg/kg i.e.) blocked the inhibitory component of the response to 5-HT,
this being similar to the block of 5-HT inhibition observed in cats following higher
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Fig. 5. Dose—response data for NaCN, obtained during three experiments, before
(O—O) an(l after (0 0), .4, mecamylamine (0-25 mg/kg i.e.), B, atropine
(2 mg/kg i.v.) and, C, a-flupenthixol (0-25 mg/kg I.v.). Data were from recordings of


















T 10 20 30
Fig. 6. Effects of dopamine (10 fig i.e.) and ACh (5 fig i.e.) on spontaneous chemo¬
receptor discharge (counts/sec), before (A) and after (B) administration ofa-flupenthixol
(0-5 mg/kg i.v.). Injections of ACh or dopamine were made at the arrows. Panels show
from above downwards: discharge frequency (counts/sec), time (sec).
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Response to vasodilator substances
Sodium nitrite. Sodium nitrite is a potent vasodilator which acts directly on
vascular smooth muscle (Weiss, Wilkins & Haynes, 1937). Injection of sodium nitrite
(25-100 /ig i.e.) evoked a very slight inhibition of chemoreceptor activity lasting
3-4 sec, but the magnitude of the inhibition did not appear to be dose-related and
was no greater than that caused by i.e. injection of an equal volume of modified
Locke solution (0-1 ml.).
1 hlli'ii
Fig. 7. Chemoreceptor units from an experiment showing the response to dopamine
(5 fig i.e.) and 5-hydroxytryptamine (5-HT) (5 fig i.e.). Details as for Fig. 2.
Sodium nitroprusside. Like sodium nitrite, sodium nitroprusside is a vasodilator
which acts directly on vascular smooth muscle (Johnson, 1929). Sodium nitro¬
prusside (10-50 pg i.e.) evoked a feeble, short lasting inhibition of chemoreceptor
activity, independent of dose, followed by a secondary stimulation which was dose-
dependent. The magnitude of the initial inhibition evoked by sodium nitroprusside
was no greater than that caused by a control injection of an equal volume (0-1 ml.)
of modified Locke solution.
DISCUSSION
The results show that ACh and dopamine both inhibit spontaneous carotid chemo-
sensory activity in anaesthetized rabbits. The inhibitory response to ACh was un¬
expected, being in complete contrast to the stimulant action obtained in other
species (see Introduction). Experiments were performed to investigate the mech¬
anisms whereby the drugs cause inhibition of chemoreceptor activity. The results
obtained are discussed below.
Vascular effects. Inhibition of chemoreceptor discharge could have resulted from
an action of ACh on vascular smooth muscle, although the short latency to onset of
the effect argues against this, at least for the early part of the response. Vasodilatation
of the carotid body vasculature would increase blood flow into the glomus and might
thereby be expected to reduce spontaneous chemosensory discharge frequency before
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any tendency for discharge to increase secondary to the delayed fall in b.p. caused
by circulation of the ACh (see Fig. 3), although autoregulation of blood flow that
can occur in the rabbit carotid body (McCloskey, 1968) complicates the speculation.
The results from our experiments show that whereas a low dose of atropine blocked
the ACh-induced fall in systemic b.p., the inhibitory response of the chemoreceptors
to ACh was only slightly reduced. The vascular explanation therefore seemed un¬
likely, providing that the carotid body vascular responsiveness to ACh is similar to
that of the peripheral vasculature. This may or may not be the case. However, the
potent vasodilators sodium nitrite and sodium nitroprusside also had little effect on
chemosensory activity when administered close-arterial to the carotid body, the
increase in discharge associated with nitroprusside probably being due to the pro¬
duction of cyanide ions during the conversion of nitroprusside to thiocyanate. These
results with atropine and the vasodilator drugs indicate that although vasodilatation
may explain a small part of the inhibition of chemoreceptor activity evoked by
ACh, it is not responsible for the greater part of the effect. This view is supported
by the recent finding that ACh inhibits chemosensory activity of the superfused
rabbit carotid body in vitro (Monti-Bloch & Eyzaguirre, 1977), this being a pre¬
paration in which vascular effects are precluded.
Characterization of the cholinergic receptors. We attempted to identify the cholinergic
receptors responsible for the effects of ACh. High doses of ACh caused a transient
slight stimulation of the chemoreceptors, an effect which preceded the inhibition.
This excitation appeared to be attributable to a nicotinic action of ACh since it was
abolished by mecamylamine. We are unable to explain why the nicotinic agonist
SDCh was inconsistent in its ability to stimulate the chemoreceptors. In any event,
as the excitatory effect was slight and only seen following injection of high doses of
ACh, it is unlikely to have much physiological significance.
The inhibitory action of ACh was evidently mediated by a muscarinic mechanism
because the muscarinic agonist bethanechol, but not the nicotinic SDCh, also caused
inhibition, and the response could be blocked by the muscarinic antagonist atropine,
although relatively high doses were needed. Interpretation of data derived from
experiments involving the use of atropine in rabbits is complicated by the presence
of an atropinase enzyme in some rabbits (Ambache, 1955), a fact which may account
for the large variation in the dose of atropine required to prevent the vascular
effects of ACh. Nevertheless, it was possible to block the vasodepressor action of
ACh with doses of atropine which were lower than those required to block the chemo¬
receptor inhibitory response.
The possibility exists that the muscarinic receptors mediating the inhibition of
chemosensory activity evoked by ACh are 'atypical', perhaps being similar to those
in the adrenal medulla (Henderson & Ungar, 1977), or in sympathetic ganglia (Hilton,
1977), which are also fairly resistant to atropine blockade. Further studies are
required to investigate this possibility.
ACh-dopamine interaction. It has been suggested that ACh may release dopamine
from the rat carotid body via a muscarinic mechanism (Hellstrom, Hanbauer &
Costa, 1976). Since we found that dopamine inhibited rabbit chemosensory activity,
and it is known to be present in the rabbit carotid body (Dearnaley et al. 1968), the
possibility that ACh-induced inhibition was secondary to dopamine release became
14-2
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attractive. However, it is unlikely to be the case because the dopamine antagonist
a-flupenthixol, in doses sufficient to block the inhibitory response to exogenous
dopamine, did not reduce the inhibitory response evoked by ACh.
Although we found that dopamine inhibited carotid chemoreceptor activity in
the rabbit, as it does in the cat (Docherty & McQueen, 1978a), it should be noted that
Monti-Bloch & Eyzaguirre (1977) reported that it increases chemoreceptor discharge
of the superfused rabbit carotid body in vitro. We found there was a delayed ex¬
citation following some doses of dopamine, but this effect was invariably preceded
by an inhibition of chemosensory activity. A possible explanation for the difference
between the in vivo and the in vitro results is that vascular effects are responsible for
the inhibition observed in vivo; such vascular changes should not occur in the super-
fused preparation. Sampson, Aminoff, Jaffe & Vidruk (1976a) presented evidence
showing that vascular effects are unlikely to account for the dopamine-induced
inhibition of chemosensory activity in cats; whether a similar situation pertains in
the rabbit remains to be established. However, we consider it unlikely that the
inhibition observed in vivo is secondary to vascular effects of dopamine, particularly
since the latency to onset of effect following the start of an injection is so short
(1-2 sec), although we cannot entirely preclude the possibility. The discrepancy
between the results seems more likely to be attributable to variability of the in vitro
preparation's responsiveness to dopamine (Zapata, 1975) or to differences in dose used
and the time during which the drug is present in the carotid body. The delayed
excitatory effect observed in vivo may be mediated by a mechanism which perhaps
involves a different type of dopamine receptor, but further studies are required to
characterize this response.
Dopamine appears to be involved in modulating chemosensory activity in the cat
(Mitchell & McDonald, 1975; Zapata, 1975; Docherty & McQueen, 1978a) and it is
tempting to speculate that it has a similar role in the rabbit carotid body. However,
this remains to be established.
Physiological significance. It is difficult to reconcile the present finding that ACh
inhibits rabbit carotid chemosensory activity with the hypothesis that ACh is an
excitatory transmitter in the chemosensory mechanism (e.g. see reviews by Heymans &
Neil, 1958; Eyzaguirre & Zapata, 1968; Torrance, 1968; Biscoe, 1971; Howe & Neil,
1972). The nicotinic action of ACh in exciting sensory nerve endings may be non¬
specific, that is a direct action on the nerve endings which can be blocked pharmaco¬
logically without affecting the response of the endings to physiological stimuli (Brown
& Gray, 1948; Gray & Diamond, 1957). It could be that whereas non-specific ex¬
citation of chemosensory afferents is observed in the cat and dog, it is not obtained,
except transiently following high doses of ACh, in the rabbit. Could the threshold
for non-specific excitation by ACh be higher in the rabbit than in other species? Is
this related to levels of acetylcholinesterase ? One could start speculating as to why
inhibition of chemosensory activity occurs in rabbits, but it would be more profitable
to study further the properties of the rabbit carotid body and sinus nerve and to
compare them with those of the cat and dog (e.g. Verna's (1975) ultrastructural
study of the rabbit carotid body).
It may well be that the inhibition evoked by ACh in rabbits is either indirectly
mediated or else non-specific and lacking physiological significance, but it seems
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worth exploring the possibility that these findings with exogenous ACh in rabbits,
free from any masking excitatory effect of the drug, provide a clue regarding the
physiological role of ACh in the carotid body. There is evidence for an efferent path¬
way running in the sinus nerve to the cat carotid body (e.g. see Biscoe & Sampson,
1968) and stimulation of this pathway inhibits carotid chemosensory activity (Neil &
O'Regan, 1969; Belmonte & Eyzaguirre, 1974). Several workers have reported that
this inhibition can be reduced by atropine (Willshaw, 1975; Goodman, 1975; Sampson,
Aminoff, Jaffe & Vidruk, 19766), although opinions differ about the mechanism of
the inhibition and the physiological significance of the pathway (McCloskey, 1975).
It remains to be established whether the rabbit carotid body receives an efferent
innervation via the sinus nerve, but the possibility exists that the inhibitory
effect of ACh on chemosensory activity in rabbits might result from an action
on receptors involved in an efferent pathway. In such a scheme ACh would be a
modulator or regulator of chemosensory activity rather than an excitatory neuro¬
transmitter.
We are grateful to K. Bell and I. Maben for technical assistance and to Lundbeck & Co. for
kindly providing the a-flupenthixol. R. J. Docherty is in receipt of an M.R.C. research student¬
ship.
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The effects of benztropine and pargyline on the response of cat carotid
chemoreceptors to sodium cyanide, acetylcholine and dopamine
By R. J. Docherty. Department of Pharmacology, University ofEdinburgh, Edinburgh
EH8 9JZ
In the pentobarbitone-anaesthetized cat, exogenous dopamine causes inhibition of
carotid chemoreceptor activity sometimes followed by a period of stimulation and it
has been suggested that endogenous dopamine may modulate chemoreceptor activity
(Docherty & McQueen, 1978).
In the present study the effects of benztropine, a dopamine uptake blocker, and
pargyline, a monoamine oxidase inhibitor, on the chemoreceptor response to NaCN,
ACh and dopamine were investigated.
DA (jug i.a.)
NaCN (jug!i.a.)
Fig. 1. Dose-response data obtained from a single chemoreceptor unit for NaCN and
dopamine (DA) before (O O) an(i after (# 0) administration of benz¬
tropine (0-25 mg/kg i.a.). Doses are plotted on a log10 scale.
Chemoreceptor activity was recorded and quantified as previously described
(McQueen, 1977) and drugs injected into the ipsilateral carotid artery. Benztropine
(0-25-0-50 mg/kg i.a.) and pargyline (2-5-5-0 mg/kg i.a.) both augmented dopamine-
induced inhibition of chemoreceptor activity and potentiated responses to NaCN
(Fig. 1), benztropine being more effective than pargyline. Responses to ACh were
unchanged by pargyline or benztropine.
It is difficult to estimate the influence of non-specific actions of benztropine or
pargyline in these preliminary experiments, but the finding that, drugs which
augment the inhibitory effects of exogenous dopamine potentiate the response to
NaCN suggests that endogenous dopamine may have an excitatory effect on carotid
chemosensory activity in the cat.
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